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Abstract 
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ABSTRACT 
 
The analysis of urinary metabolite changes can provide information on the effects 
of food supplements or health-promoting products on healthy subjects or animal 
models. Specimen collection is non-invasive, long-term experiments can be easily 
conducted and urinary biomarkers of oxidative stress can also be measured, offering the 
opportunity to study the effects of a nutritional intervention and evaluate the redox 
status of the considered organism. Compared to other biological fluids or matrices 
(plasma and feces for example), sample preparation is more straightforward in the case 
of urine because of lower sample complexity and lower protein/peptide content. Finally, 
urine samples the metabolic end-products from the organism destined for excretion, 
therefore, it is prone to high biological variations.  
Three natural extracts were selected for the work here reported, namely 
Polygonum cuspidatum Sieb. et Zucc. (rich in resveratrol), Vaccinium macrocarpon 
Aiton (cranberry, rich in type A procyanidins) and green Coffea canephora Pierre ex 
Froehn. beans (GCBE, rich in chlorogenic acids), on the basis of their distribution on 
the nutraceuticals market and on the basis of the information regarding their in vivo 
activity actually available in literature. In fact, these largely sold products are aimed to 
prevent disorders or aging (as in the case of P. cuspidatum and resveratrol), or in 
general to maintain a healthy status. On the other hand, in many cases scientific data 
regarding the efficacy and safety of nutraceuticals and their phytochemical composition 
are scarce, so there is the need to study in deep these products and how they exert their 
activity. For this reason, considering the heterogeneity of the products studied and the 
complexity of the interactions between nutraceuticals and living organisms, 
metabolomics analyses represent an attractive approach. 
In the first part of the work, the effects of P. cuspidatum dry extract were studied 
in healthy adult rats during a 49-days supplementation, using a combined 1H NMR and 
UPLC-HRMS metabolomics approach. The variations of urinary composition were 
studied using 1H NMR, UPLC-HRMS and multivariate statistical analysis. Because of 
the reported antioxidant activity of resveratrol, the urinary levels of two oxidative stress 
biomarkers were measured by targeted HPLC–MS/MS analyses and, due to the 
supposed “anti-aging” effects of resveratrol, multivariate models were designed in order 
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to compare the aging effects between control and treated animals. Specific biomarkers 
were then selected and identified, and their amounts in urine were monitored throughout 
the experimental period. 
UPLC-MS metabolomics approaches were used to evaluate the mode of action of 
cranberry against uropathogenic Escherichia coli in two independent experiments, using 
an animal model and enrolling healthy adult volunteers, respectively. The experimental 
design was similar for the two trials, and the aim was to observe if the results obtained 
from the first animal experiment were reproducible in humans, being cranberry 
supplements claimed for treatment of UTIs in human consumers. In the first 
experiment, healthy Sprague−Dawley rats were orally supplemented with a 
standardized cranberry extract for 35 days, to mimic a prolonged consumption of 
cranberry by healthy subjects. 24-h urinary outputs were collected weekly during the 
experiment, and samples were subjected to UPLC−MS analysis using an untargeted 
approach. In a second experiment on the same animal model, a single dose of cranberry 
was administered to animals and the changes of urinary composition at 2, 4, 8, and 24 h 
after extract administration were monitored. Anti-adhesive properties of all the urine 
samples were studied. Furthermore, the markers related to cranberry intake were 
discovered using a multivariate data analysis approach. Finally, a specific 
chromatographic method was developed for the measurement of unmodified PAC-A in 
urine. In the experiment involving human volunteers, these consumed an oral sachet 
containing 360 mg of dry cranberry extract and 100 mg of quercetin. Urine samples 
were collected at 2, 4, 6, 8 ad 24 hours after product administration and the anti-
adhesive properties of urine samples were tested using an in vitro assay on E. coli. In 
order to correlate possible observed bioactivity with modification of urinary 
composition, LC-MS-based targeted and untargeted metabolomics approaches were 
used. 
Finally, a clinical trial on a small number of healthy adult volunteers was 
performed to study the effects of a prolonged (30 days) supplementation with 400 mg of 
green coffee bean extract. The 24-h urinary samples were collected weekly, and 
analyzed by LC-MS. Multivariate data analysis approaches were applied and also 
targeted analysis were performed to measure urinary oxidative stress biomarkers, 
namely allantoin and 8-hydroxydeoxyguanosine (8-OHdG), in order to assess the 
potential antioxidant activity of GCBE in vivo. 
On the best of our knowledge, and on the basis of the data available in literature, 
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the works presented in this thesis project are the first reporting the application of 
metabolomics approaches in the bioactivity studies of P. cuspidatum in animal model 
and of GCBE in human volunteers. Regarding cranberry, the data here reported are the 
first to correlate the metabolomics analysis of urine after the intake of a cranberry-
containing supplement and the results obtained from anti-adhesive assays of the same 
urine samples against uropathogenic bacteria. 
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INTRODUCTION 
 
 
1. From nature to nutraceuticals: natural products used as food 
supplements 
 
1.1. Nutraceuticals: a definition 
 
The term “nutraceutical” was coined in 1989 by DeFelice, who described it as “a 
food, or part of a food, that provides medical or health benefits, including the prevention 
and/or treatment of a disease” (Brower, 1998). Nowadays, term “nutraceutical” is 
widely used in marketing and has no actual regulatory definition (Espín et al., 2007, 
Kalra, 2003). Nutraceuticals are non-medicinal health-promoting products that are used 
by a large part of the population in the developed countries. These products are 
available without medical prescription in pharmacies and regular markets. Because of 
the non-regulatory meaning of “nutraceuticals”, these products can either be considered 
as food supplements (Espín et al., 2007) or herbal products (non-registered medicinal 
herbal products). Because of their “non-medicinal” nature, no proof of efficacy and no 
premarketing approval is required for these products in Europe or in the USA by the 
U.S. Food and Drug Administration (FDA) (unless drug-like efficacy is claimed) (Van 
Breemen, 2015). Nevertheless, nutraceuticals are commonly used for their reported 
health-promoting and/or disease-preventing properties, as, for example, in the 
prevention of aging-associated diseases or in the management of oxidative, 
inflammation, arthritis, osteoporosis, gastrointestinal diseases, cardiovascular diseases, 
depression, diabetes and cancer (Bernal et al., 2011, Sut et al., 2016, Wang et al., 2016). 
Many nutraceuticals contain natural products in their composition, usually in the 
form of dried extracts or as pure or isolated compounds. Especially considering dried 
extracts, natural sources for nutraceutical products are complex matrixes, whose quali-
quantitative chemical composition is often not completely defined (Espín et al., 2007). 
For this reason, although these products are present in the market with health-promoting 
claims, in many cases the consumer does not know exactly what is the composition of 
the product that is taking. Furthermore, in many cases little is known about the specific 
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biological activities that are exerted by phytochemicals (Espín et al., 2007), and about 
their mechanism(s) of action and their pharmacokinetics and metabolic fates, especially 
if they are administered as part of complex matrixes or extracts. In fact, unlike in the 
case of single drugs, the components of natural extracts could interact among others, so 
possible synergic or antagonistic effects between them could be possible (Gertsch, 
2011, Wagner and Ulrich-Merzenich, 2009, Yang et al., 2014). Due to the fact that 
these products are “food or part of a food” (Brower, 1998), they are generally 
considered safe and tolerable, but the literature regarding their efficacy and tolerability 
is often controversy, showing inconsistent results in some cases and/or reporting 
investigations that are not well-designed. As suggested by Van Breemen (Van Breemen, 
2015), to ensure the safety and efficacy of botanical dietary supplements, their 
development should be performed in a similar way to that of pharmaceuticals. Thus, 
first of all a complete chemical characterization of extracts and the assessment of 
mechanisms of action of active constituents should be required. Furthermore, the 
chemical standardization of the active compounds and the biological standardization 
based on pharmacological activity should be performed, along with the preclinical 
evaluation of the toxicity, the study of the metabolism of active compounds and 
potential drug-botanical interactions, and finally, clinical studies on safety and efficacy 
(Van Breemen, 2015). On the other hand, all these procedures are more complex and 
time-consuming compared to single drugs, considering that many “nutraceutical” 
ingredients are complex mixtures that are obtained by extracting natural materials 
(plant, marine or terrestrial organism, microorganism, or fermentation product, etc.). 
Products standardization, for example, could not be performed by using a single 
“marker” compound or a “class” of marker compounds, because this is not sufficient to 
assess their quality and efficacy. In addition, the pharmacokinetic profile (ADME: 
absorption, distribution, metabolism, and excretion) of all the constituents of the 
extracts should be analyzed, in order to understand the relative influence of the matrix 
on the absorption of active constituents (Sut et al., 2016). In fact, the bioavailability of 
several phytochemicals could be limited by their poor solubility, by their susceptibility 
to degradation in the gastro-intestinal environment, by extensive metabolism or by the 
presence of other constituents in the matrix that could hamper their absorption (such as 
fibers or hemicellulose). An additional issue is the possible interaction of natural 
products with gut microbiota. In fact, dietary phytochemicals can cause selective stress 
or stimulus to the resident intestinal flora, creating food-microbiome networks that 
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could interfere with both the expected bioactivity of the product and the normal activity 
of intestinal flora (Ni et al., 2015). For all these reasons, the study of nutraceuticals is a 
challenge that can be solved using a medicinal chemistry approach, but considering the 
presence of multiple active agents. 
 
1.2. Classical in vitro approaches to study the bioactivity of botanicals and 
nutraceuticals 
 
As for the development of new drugs, appropriate in vitro bioassays are needed to 
identify bioactive components of nutraceuticals, to assess their mechanism of action and 
to test their efficacy and toxicity. For bioactivity assessment, bioassays on crude 
extracts, purified fractions or pure isolated compounds are performed. All these 
approaches have advantages and disadvantages that should be taken in account. The 
study of crude extracts may be considered attractive for assessing the effect of the 
whole mixture, however the complex chemical composition and the presence of 
interfering compounds (such as tannins, chlorophyll or fatty acids, for example) could 
hamper the assays and can lead to unexpected false positive or negative results (Sut et 
al., 2016). Another problem is the low water solubility of some phytocompounds, 
therefore an adequate non-toxic solvent for cells should be used. Usually, DMSO is 
used for this purpose, because of its valuable solvent properties and its relatively low 
effect on cell viability. However, DMSO might also have an effect on cells viability 
(Butterweck and Nahrstedt, 2012), furthermore dissolving the extract in DMSO might 
solubilize compounds that would never have been dissolved under more moderate 
conditions, so the effects of such compounds might be measured in the assay. Another 
problem is related to the color and auto-fluorescence of crude botanical extracts that 
could interfere with several assays.  
Another classical strategy to study the bioactivity of natural extracts and do 
identify the active constituents is the bioassay-guided fractionation (Koehn and Carter, 
2005) (Figure 1). It consists in preliminary bioassays that are used to test the specific 
bioactivity of the whole botanical extract. This latter is subsequently fractionated by 
chromatographic techniques to separate the constituents with different physicochemical 
properties, and each fraction is tested using the same bioassay. Active fractions are 
fractionated and tested again, and the entire process is repeated until the compounds 
responsible for the activity are isolated and identified by means of spectroscopic 
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techniques (Koehn and Carter, 2005).   
 
 
Figure 1. Generic scheme for bioassay-guided fractionation. Taken and re-adapted from (Koehn and 
Carter, 2005). 
 
The most important limitation of the bioassays as described above is that they 
consist in reductionist approaches, aimed to investigate the activity of single compounds 
on specific targets. However, as stated before, the effects of complex natural extracts 
could not be linked to the activity of single compounds on specific targets, but to the 
complex action of multiple constituents or to the multi-targeting activity of several 
compounds (Gertsch, 2011), so reductionist approaches could not be suitable for a 
complete investigation. Moreover, all in vitro bioassays don’t take in account the 
aspects related to pharmacokinetics and possible activation of pro-drugs that could be 
observable in vivo, along with the possible interactions between the phytoconstituents 
and gut microbiome. Thus, after a preliminary in vitro study, in vivo bioassays are 
required to depict a more complete profile on the activity and toxicity of natural 
extracts. 
 
1.3. In	  vivo	  bioactivity	  studies	  	  
 
A more complete study on the bioactivity of natural extracts is performing in vivo 
experiments using animal models, although it is a model that present differences and, in 
many cases, approximations compared to humans. In fact, variations in the body weight, 
organ size, hepatic and renal blood flow, metabolism, distribution, and elimination rate 
result in significantly different pharmacokinetic profiles between animals and humans 
(Ting et al., 2014, Van Breemen, 2015). Hence, also murine experiments should be 
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considered as approximate representations of what could be observed in humans. 
A first important aspect to consider in the performance of animal experiments is 
the route of administration of the studied product. Generally, the expected clinical route 
of administration should be chosen, that for nutraceutical products would be oral. 
However, in some experiments the intraperitoneal administration was reported, because 
it is very easy to perform in comparison with other administration routes (Pferschy-
Wenzig and Bauer, 2015). This application route has some drawbacks, such as 
unpredictable absorption characteristics, which depend on the exclusion through the GI 
tract, microbiota metabolism and portal system (Sut et al., 2016).  
The metabolic activities of the different systemic organs (most importantly, liver, 
heart and lungs) must be considered, given that they may impact the amount of ingested 
compounds (McClements, 2015, Ting et al., 2014). In fact, several phytochemicals are 
subjected to extensive metabolism by hepatic enzymes, which can lead to either the 
activation (pro-drugs) or the inactivation of these compounds. Therefore, the bioactivity 
of a native herbal product might be markedly changed by these in vivo metabolic 
reactions. To mimic in vivo metabolism, in vitro preparations such as S9-liver 
homogenate, microsomes, cryopreserved hepatocytes, cryopreserved liver slices and 
fresh liver, lung, kidney and intestinal slices have also been compared for their ability to 
metabolize xenobiotics (Sut et al., 2016). However, the intestinal environment is even 
more complex. Gut microbiota exerts an enormous impact on the nutritional and health 
status of the host by modulating its immune and metabolic functions. The microbiome 
provides additional enzymatic activities that are involved in the transformation of 
dietary compounds and on several phytoconstituents (Laparra and Sanz, 2010). For 
these reasons, the biological roles of nutraceuticals, phytochemicals and functional food 
components may be strongly related to gut microbiota interactions, and for an 
exhaustive study of their activity an in vivo model is required.  
Other information on the possible health benefits of nutraceuticals can be obtained 
from standard randomized clinical trials. In these trials, the ‘patient’ population should 
be composed by healthy individuals, the dosages are typically low and interference with 
components from the diet may be highly significant (Possemiers et al., 2011). In fact, 
botanical dietary supplements are not intended to treat a disease, but rather to modify an 
imbalance within normal physiological boundaries (Possemiers et al., 2011), so they are 
intended to promote a healthy status. Thus, nutraceutical trials have to be managed in a 
different way than conventional clinical pharmaceutical trials. Usually, from 
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pharmaceutical trials higher specific dosages, disease-specific clinical endpoints, and a 
specific patient population mean that will have more significant results than 
nutraceutical studies, in which the supplements may be administered to a wide range of 
healthy individuals. First of all, given the inherent phytochemical variability of the 
herbal materials used in the preparation of nutraceuticals, a detailed description of 
herbal products used in clinical trials is an essential prerequisite for the performance of 
the experiment (Pferschy-Wenzig and Bauer, 2015). The plant part, the extraction 
solvent, and the manufacturing process should always be reported for the correct 
interpretation of trial results. Also inter-individual variation following exposure to 
active ingredients could have a profound impact on the final clinical outcomes. In fact, 
nutraceuticals are subjected to bacterial metabolism that can generate active or inactive 
metabolites. Considering the high variability of gut microbiome, bioactivity in different 
individuals will be influenced by the final circulating metabolite patterns that can be 
highly modified both in concentration and composition. Thus, innovative analytical 
approaches such as metabolomics could be useful tools for the study of activity, 
metabolism and excretion of nutraceuticals. 
 
2. Metabolomics: an innovative tool for in vivo studies 
 
2.1. The “Omics” cascade 
 
Since the end of ‘90s, the availability of increasingly sensitive and accurate 
chromatographic and spectroscopic instruments have contributed to the development of 
systems biology, a branch of science that aims to study the complex interactions within 
biological systems, using a holistic approach (Lavrik and Zhivotovsky, 2014). The 
sequencing of DNA maps from various animal species during the late ‘90s, including 
humans, gave birth to genomics, the first of the so called “omics” techniques that 
focuses on the characterization of genetic material. Starting from the available genomic 
data, transcriptomics aims to characterize set of mRNA molecules in one cell or a 
population of cells; during the last years, its usefulness as a tool to identify new 
potential biochemical targets of drug therapies was reported (Dopazo, 2014). 
Proteomics approaches were subsequently developed to investigate signaling networks 
in living systems at the protein and protein-protein interaction levels. Finally, analytical 
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approaches aimed at studying and characterizing global metabolite profiles in living 
systems under different conditions and stimuli were developed, and these were named 
metabolomics (Figure 2).  
 
 
Figure 2. The OMICS cascade. 
 
Metabolomics focuses on metabolic pathways and processes as well as on specific 
compounds, and it relates processes and compounds to growth, development, stress, 
disease or environmental changes. Nowadays metabolomics has become an important 
tool in life sciences and it has acquired an important role in studies on plant interactions 
with other plants, insects and other living organisms (i.e., animals or humans), in the 
quality control of food or medicine and in the diagnosis of pathologies and drug 
research. 
 
2.2. Metabolomics: an evaluable tool for natural products research 
 
Metabolomics is focused on the high-throughput identification, characterization 
and quantification of small molecules (MW < 1000 Da) composing the metabolome, the 
end product of cell metabolism (Han et al., 2008). This branch of systems biology was 
born between the ‘70s and ‘80s, when researchers began to study urinary metabolic 
composition by gas chromatography–mass spectrometry (GC-MS). However, the term 
metabolomics appeared in the scientific literature only in 1998 (Mishra and Tiwari, 
2011).  
Nowadays metabolomics approaches are extensively applied in studies involving 
natural products. The mapping of metabolite profiles of natural extracts to an extensive 
degree is one of its applications in this research field, and researchers frequently apply 
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metabolomics to quality control of herbal products. In fact, variations in metabolic 
profiles may occur because of environmental changes during the growth or harvesting 
of plants, or because of adulteration, for example, and these changes could alter the 
bioactivity profiles of natural products (Chang et al., 2011). Moreover, the metabolome 
is the final downstream product of gene transcription, and its changes are amplified in 
comparison with the transcriptome and proteome changes (Urbanczyk-Wochniak et al., 
2003). An analytical methodology that allows for the monitoring of an entire class of 
metabolites in an unbiased manner, such as that of metabolomics, can be a useful tool 
(Van Der Kooy et al., 2009).  
 
 
 
Figure 3. Scheme representing a typical metabolomics workflow. 
 
Another application of metabolomics is the metabolic fingerprinting of biological 
fluids, such as urine, blood, cerebro-spinal fluid, saliva, lymph and synovial fluid 
(Wang et al., 2005). The composition of biofluids could change following stimuli, such 
as environmental, dietary or pharmacological, among others, and monitoring these 
variations could be useful to assess the efficacy, mechanism(s) of action and toxicity of 
drugs or natural products, for example. Urine and saliva could be easily sampled in a 
scarcely invasive way and pre-analytical sample treatment is straightforward, due to low 
protein and fats content, so they are frequently used for these types of investigations. 
Several high-throughput spectroscopic (NMR, MS, MS-MS) and chromatographic 
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(HPLC, GC, GC-MS, LC-MS, and TLC) techniques are widely employed in 
metabolomics, and each approach presents its own strength and weakness (Sut et al., 
2016) (Table 1).  
A typical untargeted metabolomics methodological pipeline comprises several 
steps, concerning samples collection and analysis, data pre-processing, multivariate 
statistical analysis and model building, and finally data mining (Figure 3). Along 
metabolite-identification methods, spectral pre-processing methods are highly 
dependent on the analytical technique used (e.g., NMR, LC-MS, or GC-MS). The 
different steps are described in the next paragraphs. 
 
2.2.1. Sampling 
 
Sampling times and protocols greatly affect the reproducibility of the data, so it 
should be performed with extreme care, as the risk to introduce variations in samples is 
high. Metabolomics approaches could be used to study biological samples of different 
physicochemical nature, such as blood, plasma, cell metabolites or excretion liquids. 
Each kind of sample needs a suitable sampling method that could be highly or scarcely 
invasive, as for blood sampling and urine harvesting, respectively. All samples must be 
collected, stored and treated in the same way, so a protocol must be drawn up to ensure 
standardization of the procedures. Blood collection can be carried out at regular and 
selected intervals, and small amounts (few drops) can be collected. Furthermore, 
compared to urine, it is less subject to microbial contamination. On the other hand, 
enzymatic activity is higher in blood and the risk of sample degradation is high; for this 
reason, blood samples must be handled at low temperatures. Blood is composed of 
plasma and a cell fraction; this latter should be discarded by centrifugation and 
anticoagulant agents (EDTA or heparin) should be added (Savorani et al., 2013). On the 
other hand, urine sampling is less invasive than blood collection, and this creates a 
lower stress in the animals or volunteers involved in the studies. Also sample pre-
treatment is simpler and less time-consuming than blood, usually consisting only in a 
centrifugation step to discard proteins and in a further dilution with water.  
In general, it is important to keep the samples at low temperatures to prevent 
analytes from undergoing degradation and structural modifications and to block 
enzymatic reactions. In this way, the sample metabolome is maintained stable until 
analysis. A common practice is to freeze the samples between -20 °C and -80 °C 
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immediately after harvesting. Subsequently, thawing and reheating cycles, which 
represent a thermal stress for samples, should be avoided. 
Depending on the type of analysis, the samples will undergo different treatments. 
For example, in targeted analyses, it could be necessary to purify the analytes to reduce 
the background noise, so, after protein precipitation and centrifugation, solid phase or 
liquid phase extractions are performed. As an example, if intracellular metabolites are to 
be analyzed, it is necessary to lysate the cells, extrapolate the metabolites with non-
polar (e.g. chloroform) or polar (H2O/MeOH mixtures) solvents, and finally remove the 
pellets through a centrifugation step. 
 
2.2.2. NMR and MS platforms in metabolomics and data acquisition 
 
Among others, nuclear magnetic resonance (NMR) is considered one of the best-
suited analytical platforms, because of its advantages relative to other methods. NMR is 
characterized by high reproducibility and short analysis times, furthermore pre-
analytical sample preparation is usually fast and simple and structures of known or 
unknown compounds in complex matrixes can be elucidated by analyzing the spectra 
(Kim et al., 2011, Yuliana et al., 2013). Moreover, multidimensional NMR methods 
may offer additional tools for structural elucidation, because they provide information 
for all the H and C atoms in molecules with highly reproducible chemical shifts, 
coupling constants and atom correlation (Wolfender et al., 2013). Other advantages are 
that NMR is non-destructive, non-biased and can easily be used in quantification; 
furthermore, it requires little or no separation and needs no chemical derivatization 
(Wishart, 2008). Analyte quantification is simple because it only requires an internal 
standard, whereas in other methods compounds must be quantified using calibration 
curves (Yuliana et al., 2013). However, NMR presents two major drawbacks that limit 
its use in metabolomics. The most relevant is related to its low sensitivity, especially if 
compared to modern mass spectrometric technologies (Verpoorte et al., 2007). The 
required amount of sample is often higher than the amounts needed for other analytical 
platforms and signals generated by compounds that are present in low quantities could 
not be detected, leading to a loss of information. Another limitation, especially 
concerning the analysis of complex samples, is the large number of signals measured in 
a single spectrum and their overlapping, which are factors that may hamper 
identification of parent compounds (Kim et al., 2011, Wolfender et al., 2013).  
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Table 1. Advantages and disadvantages of the main analytical platforms used in metabolomics. 
Analytical platform Advantages Disadvantages 
NMR • Fast data acquisition 
• High reproducibility 
• High resolution 
• Simple sample preparation 
• Non-destructive 
• No chemical derivatization 
required 
 
• Low sensitivity 
• High amounts of sample 
required 
• Complex spectra 
• Multiple peaks related to a 
single metabolite 
LC-MS • High sensitivity 
• Analysis conditions could be 
adapted to metabolites 
• Wide analytical range 
• Derivatization not required 
 
• Long analysis time 
• Poor spectra databases 
 
GC-MS • High sensitivity 
• Analysis conditions could be 
adapted to metabolites 
• Wide analytical range 
• Rich spectra databases 
• Long analysis time 
• Not suitable for 
thermolabile compounds 
• Derivatization could be 
necessary 
 
 
On the other hand, mass spectrometry (MS) is the other most used analytical 
technique in metabolomics. First of all, MS can be used by directly infusing samples in 
the instrument, and this approach is known as direct infusion MS (DIMS) (Wolfender et 
al., 2015). The advantage of this approach is the fast time of analysis, but long sample 
pre-treatment may be needed, especially while working with complex matrices as 
natural extracts or biological samples. For this reason, MS is usually hyphenated with 
different chromatographic techniques, those provide compound separation prior to MS 
detection: the most used in metabolomics are gas chromatography-MS (GC-MS) and 
liquid chromatography-MS (LC-MS). GC is employed for the analysis of volatile and 
thermo-stable compounds, whether LC is suitable for the analysis of a broader range of 
molecules (Wolfender et al., 2013). Compared to NMR, the main advantage of MS is its 
higher sensitivity, which allows for the detection of compounds at trace amounts 
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(Dettmer et al., 2007). Furthermore, chromatographic and mass spectrometric 
conditions could be optimized according to the sample to analyze. For LC-MS, for 
example, different stationary phases (normal phase, reverse-phase C-8, C-18, and 
HILIC) and mobile phases (water, acetonitrile, methanol, and buffers) could be selected 
to improve separation. Also, the mass spectrometric parameters could be properly set, in 
order to optimize the detection of specific classes of constituents. Specific ionization 
sources could be selected (ESI and APCI are the most frequently used) as several 
analyzers could be used to reach a proper resolution (QTOF, Orbitrap and FT-ICR have 
acquired larger popularity, among others). In particular, two steps are critical for MS-
based metabolomics, i.e., metabolite ionization and ion separation by the mass analyzer 
(Wolfender et al., 2013, Wolfender et al., 2015). Ionization is a chemical process in 
which the yield depends primarily on the chemical properties of the compounds. Thus, 
the use of positive and negative ionization modes allows for the detection of different 
metabolites, and therefore the comprehensive coverage of most metabolites requires that 
both ionization modes be used (Wolfender et al., 2015). The number of features 
detected is, however, also related to the capacity of the mass analyzer to separate ions at 
different m/z values, and thus to its resolution. Currently, high-resolution analyzers such 
as Q-TOF (R ≅ 20.000) and orbitrap (R ≅ 500.000) are frequently employed in 
metabolomics, through which molecular weights and molecular formulas can be 
determined with high accuracy. Furthermore, by employing tandem, ion-trap or orbitrap 
analyzers, multistage fragmentation MS spectra (MSn) and simultaneous fragmentation 
MS spectra at low and high collision energies (MSe) could be acquired. Important 
information on features identities are strictly related to fragmentation patterns, and 
helpful data for molecular identification could be collected through MSn and MSe 
experiments (Herrero et al., 2012, Zhang et al., 2012). The main disadvantage of MS is 
that, unlike NMR, metabolites detection is not universal, and MS ionization is strongly 
compound-dependent; thus, the intensities of the observed ions cannot be directly 
related to the concentration of the analytes (Wolfender et al., 2013), and their 
quantitation must be performed on the basis of the appropriate calibration curves 
(Yuliana et al., 2013).  
Usually, for both NMR and MS-based metabolomics, three different approaches 
could be used, namely targeted and untargeted analyses (Boccard et al., 2010) and 
metabolic fingerprinting (Krastanov, 2010) (Figure 4).  
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Figure 4. The different approaches in metabolomics analysis. Taken from (Krastanov, 2010). 
 
In targeted metabolomics, quantitative methods are used to analyze specific 
variables one by one, and their statistical significance can be tested using univariate 
methods (Commisso et al., 2013). On the other hand, if the aim is to provide a 
comprehensive view of the system under investigation, an untargeted metabolomics 
approach is employed, through which all the obtained variables are considered 
simultaneously and many known and unknown metabolites are quantified. By using 
both targeted and untargeted metabolomics, the behavior of known metabolites could be 
described, but only the untargeted approach allows for the detection of synergic effects 
between variables that cannot be observed at an individual level (Commisso et al., 
2013). Finally, metabolic fingerprinting is an approach that is not driven by a priori 
hypothesis. It is used for complete metabolome comparison, without knowledge of 
compound identification. Usually, a spectral analysis is used to perform fingerprint 
analysis. Metabolite variation is observed principally on the total chromatographic 
pattern changes without the previous knowledge of the compounds investigated, 
therefore, metabolite identification is not mandatory (Krastanov, 2010). 
 
2.2.3. Raw data pre-processing 
 
After data acquisition by NMR and MS, data processing using statistical tools and 
subsequent data mining is required to interpret the obtained results. Prior to statistical 
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processing, raw data should be treated in order to make them suitable. In fact, NMR and 
MS spectra typically show differences, as peak shape, width, and position due to noise, 
sample differences or factors related to the instrumentation employed (Blekherman et 
al., 2011, Smolinska et al., 2012). The aim of preprocessing is to make different 
samples comparable, by correcting these differences for better detection and 
quantification of metabolites (Vettukattil, 2015). Preprocessing in NMR-based 
metabolomics typically includes baseline correction, alignment, binning, normalization, 
and scaling (Smolinska et al., 2012). Baseline correction aims to correct baseline 
distortions caused by systematic artifacts (Vettukattil, 2015). Alignment is performed to 
correct peak shifts due to differences in instrumental factors or temperature and due to 
changes of pH (as for urine samples (Krumsiek et al., 2016)). Binning divides the 
spectra into segments and replaces the data values within each bin by a representative 
value (Smolinska et al., 2012). Normalization is used to correct for some systematic 
variations between samples, as sample dilution factor (Krumsiek et al., 2016), in order 
to make samples more comparable with each other. Usually, normalization is a 
multiplication of every row (sample) by a sample specific constant (Craig et al., 2006). 
Scaling methods are data pretreatment approaches that aim to adjust for the differences 
in fold differences between metabolites by converting the data into differences in 
concentration relative to the scaling factor. They divide each variable by a factor, the 
scaling factor, which is different for each variable. Most commonly used scaling 
methods are autoscaling (also referred as Unit of Variance scaling) and Pareto scaling. 
Autoscaling uses the standard deviation as the scaling factor, and after processing all 
metabolites have a standard deviation of one. In Pareto scaling, instead of the standard 
deviation, the square root of the standard deviation is used as the scaling factor. In this 
way, large fold changes are decreased more than small fold changes, thus the large fold 
changes are less dominant compared to clean data (van den Berg et al., 2006). 
Also for MS data baseline correction, normalization, peak alignment and scaling 
must be performed to render data suitable for further statistical analysis. These 
procedures are the same described for NMR analysis. Furthermore, for MS raw data, 
noise filtering, de-isotoping, spectral deconvolution and peak detection must be 
performed. Noise filtering is often applied to improve peak detection (Blekherman et 
al., 2011), and it is usually performed using different noise filters (Yang et al., 2009). 
De-isotoping can be used to cluster the isotopic peaks corresponding to the same 
compounds together to simplify the data matrix (Vettukattil, 2015). Deconvolution is 
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used to separate overlapping peaks in order to improve peak detection and 
quantification. 
Nowadays, many analytical platforms present several of these processing in 
simplified mode and using user-friendly software. With LC-MS systems, dedicated 
build-in software have been developed to help in the generation of datasets that can be 
then used in multivariate analysis. On the other hand, free downloadable software as 
MZmine (http://mzmine.github.io), for example, can also be used, and they allow the 
operator to pre-process and process data in different modes. However, in some cases, to 
obtain readable data for calculation programs, raw data from the instruments need to be 
converted using other specific software.  
 
2.2.4. Multivariate statistical data analysis 
 
After preprocessing, data are used to perform multivariate statistical analysis and 
to extract information. From a statistical point of view, in targeted analysis variables are 
analyzed using classical univariate methods, but the consideration of the large number 
of variables involved in untargeted metabolomics is not feasible using the same 
methods, thus multivariate statistical tools must be applied. For exploratory data 
analysis, unsupervised techniques such as Principal Component Analysis (PCA) could 
be used, although more complex supervised methods such as the Partial Least Squares 
Discriminant Analysis (PLS-DA) and Orthogonal Partial Least Squares Discriminant 
Analysis (OPLS-DA) may be employed to extract hidden information that helps to 
explain the system's behavior (Figure 5) (Commisso et al., 2013). In unsupervised 
methods data is unlabeled and unclassified, and they allow to discover the groups or 
trends in the dataset. On the other hand, supervised methods are employed in 
discovering biomarkers, classification and prediction, and prior to analysis data are 
classified (e.g., treated and control groups in in vivo bioactivity studies) (Krumsiek et 
al., 2016). 
From a high-dimensional dataset comprising hundreds or thousands of 
metabolites, only a few combinations of them that best explain the total variation in the 
original dataset have to be found. PCA is a dimension reduction algorithm that replaces 
all correlated variables by a smaller number of uncorrelated variables, named principal 
components (PCs), that still retain most of the information in the original dataset 
(Krumsiek et al., 2016). If the first few PCs can explain a large proportion of variation 
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in the data, it could be visualized using a two-dimensional or three-dimensional plot, 
called score plot, which is mainly used to discover groups. Another graph, indicated as 
loading plot, present the variables that are responsible for separating the groups, whose 
are represented by the points that are further from the origin than most other points in 
the plot (Krumsiek et al., 2016).  
 
 
 
Figure 5. Example of data mining procedures. Data matrix is used to perform supervised (PCA) and 
unsupervised (PLS-DA, OPLS-DA) analyses, and from the models markers are selected and further 
identified. 
 
Usually, in metabolomics PCA is used to find (dis)similarities between groups of 
observation in a dataset when variation within the groups is sufficiently less than 
variation between the groups, otherwise for classification, prediction and biomarkers 
selection supervised methods are preferred, mainly ones based on PLS (Projection to 
Latent Structures or Partial Least Squares) algorithms. PLS is a latent variable approach 
(i.e. a dimension reduction method) used to find the fundamental relations between two 
matrices (X and Y), and it is used to model the covariance structures in these two 
spaces. In other words, a PLS model will try to find the multidimensional direction in 
the X space that explains the maximum multidimensional variance direction in the Y 
space. PLS regression is particularly suited when the matrix of predictors has more 
variables than observations, and when there is multi-colinearity among X values. There 
are many variants of the PLS and corresponding algorithms, whose may have different 
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orthogonal conditions and different methods to estimate scores and loading matrices 
(Ren et al., 2015). One of the most used in metabolomics is PLS-DA (Nguyen and 
Rocke, 2002), where Y is a vector whose values represent class memberships.  On the 
other hand, OPLS-DA, another popular method (Trygg and Wold, 2002), can be 
embedded as an integrated part of PLS modeling to remove systematic variation in X 
that is orthogonal to Y, thus also enhancing the interpretation of PLS.  
PLS methods have a tendency to over-fit models to data, even identifying 
excellent class separation in completely random variables (Westerhuis et al., 2008), so 
validation is a critical step in ensuring model reliability. Model validation requires 
partitioning the data into a training set used to build a model and a validation set used to 
assess predictive ability of the model, where the validation set is in no way used to 
generate the trained model (Anderssen et al., 2006, Broadhurst and Kell, 2006). The 
quality assessment (Q2, comprised between 0 and 1) statistic is typically reported as a 
result of cross-validation and provides a qualitative measure of consistency between the 
predicted and original data. Also the R2 values (fitting values, comprised between 0 and 
1) of a given model may be used to assess its degree of fit to the data (Gromski et al., 
2015). 
From multivariate analysis different visual plots are obtained, from whose the 
data could be analyzed. The scores scatter plot shows how the observations are 
distributed in the model and how they separate according to their dissimilarities, while 
the loadings scatter plot shows how the variables distribute in the model and how they 
contribute to describe the observations trend. For PCA, observations appear grouped in 
scores only when within-class variation is less than between-class variation, conversely, 
in PLS and OPLS the data tend to be over-fitted and the models could show class 
separation even with random data (Worley and Powers, 2013). For this reason, the use 
of PLS or OPLS models necessitates validation, as previously described. Due to the 
complementary nature of scores and loadings as explanations of the data matrix, the two 
may be used together. In the loadings plot, variables with loadings in a given position 
contribute to observations whose scores are found in a similar position in a scores plot, 
so the loadings closest to the scores are expected to have the highest contribution to 
class separation. One of the most useful method of variable selection is to use VIP 
(Variable Importance on Projection)-based models, from whose it is possible to extract 
a reduced subset of descriptive variables on the basis of their VIP values. In this case, 
only variables having VIP value over a specific threshold are considered as significant 
Introduction 
	  24	  
descriptors for a specific observation group, and the threshold could be estimated by 
maximizing the Q2validated of the model (Peron et al., 2017).  
 
2.2.5. Variables identification 
 
On the basis of the analytical platform used, NMR or MS, variable identification 
can be performed in different ways. In both the cases, spectral signals can be identified 
by comparing them with reference data from the literature or with freely available web 
libraries of reference compounds (Wolfender et al., 2013). Among these latter, the most 
commonly used are Human Metabolome Database (HMDB, http://www.hmdb.ca; for 
both NMR and MS), Metlin (https://metlin.scripps.edu; for MS) and MassBank 
(http://www.massbank.jp; for MS). The second strategy is to identify the metabolites by 
studying the collected spectra. Concerning NMR, along with 1D NMR techniques, 2D 
NMR methods are required for identification (Wolfender et al., 2013). 2D NMR 
correlations between protons (1H-1H) or proton-carbons (1H-13C) can be useful to 
confirm whether the observed signals are derived from a single variable or not. 
Correlation spectroscopy (COSY) is a common experiment that shows which signals in 
a 1H-NMR have mutual spin-spin couplings. The resulting spectrum has the 
conventional 1D NMR spectrum along the diagonal cross-peaks at chemical shifts that 
correspond to pairs of coupled nuclei. Another commonly used 2D correlation 
technique is total correlation spectroscopy (TOCSY), which provides information such 
as the unbroken chains of coupled protons in the same molecule (Wolfender et al., 
2013). A direct correlation between carbons and protons can be detected by 
heteronuclear multiple quantum coherence (HMQC) or heteronuclear single quantum 
coherence (HSQC). In the resulting spectra, any carbon that is directly attached to a 
proton is detected, and so, the chemical shift of a 13C connected to a specific proton can 
be obtained. Long-range correlations between carbons and protons can be observed by 
heteronuclear multiple bond correlation (HMBC) spectra, by which carbon-carbon 
correlations can be indirectly obtained with the aid of HMQC or HSQC. In addition, 
correlations between quaternary carbons such as carboxylic acid and nearby protons can 
be observed in the spectra. The long-range couplings in HMBC spectra can provide 
information on the connectivity between two moieties that are connected only by 
quaternary carbons or heteroatoms. 
Concerning MS-based approaches, the first useful information that could be 
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obtained from the analysis is the molecular weight (MW) of the metabolites. Using 
High Resolution (HR) mass spectrometers, the accurate MW value could be obtained 
(i.e., accuracy to the forth decimal point). This data, together with the isotopic patterns, 
could be used to determine the molecular formula of the compounds. Currently, most 
HR-MS instruments (TOF, Orbitrap) routinely provide mass accuracy < 5 ppm, and this 
can reach 1 ppm or less on high-end FT-ICR-MS (Tsybin et al., 2011, Wolfender et al., 
2013). An effective biomarker identification could be performed comparing HR 
experimental m/z values and calculated molecular formula with compound libraries and 
databases (HMDB, Metlin, MassBank). To obtain additional structural information, 
molecular ion species could be fragmented in tandem analyses using MS/MS, MSn 
(using Ion-trap mass spectrometers) or MSe experiments. For high-resolution 
measurements in MS/MS, either a hybrid instrument such as a Q-TOF-MS or an Ion 
Trap-MS such as an Orbitrap provides high quality spectra for metabolite identification. 
Concerning GC-MS, the electron impact MS spectra (EI-MS) that can be recorded are 
very reproducible, due to the high energy used in the ion source. This has the important 
advantage that large EI-MS databases, such as NIST database, can be used for spectra 
comparison and further peak annotation. In general, identification in GC-MS is also 
completed by the calculation of experimental measurement of retention index, such as 
Kovats index in different chromatographic columns. 
In order to assess the identity of detected compounds, the best approach could be 
the use of different techniques. Furthermore, the identification could be confirmed by 
the comparison with authentic standards, when available, that can be added to the real 
sample in spiking experiments, allowing an unequivocal identification. However, this 
approach presents the strong drawback of the non-commercially availability of several 
standard compounds, furthermore it can be extremely expensive and time-consuming. 
Thus, for many applications, HR-MS coupled to fragmentation pattern analysis and 
NMR assignments can be considered sufficient to tentatively identify the metabolites. 
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3. Natural extracts used as nutraceuticals: focus on Polygonum cuspidatum 
Sieb. et Zucc., Vacciunium macrocarpon L. and green coffee (Coffea 
canephora Pierre ex Froehn.) beans 
 
3.1. Polygonum cuspidatum Sieb. et Zucc. 
 
3.1.1. Plant description 
 
Poligonum cuspidatum Sieb et 
Zucc. (Japanese knotweed, Figure 6) is 
an herbaceous perennial plant of the 
family Polygonaceae, native to Asia. P. 
cuspidatum appears as a shrub that could 
reach 1-3 m in height. The round stems 
are hollow and covered with scales, the 
shoots grow from spreading rhizomes that 
can reach 20 m in length. The leaves are 
broadly oblong-ovate or ovate-lanceolate, 8-15 cm long and 5-12 cm wide. The tips of 
the leaves are abruptly acuminate, while the bases of the leaves are truncate. The 
numerous, greenish-white flowers are borne in panicles from the upper axils. The 
flowers are functionally unisexual: each of the male and female flowers still have the 
complementary organs, but they are vestigial. The inflorescences of the male flowers 
tend to be upright, while those of the female flowers tend to be drooping. Flowers 
appear from August to September. The fruit are papery and winged, and are 6-10 mm 
long. These fruits contain black, smooth, shiny, 3-angled achenes that are 3-4 mm long 
(Seiger, 1996). 
P. cuspidatum is frequently used as active ingredient of nutraceuticals and food 
supplements, due to its content in resveratrol. In fact, P. cuspidatum is considered one 
of the best sources of resveratrol, because it is a world-diffused invasive plant and it 
contains higher amounts of this compound than other plants or fruits (Wang et al., 
2013).  
 
 
	  	  	  	  	  	  	  	  	  	  
Figure 6. Polygonum cuspidatum. 
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3.1.2. Resveratrol: a multi-target phytocompound 
 
Resveratrol (3,5,4’-trihydroxystilbene; 
structure reported in Figure 7) is a simple 
polyphenol that has received widespread attention 
because of its supposed beneficial health effects. It 
is found in grapes, berries and peanuts (Jasinski et 
al., 2013) and in various plants, and it is used as 
component of several nutraceutical products. 
Resveratrol exists in two isomers, trans-resveratrol and cis-resveratrol, and their 
glucosides, trans-piceid and cis-piceid, but actually, the most studied is the aglycone of 
trans-isomer, being the most stable (Caruso et al., 2004). 
Scientific interest in resveratrol has grown since the late 1990s, when it was first 
demonstrated to prevent carcinogenesis in mice (Jang et al., 1997). Since then, its 
potential health promoting effects have been studied through numerous in vitro and in 
vivo experiments. A large number of pharmacological targets were discovered and 
numerous health benefits and disease-preventing activities, such as chemo-preventive 
(Chen et al., 2004) and anti-inflammatory (Tomé-Carneiro et al., 2012) ones, were 
related to resveratrol administration in animal models. Furthermore, many authors have 
considered resveratrol for its supposed usefulness in cancer, cardiovascular disease, 
ischemic injuries, and also as a possible enhancer of stress resistance. Finally, others 
considered this compound for its effects on the lifespan extension of various organisms 
from yeast to vertebrates (Baur et al., 2006, Pearson et al., 2008). Because of its 
antioxidant properties and its caloric restriction mimetic role (Pearson et al., 2008), also 
a preventive activity in many age-related and metabolic diseases has been attributed to 
resveratrol, most importantly in inflammation and obesity-related disorders such as 
diabetes and cardiovascular diseases (Baur et al., 2006, Howitz et al., 2003). However, 
the mechanism by which it exerts such a range of beneficial effects is not yet clear. A 
summary of the effects of resveratrol is reported in Figure 8.  
 
	  	  	  	  	  Figure 7. Resveratrol structure.   
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Figure 8. Summary of the in vivo effects of resveratrol. The symbol ↔ denotes lack of effect, and ↑↓ 
opposite action in some trials. The figure was re-adapted from (Novelle et al., 2015). 
 
Several papers were published describing in vitro and in vivo effects of 
resveratrol, but doubts on its effectiveness are still present because of its low 
bioavailability. In fact, as several other polyphenols, it is absorbed at the intestinal level, 
but it is rapidly metabolized both in the intestinal lumen and in the liver to more 
hydrophilic derivatives, that are then excreted in the urine as glucuronides and sulfates. 
Moreover, gut microbiota transforms resveratrol in dihydroresveratrol and also this 
metabolite is absorbed and further metabolized and conjugated (Juan et al., 2010). 
Resveratrol could exert such different biological activities through multiple targets and 
multiple molecular mechanisms, thus metabolomics-based approaches offer the 
opportunity to get new information for the study of the bioactivity of this natural 
product (Sut et al., 2016).  
A recent review summarized the results of in vivo trials reporting the effectiveness 
of resveratrol in clinical management of chronic diseases (Wahab et al., 2017). 
Concerning type 2 diabetes, resveratrol was reported to exert tissue-specific anti-
hyperglycemic effect in insulin deficient states (Kang et al., 2012) and to induce an 
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improvement in insulin sensitivity and glucose-regulation in diabetic subjects 
(Hausenblas et al., 2015, Liu et al., 2014). Also chronic experiments were reported, in 
whose, for example, a 28-days consumption of 5 g daily of resveratrol by diabetic type-
2 patients caused a significant reduction in insulin and glucose levels (Elliott et al., 
2009). In another chronic study, a reduction of the level of oxidative stress markers as 
well as an amelioration of insulin resistance related to the activation of AKT signaling 
were observed in male diabetic patients (Brasnyó et al., 2011), after consumption of 5 
mg of resveratrol twice a day, for one month. Concerning cardiovascular disorders 
(CVD), resveratrol was reported to decrease systolic blood pressure without affecting 
diastolic blood pressure, after daily treatment with 150 mg/day (Bhatt et al., 2012, Liu 
et al., 2015, Movahed et al., 2013). The mechanism of action was further supposed to be 
related to the improvement of endothelial function by stimulation of Ca2+-activated 
potassium-channels and by increasing nitric oxide signaling (Magyar et al., 2012). 
Resveratrol was also reported to affect the levels of pro-inflammatory cytokines in 
plasma, as shown after supplementation of CVD patients with 350 mg/die dose of 
resveratrol for six months to one year. In this trial, a reduction of the production of IL-6, 
IL-10 and TNF (three of the main pro-inflammatory cytokines) was reported (Tomé-
Carneiro et al., 2013). Similarly, other authors showed a decreased production of 
inflammatory biomarkers, such as high sensitivity CRP (hs-CRP), and increased 
circulating levels of various anti-inflammatory biomarkers, such as adiponectin 
(Militaru et al., 2013).  
The effects of resveratrol supplementation were also studied in healthy subjects, 
also if in this case the number of clinical trials is scarce and sometimes controversial. 
Some authors reported that positive effects of resveratrol consumption are exerted only 
in pathological subjects, while no significant preventive activity was observable in 
healthy consumers. Thus, the metabolic condition of patients seems to state the 
effectiveness of resveratrol treatment (Wahab et al., 2017), although further 
investigations are required. 
 
3.1.3. The anti-aging effects of resveratrol 
 
The term aging refers to a gradual decline of all physiological functions (e.g. 
decreased kidney and heart capacities, lowered secretion of sexual hormones, bone and 
joint degeneration) that, in humans, starts after puberty. Still nowadays, the exact 
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mechanisms on the basis of aging are not known, but several factors play a concomitant 
role in the decrease of body functions. One theory states that aging could be related to 
two interconnected processes, referred as primary and secondary aging (Fontana and 
Klein, 2007). Primary aging consists in progressive decline of biological functions and 
of physical structure that occurs with advancing age, independent of other factors. On 
the other hand, secondary aging is related to the deterioration of organ structure and 
function that is mediated by diseases (e.g. diabetes or hypertension) or to harmful 
lifestyle (e.g. smoking or excessive alcohol intake) and environmental factors (Fontana 
and Klein, 2007). 
 
 
 
Figure 9. Free radical oxidative stress and related dysfunctions. 
 
As reported by Fontana and Klein (Fontana and Klein, 2007), several complex 
and interrelated factors are involved in aging mechanisms, including oxidative stress–
induced protein and DNA damage in conjunction with inadequate DNA damage repair, 
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chronic inflammation states caused by increased adipokine and cytokine production, 
alterations in fatty acid metabolism, including excessive free fatty acid release into 
plasma with subsequent tissue insulin resistance, accumulation of cellular metabolic 
end-products that interfere with normal cell function and, finally, loss of post-mitotic 
cells, resulting in a decreased number of neurons and muscle cells as well as 
deterioration in structure and function of cells in all tissues and organs (Fontana and 
Klein, 2007). 
Several studies highlight the implication of oxidative stress in the development of 
a variety of degenerative processes, diseases and syndromes, including, for example, 
atherosclerosis and cardiovascular diseases, chronic inflammatory diseases (e.g. 
rheumatoid arthritis or psoriatic arthritis), neurological disorders and cell mutations 
leading to cancer (Pham-Huy et al., 2008) (Figure 9). However, also normal metabolism 
leads to a mild oxidative stress. This could induce several damages to biomolecules and 
cells that, in some cases, cannot be totally repaired or removed by cells. A low 
percentage of metabolized oxygen produced by mitochondrial processes is converted to 
the superoxide ion, which can be converted subsequently to hydrogen peroxide, 
hydroxyl radical and eventually other reactive species, referred as Reactive Oxygen 
Species (ROS). These latter, including peroxides and singlet oxygen, can in turn 
generate free radicals that can cause damages to DNA and structural proteins (Beckman 
and Ames, 1998, Casteilla et al., 2002). Oxidative stress and related damages could be 
prevented in some extent with the regular intake of exogenous antioxidants from fruits 
and vegetables, such as vitamin C and E, carotenoids and polyphenols. In fact, their 
antioxidant properties (although largely investigated only in vitro) are often claimed to 
be responsible for the protective effects of these food components against several 
diseases (Rietjens et al., 2002). Resveratrol, that is frequently claimed to prevent aging  
(Baur et al., 2006), was reported to exert antioxidant activity in vitro and in animal 
models, although the molecular mechanisms on the basis of its activity are not yet 
established. As an example, in a study by Chen and collaborators was observed that 
resveratrol could alleviate juglone-induced lethal oxidative stress in Caenorhabditis 
elegans, and it extended the lifespan of the same species under conditions of acute 
oxidative damage and oxidative stress caused by high concentrations of glucose (Chen 
et al., 2013). However, no extension of the normal life span of C. elegans was observed 
either in liquid or solid growth media containing different concentrations of resveratrol 
only (Chen et al., 2013).  
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Another activity of resveratrol on the basis of its supposed anti-aging effects is 
related to the activation of a family of NAD+-dependent deacetylases named sirtuins, 
whose main function might be to promote survival and stress resistance in times of 
adversity (Baur et al., 2006). Extra copies of the genes that encode for sirtuins are 
associated with extended lifespan in yeast, worms and flies (Kaeberlein et al., 1999, 
Rogina and Helfand, 2004, Tissenbaum and Guarente, 2001), and, in particular, 
activation of SIRT1 is related to survival and extended lifespan in mice. An in vitro 
screen for activators of SIRT1 identified resveratrol as the most potent of 18 inducers of 
deacetylase activity (Baur et al., 2006). In vivo studies showed an extension of the 
lifespans of Saccaromyces cerevisiae, Caenorhabditis elegans and Drosophila 
melanogaster after treatment with resveratrol, but only if the gene that encodes SIR2 
was present in these organisms (Baur et al., 2006). In a more recent study by Park and 
collaborators, it was reported that resveratrol indirectly activates SIRT1 through a 
signaling cascade involving cAMP, Epac1 (a cAMP effector protein) and AMPK (Park 
et al., 2012). In mice on a high-fat diet, the same authors showed that administration of 
the PDE4 inhibitor rolipram induced similar beneficial metabolic effects to resveratrol, 
including prevention of diet-induced obesity (Guarente et al., 2012, Park et al., 2012). 
 
3.2. Vaccinium macrocarpon Ait. (cranberry) 
 
3.2.1. Plant description 
 
Vaccinium macrocarpon Ait. 
(cranberry) is a low-growing, trailing, 
woody vine with a perennial habit (Figure 
10). This plant is native to North America. It 
is characterized by vertical upright branches 
(uprights), whose are formed from the buds 
along the stems, usually 30 to 180 cm long. 
Leaves are tiny, 0.5 - 1.5 cm long, evergreen, 
thick, and oval/oblong in shape with entire 
margins. During the growing season, they are dark green and glossy, turning reddish-
brown during the dormant season. The uprights have a vertical growth habit and form 
	  	  	  	  	  	  	  	  	  	  
Figure 10. Vaccinium macrocarpon. 
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the terminal buds that contain the flower buds. Most of the fruit is formed from the 
flowers on the uprights, with some berries arising from flowers on the runner ends. 
Flowers are borne singly in leaf axils on the basal portion of a newly expanded, terminal 
mixed bud. Flowers, white/pink colored, are inverted, have four petals and inferior 
ovaries. The fruit are bright red berries with waxy bloom at maturity, giving dark red to 
black appearance; color changes from green to white, then red during development 
(Brown and Mcneil, 2006) . 90% of the world’s annual production comes from the 
states of Massachusetts, New Jersey and Wisconsin in the US, and 8% comes from the 
provinces of Quebec and British Columbia in Canada. The fruit is harvested in 
September and October (Guay, 2009). 
 
3.2.2. Procyanidins in cranberry and their activity as anti-adhesive agents 
 
Cranberry fruits are a good 
natural source of phenolic 
compounds, most importantly 
anthocyanins, flavones, phenolic 
acids and flavan-3-ols, namely 
procyanidins (PACs), (Feliciano et 
al., 2016). These latters could be 
monomers, dimers or higher order 
polymers, and in cranberry the main 
monomer is (−)-epicatechin. The 
building blocks of PACs can be condensed either via C4β → C8’ and C2β → O7’ 
interflavanoid bonds (A-type procyanidins) or via a single C4 → C8’ interflavanoid 
bond (B-type procyanidins) (Figure 11). PAC with at least 1 A-type linkage (PAC-A2 
or bigger) account for 51–91% of total PACs in cranberry (Blumberg et al., 2013), 
hence this berry is considered one of the richest source of these compounds.  
In nature, anthocyanidins and proanthocyanidins protect the plant from infections 
through their anti-adhesion properties. The class of PAC-A is considered to exert anti-
adhesive activity against p-fimbriated uropathogenic bacteria, although their 
effectiveness as anti-adhesive agents is still under debate. Due to their peculiar 
composition, cranberry fruits are employed in the preparation of juices, sauces and dried 
Figure 11. Structures of PAC-A and PAC-B. 
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extracts, whose are used as active ingredients of food supplements or nutraceuticals for 
prevention and treatment of non-complicated urinary tract infections (UTIs) (Hisano et 
al., 2012). 
 
 
 
Figure 12. Examples of microbial degradation products of flavan-3-ol derivatives. Image taken from 
(Zhang et al., 2016). 
 
The efficacy of cranberry in prevention and treatment of UTIs is supported by 
clinical evidence and was reported by several published papers; in many cases, authors 
have claimed its activity to oligomeric A-type procyanidins (Foo et al., 2000, Howell et 
al., 1998, Howell et al., 2005). Nevertheless, a comprehensive understanding of possible 
mechanisms of action is still lacking and, due to poor bioavailability of PACs, many 
doubts about their activity are emerging. In fact, intact oligomeric PACs are scarcely 
absorbed by the intestine, while large amounts of low molecular weight catabolites are 
absorbed after biotransformation by the colon microflora (Del Rio et al., 2013). The 
highest amounts of ingested flavan-3-ols are converted to phenolic and aromatic acids 
of microbial origin (phenols and benzoic, phenylacetic and phenylpropionic acids, 
valerolactone derivatives) (Zhang et al., 2016), that enter the bloodstream and are 
excreted in urine (Del Rio et al., 2013, Monagas et al., 2010). Examples of such 
metabolites are reported in Figure 12. Furthermore, several studies available in the 
literature report effective anti-adhesive activity of isolated PAC-A in vitro (Gupta et al., 
2016, Polewski et al., 2016, Rodríguez-Pérez et al., 2016), without taking in account the 
whole composition of cranberry phytocomplex and all the factors that may positively or 
negatively contribute to its effects in vivo, mainly related to pharmacokinetic processes. 
The mechanism exerted by PAC-A relies in hindering bacterial binding to urinary 
epithelium, thus promoting its elimination in urine. Uropathogenic bacteria bind to the 
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uroepithelium thanks to the presence of lipids and carbohydrates in lipopolysaccharides 
(LPS) and in the extracellular matrix that allow the binding of the bacteria to the 
epithelium by non-specific short-range interactions (van der Waals forces, H-bonds, 
hydrophobic interactions) (Johnson-White et al., 2006, Wojnicz et al., 2012). 
Furthermore, some bacteria could bind to specific carbohydrate ligands thanks to the 
presence of appendages on their surface, named fimbriae. PACs are big oligomers with 
a hydrophobic aromatic skeleton and hydrophilic -OH and –COOH residues, so they 
can interact with both hydrophobic and hydrophilic elements of bacteria. Experiments 
conducted in vitro show that cranberry constituents decrease hydrophobicity, thus 
decreasing the opportunity for short-range interactions, as well as reducing all other 
nonspecific interactions (Liu et al., 2008), hampering the binding capacity of bacteria to 
the epithelium.  
 
 
Figure 13. Interaction of P-fimbriated E. coli with uroepithelium and supposed mechanism of action of 
PAC-A. 
 
The fimbriae present on the surface of uropathogenic bacteria allow the formation 
of specific bonds with carbohydrate moieties on the epithelium (Figure 13). In a paper 
by Liu and collaborators was shown that cranberry extract provoked a decrease in P-
fimbriae length of a P-fimbriated E.coli strain (E.coli HB101pDC1), from 148 to 48 nm 
after cranberry juice treatment, which resulted in a reduced adhesion of bacteria to 
human kidney epithelial cells (Liu et al., 2008). The adhesion forces were measured by 
atomic force microscopy (AFM) and it was observed that they decreased from 9.64 to 
0.5 nN after cranberry juice treatment (Liu et al., 2008). This phenomenon was due to 
conformational changes, meaning that the fimbriae were more compressed on the 
bacterial surface in the presence of cranberry and their binding activity was reduced. 
Recently, many papers dealing with the use of cranberry in the treatment of UTIs 
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in human subjects were published, reporting positive activity results. Occhipinti and 
coll. studied the efficacy of supplementation with a commercially available product 
containing a 36% PAC-A cranberry extract (Occhipinti et al., 2016). The effects of 
treatment were monitored in a group composed by 30 female and 5 male volunteers, 
with at least 2 culture-documented symptomatic UTIs in the year prior to recruitment. 
The experiment took 7 days, during whom volunteers were given 1 capsule containing 
112 mg cranberry extract, twice per day. Results showed that the administration of 
cranberry supplement significantly ameliorated UTI in the treated group compared to 
control. Furthermore, authors reported a significant variability in the effects of treatment 
related to the age of volunteers (Occhipinti et al., 2016). In another recently published 
study, the efficacy and tolerability of a treatment with cranberry extract were evaluated 
in patients with subclinical or uncomplicated recurrent UTI (r-UTI) (Singh et al., 2016). 
Treated group received one capsule twice a day of a commercially available supplement 
containing cranberry extract (60 mg PAC-A per capsule), for 12 weeks. 33% of patients 
in treated group developed r-UTI over 12 weeks, compared to 89% in placebo-treated 
group, showing that the overall efficacy and tolerability of treatment with cranberry 
supplement were superior to placebo in terms of reduced bacterial adhesion (Singh et 
al., 2016). Conversely, a meta-analysis reported in a recent review showed that, 
compared to control groups, cranberry products did not significantly reduce the 
occurrence of symptomatic UTI overall, and the efficacy of treatment was 
heterogeneous (Jepson et al., 2012). Hence, the contrasting opinions about the efficacy 
of cranberry in the treatment of UTIs underline the need for new investigations on the 
mode of action of this herbal remedy.  
 
3.3. Green coffee beans (Coffea canephora Pierre ex Froehn.) 
 
3.3.1. Plant description 
 
Coffee plants (Coffea species) are member of the family of Rubiaceae. They are 
shrubs or small trees native to tropical and southern Africa and tropical Asia that are 
cultivated mainly for the production of the “beans”. In fact, the trees produce edible red 
or purple fruits (called cherries) that contain two seeds, the so-called "coffee beans". 
These latters are commonly used to prepare beverages after roasting, while the non-
roasted (referred as green coffee beans) are frequently used in the preparation of food 
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supplements due to their beneficial effects. Coffee plants have bright green opposite 
leaves with smooth margins. The 
flowers grow in clusters on the axils of 
the leaves and are white colored. Fruits 
are born from them (Davis et al., 
2006).  
Among the approximately 40 
species of coffee plants, two are the 
most diffused: C. arabica and C. 
canephora. C. arabica (Figure 14) is a 
shrub which grows 9 to 12 m tall, but 
the height can be regulated in order to 
give more crops (up to 4.5 m). The 
plant stands out from a deep root 
system and has an open branching 
system. It has opposite, bright green 
leaves with elongated form (6–12 cm long and 4–8 cm broad). The blossom is small and 
white colored. The drupaceous fruit, dark green, glossy at first, becomes dark red when 
it ages. C. arabica is native to Ethiopia, where it grows in the wild at altitudes of about 
1.000 – 2.000 m above sea level, although nowadays it is cultivated in several tropical 
and sub-tropical regions in the world at altitudes of about 1.300 – 2.800 m above sea 
level. On the other hand, C. canephora is a shrub that could reach approximately the 
same height of C. arabica, but it grows at lower altitudes, being cultivated at 700 m 
above sea level, and it needs higher temperatures (24-30 °C) (Davis et al., 2006). C. 
canephora is easier to cultivate than C. arabica, due to its higher resistance to diseases, 
especially in regard to Hemileia vastatrix, Pellicularia koleroga and nematodes 
(Santana-Buzzy et al., 2007). It is much more productive than the arabica variety, 
producing more oval seeds having higher caffeine content. C. canephora is native to 
West Africa, but as C. arabica  is nowadays cultivated in many tropical areas of the 
world. 
 
 
Figure 14. Coffea arabica. 
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3.3.2. Green coffee and chlorogenic acids: their usage in weight-management 
 
Green coffee bean extract (GCBE) is produced from coffee beans that have not 
been roasted, mainly obtained from C. canephora (Thom, 2007). Roasting can cause 
partial degradation of the phenylpropanoid esters of quinic acid (as chlorogenic acids, 
CGA) during high temperature treatments (Farah and Donangelo, 2006). CGA are esters 
of hydroxycinnamic acids, mainly caffeic, ferulic and p-coumaric acids, with (-)-quinic 
acid (Figure 15), and are considered the main constituents of GCBE (Farah and 
Donangelo, 2006).  
 
 
 
Figure 15. Structures of main CGA constituents in coffee; CQA: Caffeoylquinic acid. 
 
Although the content of CGA may vary according to several factors as species 
and cultivar, degree of maturation, agricultural practices, climate and soil, the amounts 
of total CGA in regular green coffee beans, on dry matter basis, may vary from 4 to 8.4 
% for C. arabica, and from 7 to 14.4 % for C. canephora, with some hybrids presenting 
intermediate levels (Farah and Donangelo, 2006). Examples of CGA present in coffee 
beans are reported in Figure 16. GCBE is supposed to exert weight loss and anti weight-
gaining activities, whose are thought to be related to the high content of CGA. Among 
constituents of GCBE there is also caffeine, which is also considered to exert potential 
weight loss activity (Shimoda et al., 2006). 
The effects of consumption of GCBE observed in animal models and in humans 
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are related to modulation of glucose metabolism, inhibition of fat accumulation, weight 
reduction and alteration of body fat distribution, exerted by CGA (Shimoda et al., 
2006). Moreover, other proposed mechanisms are the reduction of the intestinal 
absorption of glucose (Shimoda et al., 2006) and the inhibition of the enzymatic activity 
of hepatic glucose-6-phosphatase (Arion et al., 1997, Shimoda et al., 2006). More 
recently, in an in vivo study CGA of green coffee were demonstrated to improve the 
blood lipid metabolism in rats by alleviating the levels of fatty acids and triglycerides 
and modulating the multiple factors in liver through AMP-activated protein kinase 
(AMPK) pathway, showing a possible mode of action of this ingredient in the 
management of obesity (Sudeep et al., 2016). The presence of caffeine can be 
considered useful because of its stimulant effect, hence it increases energy expenditure 
in humans, contributing to weight loss effects of coffee (Dulloo et al., 1989). 
Furthermore, other proposed mechanisms for caffeine effects on weight loss include 
increased thermogenesis, which consequently enhances lipolysis and lipid metabolism 
(Dulloo et al., 1989, Greenberg et al., 2006). 
 
Figure 16. Structures of some typical CGA present in green coffee. 
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Food supplements containing GCBE are increasing in use to control weight gain, 
but the efficacy of these products is still under debate, due to contradictory data 
published in literature. In a review of 2013, Buchnan and Beckett indicated that a 
limited number of clinical studies were published related to the efficacy of GCBE, and 
that in most of them the clinical significance of the weight loss was minimal (Buchanan 
and Beckett, 2013). The same authors underlined the significant limitation of the 
reviewed studies as lack of blinding, direct comparisons, safety assessment, lack of 
comprehensive endpoints, very low sample size, and not inclusion of lifestyle 
modifications (Buchanan and Beckett, 2013). On the other hand, other papers reported 
moderate effects of GCBE on weight loss (Onakpoya et al., 2011, Quick and Kiefer, 
2013, Shimoda et al., 2006). Revuelta-Iniesta and coll. compared the effects of a 2-
weeks green coffee and black coffee consumption in 20 healthy subjects, observing that 
that systolic blood pressure were significantly reduced after green coffee, as well as 
body mass index and abdominal fat, with no changes in energy intake. Furthermore, 
cortisol/cortisone ratio in urine was reduced after green coffee, suggesting that green 
coffee can play a role in reducing cardiovascular risk factors overall (Revuelta-Iniesta 
and Al-Dujaili, 2014).  
Other papers focused their attention only on CGA, without studying the effects of 
a treatment with a complete green coffee extract. For example, Cho and coll. compared 
the effects of treatment with CGA and caffeic acid (0.02% w/w) in obese mice (Cho et 
al., 2010). Both caffeic acid and CGA significantly lowered body weight, visceral fat 
mass and plasma leptin and insulin levels, compared to the high-fat control group. They 
also reported lowered triglyceride (in plasma, liver and heart) and cholesterol (in 
plasma, adipose tissue and heart) levels. Both treatments significantly inhibited fatty 
acid synthase, 3-hydroxy-3-methylglutaryl CoA reductase and acyl-CoA:cholesterol 
acyltransferase activities, while they increased fatty acid β-oxidation activity and 
peroxisome proliferator-activated receptors α (PPAR-α) expression in the liver 
compared to the high-fat group (Cho et al., 2010). Hence, despite the large diffusion of 
GCBE, studies are still needed to fully understand the possible mode of action and the 
role that this plant extract may have as treatment of obesity and its clinical relevance.  
The green coffee extract may present some effect in the weight management but 
the evaluation of its effects and mode of action may be difficult due to the complex 
phytochemical composition and due to the multiple possible molecular targets of its 
constituents.
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AIM OF THE WORK 
 
The aim of the thesis project here presented was that to apply both LC-MS and 
NMR metabolomics approaches to study the in vivo bioactivity of selected natural 
extracts used as food supplements, namely P. cuspidatum (rich in resveratrol), cranberry 
(rich in type A procyanidins) and green coffee beans (rich in chlorogenic acids). The 
three extracts were selected on the basis of their commercial value as active ingredients 
of nutraceuticals and on the basis of the information regarding their in vivo activity 
actually available in literature.  
In the first part of the work, the effects of P. cuspidatum dry extract were studied 
in healthy adult rats during a prolonged supplementation, using a combined 1H NMR 
and UPLC-HRMS metabolomics approach. Rats were supplemented with a P. 
cuspidatum extract (100 mg/kg containing 20% of resveratrol) for 49 days and the 
variations of urinary composition were studied using 1H NMR, UPLC-HRMS and 
multivariate statistical analysis. Because of the reported antioxidant activity of 
resveratrol, the urinary levels of 8-hydroxydeoxyguanosine (8-OHdG) and allantoin, 
two well-known oxidative stress biomarkers, were measured by targeted HPLC–
MS/MS analyses. Monitoring the urinary amounts of allantoin and 8-OHdG is a 
straightforward strategy to assess the oxidative status of an organism, due to the non-
invasive recovery of urine and the rapid sample preparation. Finally, due to the 
supposed “anti-aging” effects of resveratrol, mainly related to its caloric restriction 
mimetic role and to its antioxidant activity, multivariate models were designed in order 
to compare the aging effects between control and treated animals. Specific biomarkers 
were then selected and identified, and their amounts in urine were monitored along the 
experimental period. 
Regarding cranberry, an UPLC-MS metabolomics approach was used to evaluate 
the mode of action of cranberry against uropathogenic E. coli in two independent 
experiments, using an animal model and enrolling healthy adult volunteers, 
respectively. The experimental design was similar for the two trials, and the aim was to 
observe if the results obtained from the first animal experiment were reproducible in 
humans, being cranberry supplements claimed for treatment of UTIs in human 
consumers. In the first one, healthy Sprague−Dawley rats were orally supplemented 
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with a standardized cranberry extract (100 mg/kg of extract, containing 15% of total 
PACs, every day) for 35 days, to mimic a prolonged consumption of cranberry by 
healthy subjects. The 24-h urinary outputs were collected weekly at days 0, 7, 14, 21, 
and 35 during the experiment, and samples were subjected to UPLC−MS analysis using 
an untargeted approach. In a second experiment on the same animal model, a single 
dose of cranberry (oral gavage of 100 mg/kg of extract containing 15% of total PACs) 
was administered to animals (n = 6) and the changes of urinary composition at 2, 4, 8, 
and 24 h after extract administration were monitored. Anti-adhesive properties of all the 
urine samples were studied. Furthermore, the markers related to cranberry intake were 
discovered using a multivariate data analysis approach. Finally, a specific 
chromatographic method was developed for the measurement of unmodified PAC-A in 
urine. In the experiment involving human volunteers, they consumed an oral sachet 
containing 360 mg of dry cranberry extract (fully characterized for the PAC and 
flavonoid contents) and 100 mg of quercetin, in order to administrate both the potential 
active class of constituents. Urine samples were collected at 2, 4, 6, 8 ad 24 hours after 
product administration and the anti-adhesive properties of urine samples were tested 
using an in vitro assay on E. coli. In order to correlate possible observed bioactivity 
with modification of urinary composition, LC-MS-based targeted and untargeted 
metabolomics approaches were used. 
Finally, a clinical trial on a small number of healthy adult volunteers was 
performed to study the effects of a prolonged supplementation with GCBE. Ten healthy 
adult volunteers with normal body mass index (BMI), no metabolic, cardiovascular, 
overweight or obesity problems assumed 400 mg of dry GCBE daily for 30 days. The 
24-hours urinary samples were collected weekly, and analyzed by LC-MS. Multivariate 
data analysis approaches were applied and also targeted analysis were performed to 
measure urinary oxidative stress biomarkers, namely allantoin and 8-
hydroxydeoxyguanosine (8-OHdG), in order to assess the potential antioxidant activity 
of GCBE in vivo. 
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MATERIALS AND METHODS 
 
 
1. Polygonum cuspidatum 
 
1.1. Materials 
 
P. cuspidatum dried extract was purchased from a local supplier. Resveratrol 
content was measured by HPLC-DAD and the amount found was 20.0 ± 0.1% w/w. 
Allantoin, 8-hydroxydeoxyguanosine (8-OHdG) and resveratrol standards were 
purchased from Sigma Aldrich. HPLC-grade acetonitrile and formic acid were 
purchased from Sigma Aldrich. Deionized water used in HPLC and UPLC analysis was 
filtered through a Milli-Q system equipped with a 0.22 µm cut-off filter (Millipore). 
Sodium 3-trimethylsilylpropionate-2,2,3,3,-d4 (TSP) was purchased from Sigma 
Aldrich. 
 
1.2. Methods 
 
1.2.1. Determination of resveratrol content in P. cuspidatum extract 
 
Resveratrol content in P. cuspidatum extract was measured by HPLC-DAD. An 
Agilent 1260 HPLC system equipped with a diode array detector (DAD) was employed. 
Dried extract was exactly weighted (50 mg) and extracted with 25 mL of a mixture 
methanol/water 50/50. Extraction was performed on ultrasound bath for 10 minutes at 
room temperature. Sample was centrifuged and supernatant was collected in a flask. 
Solid matter was re-extracted with other 15 mL of solvent in the same conditions. After 
centrifugation liquids were pooled in a 50 mL volumetric flask and used for the HPLC 
analysis. Quantification was obtained on the basis of calibration curve, obtained 
analyzing standard resveratrol solutions in a concentration range of 1.4-140 µg/mL 
reading chromatograms at 325 nm. The equation of the obtained linear curve was y = 
83.706x + 5.6543 (R2: 0.9996). 
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1.2.2. Experimental design 
 
 
 
Figure 17. Scheme of P. cuspidatum experiment. 
 
A longitudinal design was implemented to evaluate the effects of P. cuspidatum 
supplementation on the metabolite content of the 24-hours urine collected during the 49 
days of experiment (Figure 17). The treated group received daily by gavage 100 mg/kg 
of P. cuspidatum extract suspended in water, while an equal dose of water was given to 
the control group. 24-hours urinary outputs were collected at day 0, 7, 14, 21, 28, 35 
and 49 during the experiment and the samples were subjected to UPLC-HRMS and 1H-
NMR analysis. The P. cuspidatum dose (100 mg/kg) was selected on the basis of the 
resveratrol content (20.0 ± 0.1% w/w, corresponding to 20 mg/kg resveratrol), and 
considering previous published studies on rats showing both efficacy (Eḿlia Juan et al., 
2002, Tiwari and Chopra, 2011) and safety of such resveratrol oral dose (Eḿlia Juan et 
al., 2002). 
All animal procedures were approved and conformed to the directives of the 
Ethical Committee for animal experiments of the University of Padova (CEASA). Six 
male and six female Sprague-Dawley rats, 6 ± 2 weeks of age and weighing 108.0 ± 2.0 
g, where used for the study. Animals were fed standard laboratory diet and water ad 
libitum and were maintained in a temperature- and photoperiod- controlled room (12-h 
light/dark cycle). Rats were divided randomly in a P. cuspidatum treated group (three 
Materials and Methods 
	   45 
males and three females) and a control group (three males and three females). No 
differences were observed between control and treated groups at the beginning of the 
experiment on the basis of a preliminary metabolomics investigation. Rats were housed 
individually in metabolic cages for the collection of the 24-h urine outputs. Urine 
samples were then stored at -80 °C to avoid chemical degradation.  
 
1.2.3. UPLC-HR-MS analysis of 24-h urine output 
 
To obtain a metabolic profile of urine, a UPLC-QTOF HRMS full-scan method 
was used. An Agilent 1290 Infinity UPLC system equipped with a Waters Xevo G2 
QTOF mass spectrometer was employed. The detector was equipped with an 
electrospray (ESI) ionisation source and was operating in positive resolution mode. The 
sampling cone voltage was adjusted to 40 V, the source offset to 80 V. The capillary 
voltage was adjusted to 1500 V. The nebulizer gas used was N2 at a flow rate of 800 
L/h. The desolvation temperature was 450 °C. The mass accuracy and reproducibility 
were maintained by infusing lock-mass (leucine–enkephalin, m/z 556.2771) thorough 
Lock-spray at a flow rate of 20 µL/min. Centroided data were collected for each sample 
in the mass range 50 – 1200 Da, and the m/z value of all acquired spectra was 
automatically corrected during acquisition based on lockmass. An Agilent XDB C-8 
column (2.1 mm x 150 mm, 3.5 µm) was used as stationary phase. The mobile phase 
was composed of solvent A (acetonitrile with 0.1% formic acid) and solvent B (water 
with 0.1% formic acid). Linear gradients of solvents A and B were used, as follows: 0 
min, 8% A; 14 min, 48% A; 16 min, 100% A; 17 min, 100% A; 17.5 min, 8% A; 24 
min, 8% A. The flow rate was 200 µL/min and the injection volume was 1 µL. 
Collected urine samples were centrifuged at 13,000 rpm for 5 min before analysis and 
directly injected in the UPLC. Quality control (QC) samples (n=6) were prepared 
mixing 100 µL of each urine sample and used to monitor the UPLC-MS performances. 
Sequence of injection comprising QC, control and treated samples were randomized in 
order to avoid any bias due to samples order. 
Centroided and integrated chromatographic mass data were processed by 
MarkerLynx Applications Manager version 4.1 (Waters) to generate a multivariate data 
matrix. A method for data deconvolution, alignment and peak detection was created. 
The parameters used were retention-time range 2.00–17.00 min, mass range 100–650 
Da and mass tolerance 0.01 Da. Noise elimination level was set to 10.00, minimum 
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intensity was set to 15% of base peak intensity, maximum masses per RT were set to 6 
and, finally, RT tolerance was set to 0.01 min. Isotopic peaks were excluded from 
analysis. A list of the ion intensities of each peak detected was generated, using 
retention time and the m/z data pairs as the identifier for each ion. The resulting three-
dimensional matrix contained arbitrarily assigned peak index (retention time-m/z pairs), 
sample names (observations), and ion intensity information (variables). After the 
exclusion of the variables having more than 30% of missing data in both groups under 
investigation and log-transformation, the obtained data set composed of 483 time x 
mass variables was normalized by Median Fold Change normalization and mean 
centred. 
 
1.2.4. 1H-NMR 24-h urine analysis 
 
Sample preparation was performed as described in (Beneduci et al., 2011), with 
minor modifications. Frozen urine samples were thawed in a fuming hood for 30 min 
and then 1 mL of urine was transferred into a 1.5 mL eppendorf vial. The pH value was 
adjusted to 1.2 ≤ pH ≤ 2 by adding 3 M HCl (120 ± 80 µL) and the sample was 
centrifuged at 13,000 rpm for 10 min. To 700 µL of supernatant, 70 µL of 2 mM 
sodium 3-trimethylsilylpropionate-2,2,3,3,-d4 (TSP) in D2O were added. Finally, 700 
µL were transferred into an NMR tube and the pH was monitored by inspection of the 
chemical shift of the citrate signal and sometimes adjusted by adding 5 µL of 1 M 
NaOH or HCl. 2D-experiments were performed on a urine sample three times more 
concentrated, obtained by pooling several samples and partially evaporating the solvent. 
All 1H-NMR spectra were acquired on a Bruker Avance DMX600 MHz 
spectrometer equipped with a 5 mm TXI xyz gradient inverse probe at room 
temperature. 1D 1H-NMR spectra were acquired with the NOESYGPPR1D pulse 
sequence and the following parameters: 64 scans; 32k data points; spectral width, 
8389.26 Hz; relaxation delay, 2 s; mixing time, 50 ms. The 1H-1H NOESY spectrum 
was recorded with the NOESYGPPRTP pulse sequence, with a spectral window of 13 
ppm in both dimensions, 2048×512 data points, 1.2 s relaxation delay, 0.6 s mixing 
time, and 256 scans. Prior to Fourier transformation, the FIDs were zero-filled to 64K 
points and an exponential line-broadening factor of 0.3 Hz was applied. All spectra 
were processed using ACD/NMR Manager 12.01 (Advanced Chemistry Development 
Inc.). Spectra were referenced to 0.0 ppm using the resonance of TSP and manually 
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corrected for phase and baseline distortions. Intelligent bucketing was applied to the 
region between 0.6 ppm and 9.5 ppm excluding the regions where resveratrol 
derivatives (6.24-7.50 ppm, 5.10-5.22 ppm, 4.10-4.26 ppm, 3.56-3.96 ppm, 2.74-2.82 
ppm) and water (4.70-4.95 ppm) resonate. Total sum normalization was applied to 
compensate for differences in overall concentration between individual urine samples. 
The obtained data set composed of 229 variables was mean centered and Pareto scaled. 
 
1.2.5. Statistical data analysis 
 
Data modelling was performed by applying multivariate techniques based on 
projection. Specifically, Principal Component Analysis (PCA) was used for exploratory 
data analysis and for highlighting the presence of outliers while Projection to Latent 
Structures by partial least squares regression (PLS) was applied to investigate the 
relationships between the metabolite content of the urines collected during the 
experiment and the time of treatment and type of diet. To perform an efficacy data 
modelling able to extract the whole information contained into the collected data, a 
design matrix supporting an interaction model including time, treatment and time x 
treatment effects, was explicitly considered. The measured variables and the design 
matrix were used as X-block and Y-block, respectively, in the PLS regression. N-fold 
full cross-validation with different values of N (N = 6,7,8) and permutation test on the 
responses (1000 random permutations) were performed, in order to avoid over-fitting 
and prove the robustness of the obtained models. The number of components of the PLS 
models was estimated on the basis of the first maximum of Q2 calculated by 7-fold full 
cross-validation (Q27-fold CV) under the constraint to pass the permutation test on the 
responses. To better interpret the obtained model, a new method for rotating the PLS 
model, called post-transformation of PLS2 (ptPLS2), was applied (Stocchero and Paris, 
2016). The main advantage to use the post-transformation of the PLS model is the 
possibility to obtain a new model where the structured variation of the X-block 
discovered by PLS is decomposed into two blocks, corresponding to the variations 
correlated (predictive part of the model) and orthogonal (non-predictive part) to the Y-
block. The post-transformed model maintains the same power in prediction of the PLS 
model but simplifies model interpretation because the dimension of the predictive latent 
space is usually lower than that of the whole latent space discovered by PLS. 
Recently, stability selection was introduced in metabolomics to avoid false 
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discoveries due to overtraining (Wehrens et al., 2011). The central idea of stability 
selection is that real differences or effects should be present consistently, and therefore 
should be found even under perturbation of the data by subsampling or bootstrapping. 
Thus, stability selection by Monte-Carlo subsampling using PLS VIP-based as 
regression technique (Wehrens et al., 2011) was used for identifying putative markers. 
Specifically, 200 random subsamples were extracted by Monte Carlo sampling of the 
collected urine samples (with prior probability of 0.70), and then PLS VIP-based 
applied to each subsample, obtaining a set of 200 regression models. Within this set of 
PLS VIP-based models, variables related to the effects of time and/or treatment were 
identified as the most frequently selected variables. The threshold of the VIP score to 
use in variable selection within PLS VIP-based was estimated by maximizing the Q27-
fold CV. As a result, a small number of metabolites changing during the experiment was 
extracted and the behavior of each single metabolite was studied by linear mixed-effects 
model for longitudinal studies (Chong and Jun, 2005). 
PCA was performed using SIMCA 13 (Umetrics, Umea, Sweden) while the 
platform R 3.0.2 (R Foundation for Statistical Computing) was used for statistical data 
analysis on single variable, to build the ptPLS2 model and to perform Monte-Carlo 
stability selection. 
 
1.2.6. Focus on the effects of P. cuspidatum supplementation on rat aging 
 
Data regarding urine samples collected at day 0 of the experiment (beginning) and 
at day 49th of the supplementation period (end) were isolated from the dataset described 
in Paragraph 1.2.3., and used to compare aging-related composition changes of urine 
collected from control animals and treated ones. Using SIMCA 13 (Umetrics, Umea, 
Sweden), OPLS-DA models comparing control urine samples at day 0 and day 49th, 
treated urine samples at day 0 and day 49th, and control and treated urine at day 49th 
were created. N-fold full cross-validation and permutation test on the responses were 
performed using the same software, as previously described. Descriptive variables were 
selected on the basis of their significance value (p<0.05) and on the basis of their VIP-
value (VIP>2). Only significant variables that were detectable in both the OPLS-DA 
comprising controls and treated animals separately were considered as descriptive and 
further tentatively identified, as described in the previous sections. The urinary 
excretion of N-Methyl-2-pyridone-5-carboxamide and phenylacetylglycine, that were 
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identified as aging markers from the obtained multivariate models and were previously 
reported as markers of aging in rats (Slominska et al., 2004, Zhang et al., 2012), was 
monitored in both treated and control groups throughout the supplementation period, 
extracting the respective AUC values from the dataset and normalizing the data with 
urinary creatinine. The plots obtained from the two groups were finally compared. 
 
1.2.7. Targeted analysis of allantoin and 8-OHdG in 24-h urine samples 
 
Allantoin and 8-OHdG were quantified in urine samples from both treated and 
control rats using appropriate HPLC-MS/MS methods. A Varian 212 HPLC system 
equipped with a Varian MS 500 IT detector was used for HPLC-ion trap mass 
spectrometry. A Phenomenex Kinetex EVO C-18 column (3 mm x 100 mm, 5 µm) was 
used as stationary phase. The detector was equipped with an ESI source and was 
operating in positive resolution mode. For allantoin quantification, the operating 
parameters used were as follows: nebulizing gas, nitrogen; nebulizing pressure, 35.0 
psi; needle voltage, 4500 V; capillary voltage, 600.0 V; drying gas temperature, 350 °C; 
drying gas pressure, 10.0 psi. The mobile phase was composed of solvent A 
(acetonitrile with 0.1% formic acid) and solvent B (water with 0.1% formic acid). 
Linear gradients of A and B were used, as follows: 0 min, 15% A; 7 min, 100% A; 7.06 
min, 15% A; 10 min, 15% A. The flow rate was 200 µL/min and the injection volume 
was 10 µL. An MSn experiment was performed, monitoring the fragmentation of 
allantoin precursor ion ([M+H]+, m/z 159) in the product ion mass range 65-169 Da. 
Allantoin was finally quantified on the basis of its major fragment (m/z 116) using a 
standard titration curve obtained by eluting 0.3 - 1 µg/mL allantoin solutions in water (y 
= 97216x + 51629; R2 = 0.9833). LOD and LOQ were 0.1 and 0.5 ng/mL, respectively. 
For 8-OHdG quantification, the operating parameters used were as follows: 
nebulizing gas, nitrogen; nebulizing pressure, 20.0 psi; needle voltage, 4500 V; 
capillary voltage, 600.0 V; drying gas temperature, 280 °C; drying gas pressure, 15.0 
psi. The mobile phase was composed of solvent A (acetonitrile with 0.5% formic acid) 
and solvent B (water with 0.1% formic acid). Linear gradients of A and B were used, as 
follows: 0 min, 10% A; 1 min, 10% A; 10 min, 60% A; 12 min, 10% A; 16 min, 10% 
A. The flow rate was 200 µL/min and the injection volume was 10 µL. An MSn 
experiment was performed, monitoring the fragmentation of 8-OHdG precursor ion 
([M+H]+, m/z 284) in the product ion mass range 155-175 Da. 8-OHdG was finally 
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quantified on the basis of its major fragment (m/z 168) using a standard titration curve 
obtained by eluting 3 - 100 ng/mL 8-OHdG solutions in water (y = 48.853x + 1002.5; 
R2 = 0.9981). LOD and LOQ were 1 and 5 ng/mL, respectively. 
Before analyses, urine samples were centrifuged at 13,000 rpm for 5 minutes and 
supernatants were directly injected in the instrument.  
 
2. Vaccinium macrocarpon (Cranberry) 
 
2.1. Materials 
 
The dry cranberry extract used in animal experiments and the supplement used in 
the human trial were purchased from a local market. The powder content of each sachet 
used in the human trial was 500 mg, 180 mg of which was dry cranberry extract and 
100 mg was quercetin. Standard PAC-A2 (Extrasynthese, France), Sephadex LH-20 and 
epigallocatechin gallate were purchased from Sigma Aldrich. HPLC-grade acetonitrile 
and formic acid were purchased from Sigma Aldrich. Deionized water used in HPLC 
and UPLC analysis was filtered through a Milli-Q system equipped with a 0.22 µm cut-
off filter (Millipore).  
 
2.2. Methods 
 
2.2.1. Animal experiment 
 
2.2.1.1. Profiling of PACs in cranberry extract 
 
30 mg of dry cranberry extract were suspended in 5 mL of an acetone/water 
(70/30% v/v) mixture and were extracted using an ultrasound bath for 15 minutes. 
Sample was centrifuged at 3,500 rpm for 10 minutes and liquid was collected in a flask. 
The solid residue was re-extracted with a further amount of 5 mL of solvent and 
sonicated for further 15 minutes. Extraction was repeated 4 times. Liquids were 
collected in round bottom flask and volume was reduced under vacuum at 30°C to 5 
mL. Liquid was then transferred to a volumetric flask and volume was adjusted to 25 
mL with methanol.  
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Analyses of PAC-A and PAC-B were performed by HPLC-MS. The 
chromatographic system was composed by a Varian 212 binary pump, coupled to a 
Varian 500-MS Ion Trap mass spectrometer (MS). A Tosoh TSKgel Amide-80 column 
(3,5 µm, 2.1 x 150 mm) was used as stationary phase. 0.5% formic acid in acetonitrile 
(A) and 2% formic acid in water (B) were used as mobile phase. Gradient elution was as 
follows: starting with 90% A, then in 20 min to 80% A, isocratic conditions (80% A) 
until 25 min, then to 35% A in 45 min and isocratic (35% A) until 51 min. Finally, 
column was left to riequilibrate to the initial conditions for 9 minutes. Flow rate was 
200 µL/min and injected volume was 10 µL. The MS parameters were as follows: spray 
chamber temperature, 50°C; nebulizer gas pressure, 25 psi; drying gas pressure, 25 psi; 
drying gas temperature, 385°C; needle voltage, ± 4500 V; spray shield voltage, 600 V. 
Mass spectra were acquired in negative mode in the spectral range 150-2000 Da. For 
PAC-A, [M-H]- ions at m/z 575, 863 and 1151 were monitored for dimers, trimers and 
tetramers, respectively. For PAC-B, [M-H]- ions at m/z 577, 865 and 1153 were 
monitored for dimers, trimers and tetramers, respectively. Being other trimeric or 
tetrameric procyanidins not commercially available, PAC-A2 was used as standard 
compound for quantitative purposes. Calibration curve was built in the range 1-20 
µg/mL, and all samples and calibration solutions were analysed in triplicate. The 
obtained linear curve had function y = 0.6915x (R2 = 0.9989), showing a good linear 
response. Limit of detection (LOD = 0.45 µg/mL) and limit of quantification (LOQ = 
0.7 µg/mL) were determined following USP methods. For LOD, samples with known 
concentration of PAC-A2 were analysed and minimum concentration at which analyte 
could be reliably detected was established. On the other hand, LOQ was established by 
visual evaluation. 
 
2.2.1.2. Animal procedures 
 
All experimental protocols were approved by the Animal Care and Use Ethics 
Committee of the University of Padova (number 3112017PR) under license from the 
Italian Ministry of Health and they were in compliance with the National and European 
guidelines for handling and use of experimental animals. In the first experiment (Figure 
18), twelve healthy Sprague-Dawley rats (six males and six females) of 7 ± 2 weeks of 
age and weighing 173.0 ± 3.1 g, were used. Animals were fed standard laboratory diet 
and had free access to water during the experiments. Rats were maintained in a 
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temperature- and photoperiod- controlled room (12-hrs light/dark cycle). Rats were 
divided randomly in a cranberry treated group (three males and three females) and a 
control group (three males and three females). No differences were observed between 
control and treated groups at the beginning of the experiment. The treated group 
received by intra-gastric gavage a daily dose of 100 mg/kg body weight of cranberry 
extract in 2 mL of water for a total of 35 days. The control group received daily an 
identical volume of water by intra-gastric gavage. Rats were housed individually in 
metabolic cages and 24-hrs urine output was collected and stored at -80 °C to avoid 
chemical degradation. Urine samples were collected on days 0, 7, 14, 21 and 35 during 
the experiment and further subjected to UPLC-ESI-QTOF analysis. 
 
 
 
Figure 18. Scheme of cranberry longitudinal experiment. 
 
A second experiment was performed (Figure 19), involving six healthy Sprague-
Dawley rats (three males and three females), 6 ± 1 weeks of age and weighing 125 ± 7.4 
g. They were orally given a single dose of 100 mg/Kg of 15% PACs cranberry extract 
suspended in 1 mL of water by gavage. Before treatment, animals were individually 
positioned in metabolic cages to collect 24-h control urine. After cranberry 
administration, urinary outputs at 2, 4, 6, 8 and 24 hours were collected following the 
same procedure. Urine samples were then stored at -80 °C until used for UPLC-ESI-
QTOF and HPLC-MS/MS analyses and for adhesion studies, to avoid chemical 
degradation. 
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Figure 19. Scheme of the “single intake” cranberry experiment. 
 
2.2.1.3. Profiling of 24-h urine by UPLC-ESI-QTOF 
 
To obtain a metabolic profiling of urine, a UPLC-HRMS full-scan method was 
used. An Agilent 1290 Infinity UPLC system equipped with a Waters Xevo G2 Q-TOF 
MS was employed. The detector was equipped with an ESI ionisation source and was 
operating in both positive and negative resolution mode. Instrument settings and 
chromatographic conditions were the same reported in Paragraph 1.2.3. Collected urine 
samples were centrifuged at 13,000 rpm for 10 minutes prior to analysis and directly 
injected in the UPLC. Quality control samples (QC, n=6) were prepared mixing 100 µL 
of every collected urine sample and they were centrifuged at 13,000 rpm for 10 minutes. 
Sequence of injection comprising pool, control and treated samples were randomized in 
order to avoid any bias due to samples order. 
 
2.2.1.4. Multivariate data analysis 
 
Centroided and integrated chromatographic mass data were processed by 
MarkerLynx Applications Manager version 4.1 (Waters) to generate a multivariate data 
matrix. An appropriate method for data deconvolution, alignment and peak detection 
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was used, as previously described in Paragraph 1.2.3. Data modelling was further 
performed using SIMCA 13 software (Umetrics), applying multivariate techniques 
based on projection. PCA was used for exploratory data analysis and for identification 
of outliers. PLS-DA was applied to investigate the relationships between urine 
composition and cranberry administration. The measured variables and the matrix were 
used as X-block and Y-block, respectively, in the PLS regression. N-fold full cross-
validation with different values of N (N = 6,7,8) and permutation test on the responses 
(999 random permutations) were performed. Biomarkers were identified as previously 
reported in P. cuspidatum protocol. 
 
2.2.1.5. Profiling of urinary outputs at 2, 4, 8 and 24 hours after cranberry 
administration 
 
To obtain a metabolic profiling of urine collected at 2, 4, 8 and 24 hours after 
cranberry administration, UPLC-ESI-QTOF full-scan method was used. The 
instrumentation employed was the same described for the profiling of 24-h urine, as 
well as the settings of the ESI-QTOF mass detector. An Agilent Zorbax Rapid 
Resolution High Definition (RRHD) SB-C18 column (2.1 mm x 50 mm, 1.8 µm) was 
used as stationary phase and the mobile phase was composed of solvent A (acetonitrile 
with 0.1% formic acid) and solvent B (water with 0.1% formic acid). Linear gradients 
of solvents A and B were used, as follows: 0 min, 2% A; 1 min, 2% A; 8 min, 55% A; 
10 min, 55% A; 10.5 min, 98% A; 11.5 min, 98% A; 12 min, 2% A and isocratic for 1 
minute. The flow rate was 300 µL/min and the injection volume was 1 µL. As for 24-h 
urine analysis, samples were pre-treated in the same way and QC samples (n=5) were 
prepared and randomly injected in the UPLC.  
Data extraction was performed as previously described, using MarkerLynx 
Applications Manager version 4.1 (Waters) and setting time-range between 1.00–10.00 
min; the obtained matrix was then processed using SIMCA 13 software. 
 
2.2.1.6. HPLC-MS/MS determination of oligomeric PAC-A in treated animal’s 
urine 
 
Urine samples were purified prior to analysis to isolate PACs from lower 
molecular weight polyphenols and increase sensitivity of mass spectrometric analysis. 1 
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mL of urine samples were added with 10 µL of a 10 µg/mL epigallocatechin gallate 
solution (equivalent to 100 ng of epigallocatechin gallate), used as internal standard 
(ISTD). Samples were loaded on a 20 x 3 cm glass column pre-packed with 400 mg of 
Sephadex LH-20, which was left to equilibrate in 70% MeOH in water for 30 min prior 
to sample loading. Loaded resin was then washed with 4 mL of 70% MeOH in water to 
elute low molecular weight polyphenols. Subsequently, the resin was washed with 5 mL 
of 70% acetone in water to elute PACs. Acetone fraction was evaporated under vacuum 
to dryness and residue was dissolved with 100 µL of methanol for analysis. Calibration 
curves using different amount of ISTD and PAC-A2 were obtained, namely adding to 1 
mL of urine 100 ng of ISTD and 2, 4, 8, 10, 20 ng of PAC-A2. Urine samples with 
added ISTD were purified through Sephadex as described and final solutions used to 
build a calibration curve. Calibration curve (y = quantity of ISTD/quantity of PAC; x = 
area ISTD/area PAC) was the following: y = 0.3683x (R2 = 0.9991). LOD and LOQ 
were 0.2 and 0.4 ng/mL, respectively, and they were established using USP methods, as 
previously described. 
An Agilent 1260 Infinity HPLC binary pump coupled to a Varian 320-MS TQD 
MS was employed. The detector was equipped with an ESI ionisation source and was 
operating in negative mode. The MS conditions were as follows: spray chamber 
temperature, 50°C; nebulizer gas pressure, 25 psi; drying gas pressure, 25 psi; drying 
gas temperature, 385°C; needle voltage, ±4500 V; spray shield voltage, 600 V. Mass 
spectra were acquired in negative mode in the spectral range 150-2000 Da. MRM traces 
were used for quantitation purposes. For PAC-A dimer, the m/z transition 575-285 was 
monitored, corresponding to the fragmentation of [M-H]- parent ion. m/z transitions 
monitored for trimers and tetramers were 863-289 and 1151-285, respectively, 
corresponding to the fragmentations of [M-H]- parent ions. A Tosoh TSKgel Amide-80 
column (2.1 mm x 150 mm, 3.5 µm) was used as stationary phase. The mobile phase 
was composed of solvent A (0.1% formic acid in water) and solvent B (0.1% formic 
acid in acetonitrile). Linear gradients of solvents A and B were used, as follows: 0 min, 
8% A; 14 min, 48% A; 16 min, 100% A; 17 min, 100% A; 17.5 min, 8% A; 24 min, 8% 
A. The flow rate was 200 µL/min and the injection volume was 10 µL.  
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2.2.1.7.  Microbiology and in vitro adhesion assays 
 
A freshly isolated uropathogenic P-fimbriated E. coli from a woman with urinary 
tract infection (UTIs) was obtained from University Hospital of Padova. The microbe 
was characterized by biochemical and molecular tests and then used in the adhesion 
assays. A single colony was inoculated in trypticase soy broth at 37 °C with shaking at 
200 r.p.m. After 16 hours the microbes were collected by centrifugation, resuspended in 
fresh sterile trypticase soy broth and E. coli concentration adjusted to of 107 CFU/mL. 
Then bacteria were incubated in urine samples, both from control or after consumption 
of cranberry extract, at 105 CFU/mL final concentration for four hours at 37 °C. 
Bacteria were then harvested from the urines by centrifugation (2,500 rpm x 10 min), 
suspended in DMEM at a concentration of 5 x 108 CFU/ml and quantified by vital count 
assay seeding on LB agar plates. The remaining microbes were added to human 
intestinal epithelial cells (HT-29 cells, from ATCC) confluent monolayers (MOI 1:10) 
cultured in DMEM supplemented with 10% heat inactivated faetal calf serum. Tissue 
cultures were incubated with E. coli at 37 °C. After 30 minutes the culture medium was 
removed and monolayers were carefully washed three times with 2 ml of warm sterile 
DMEM to remove non adhering microbes. Following the last washing step, to quantify 
the adhering E. coli to HT-29 cells, monolayers were detached, collected and lysed. 
Living bacteria were enumerated by vital count assay. Serial dilutions were seeded on 
LB agar plates, incubated at 37 °C for 24 hours and CFU enumerated.  
Adhesion data were given as mean ± standard error of the mean (SEM), and one-
way analysis of variance followed by Bonferroni multicomparison tests was used to 
compare data using GraphPad Prism 3.03 software (GraphPad, San Diego, CA). A p-
value of <0.05 was considered statistically significant. 
 
2.2.2. Human pilot trial 
 
2.2.2.1. Phytochemical composition of the cranberry-containing product 
 
Five hundred milligrams of supplement were suspended in 15 mL of an 
acetone/water (70/30% v/v) mixture and were extracted using an ultrasound bath for 10 
minutes. The extraction protocol was the same previously described in Paragraph 
2.2.1.1.  
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Analyses of PAC-A and PAC-B were performed by HPLC-MSn, as previously 
described. In this case, the PAC-A2 calibration curve was: y = 0.7143x + 0.012 (R2 = 
0.9988).  
For flavonoids analysis, an Agilent 1260 HPLC system coupled to a DAD and to 
a Varian 500-MS IonTrap detector was used. An Agilent XDB C-8 (3.5 µm, 3 x 150 
mm) column was used as stationary phase. For elution, acetonitrile (A) and water with 
0.1 % formic acid (B) were used. Gradient started with 90% B and in 20 minutes 
decreased to 10% B, then isocratic conditions were kept up to 25 minutes. After the 
column separation, eluate was splitted to DAD and to MS detectors. DAD traces were 
collected at wavelength of 280 and 350 nm, UV spectra were acquired in the range 190-
400 nm. Quercetin was used as reference standard for aglycones, while rutin was used 
as reference compound for glycosylated derivatives. Calibration curves were built in the 
range 1-1000 µg/mL, and all samples and calibration solutions were analysed in 
triplicate. The obtained linear curves were y = 0.7143x + 0.012 (R2 = 0.9988) for 
quercetin, and y = 0.4143x + 0.007 (R2 = 0.9998) for rutin. Both analytes showed a 
good linear response in the considered concentration range. Limits of detection and 
quantification for both the analytes were LOD = 0.5 µg/mL and LOQ = 1.5 µg/mL and 
were determined following USP method. Peaks were identified on the basis of MS 
fragmentation patterns. MS spectra were acquired in the range 50-2000 Da in negative 
ion mode using tdds® utility, which allowed the observation of fragmentation 
pathways.  
For quercetin determination, the same HPLC-MS/MS system was used but an 
Agilent Poroshell EC 120 C-18 (3.5 µm, 2.1× 50 mm) was used as stationary phase. 
Mixture of 0.1% formic acid and acetonitrile were used as mobile phase, with the 
following gradient: 0 min, 10% A; 6 min, 80% A; 8 min, 80% A; 10 min, 10% A; 13 
min, 10% A. The flow rate was 200 µL/min and the injection volume was 10 µL. For 
quantitative purposes, quercetin was used as reference standard. Calibration curve was 
built in the range 1.4–1400 ng/mL, and all samples and calibration solutions were 
analysed in triplicate. The obtained linear curve was: y = 134,300x +124 (R2 =0.9991), 
showing a good linear response. Limit of detection (LOD = 1.5 ng/mL) and limit of 
quantification (LOQ = 5 ng/mL) were determined following USP method. 
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2.2.2.2. Human pilot trial methodology 
 
 
Figure 20. Scheme of the cranberry experiment involving human volunteers. 
 
The scheme of the experiment is reported in Figure 20. Six healthy adult 
volunteers (four women and two men, 31±8 years, BMI 22.8±1.8) were enrolled for the 
study and informed consent was obtained. The in vivo procedures were conducted at the 
University of Trieste, Italy. The protocol was conducted in compliance with the 
Declaration of Helsinki and the International Conference on Harmonization Guidelines 
and each participant signed an informed consent form. All subjects were non-smoking, 
normally active and with no history of urinary tract infections in the last 12 months. No 
medications were taken during the study (wash out period: 7 days). They were required 
to maintain a low-polyphenol diet for 48 h before laboratory visit, free of green 
vegetables, fruits, fruit juices and red wine, to reduce as much as possible the amounts 
of polyphenols and related metabolites excreted in urines. Nothing except water could 
be consumed for 8 h prior to laboratory arrival. Volunteers took orally two sachets of 
product, corresponding to 360 mg of dried cranberry extract and 200 mg of quercetin, 
dispersed in 100 mL of tap water. Urine samples were collected 1 h before supplement 
consumption (control sample) and 2, 4, 6, 8 and 24 h after cranberry intake. Urine 
samples were immediately centrifuged at 5,000 rpm for 10 minutes, sampled in 50 mL 
vials and stored at -80 °C until analysis. 
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2.2.2.3. UPLC–MS analysis of urine samples 
 
For untargeted analysis, an UPLC-ESI-QTOF full-scan method was used, as 
previously described in Paragraph 2.2.1.5. The stationary phase used was an Agilent 
Zorbax Rapid Resolution High Definition (RRHD) SB-C18 column (2.1 mm x 50 mm, 
1.8 µm) and the mobile phase was composed of solvent A (acetonitrile with 0.1% 
formic acid) and solvent B (water with 0.1% formic acid). Linear gradients of solvents 
A and B were used, as previously reported. Quality control samples (QC, n=6) were 
used to monitor the instrument performance. They were prepared mixing 100 µL of 
each urine sample and centrifuged at 13,000 rpm for 10 minutes. Sequence of injection 
comprising pool, control and treated samples was randomized in order to avoid any bias 
due to samples order. 
Data extraction was performed using MarkerLynx Applications Manager version 
4.1 (Waters), using the same protocol described in the animal experiment. 
 
2.2.2.4. Multivariate data analysis 
 
After extraction, data were mean-centered, Pareto scaled and log-transformed for 
further PCA and PLS-DA analyses. These latters were performed using SIMCA 13 
(Umetrics, Umea, Sweden) platform. N-fold full cross-validation (N = 7) and 
permutation test on the responses (300 random permutations) were also performed, in 
order to avoid over-fitting and prove the robustness of the obtained models. Finally, 
biomarkers were identified as previously described. 
 
2.2.2.5. HPLC-MS/MS determination of oligomeric PAC-A in urine after 
cranberry consumption 
 
Urine samples were purified prior to analysis, in order to isolate PACs from lower 
molecular weight polyphenols and increase sensitivity of mass spectrometric analysis. 
The protocol used was the same described in Paragraph 2.2.1.6. The calibration curve 
used to quantify PAC-A by HPLC-MS/MS (y = quantity of ISTD/quantity of PAC; x = 
area ISTD/area PAC) was the following: y = 0.3841x +0.0122 (R2 = 0.999). LOD and 
LOQ were 0.2 and 0.4 ng/mL, respectively, and they were established using USP 
method. 
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2.2.2.6. HPLC-MS/MS determination of PAC-A degradation products in urine 
after cranberry consumption 
 
Three microbial degradation products of cranberry PACs, namely 5-(3’,4’-
dihydroxyphenyl)-γ-valerolactone, 5-(4'-hydroxyphenyl)-γ-valerolactone-4'-O-
glucuronide and 5-(4'-Hydroxyphenyl)-γ-valerolactone-4'-O-sulfate, were selected from 
the results of untargeted metabolomics and comparing literature data (Feliciano et al., 
2016, Urpi-Sarda et al., 2009), and they were monitored in urines collected after 
cranberry consumption. An appropriate chromatographic method was developed, and an 
Agilent 1260 Infinity HPLC binary pump coupled to a Varian 320-MS TQD MS was 
employed. The detector was equipped with an ESI ionization source and was operating 
in negative mode. The MS conditions were as follows: spray chamber temperature, 50 
°C; nebulizer gas pressure, 25 psi; drying gas pressure, 25 psi; drying gas temperature, 
385 °C; needle voltage, ±4000 V; spray shield voltage, 600 V. Fragmentation traces 
were used for the detection of the metabolites. m/z transitions 207→163, 363→191 and 
271→191 were monitored respectively for 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone, 
5-(4'-hydroxyphenyl)-γ-valerolactone-4'-O-glucuronide and 5-(4'-hydroxyphenyl)-γ-
valerolactone-4'-O-sulfate. An Agilent Poroshell EC 120 C-18 column (2.1 mm x 100 
mm, 2.7 µm) was used as stationary phase. The mobile phase was composed of solvent 
A (water with 2% formic acid) and solvent B (acetonitrile with 0.1% formic acid). 
Linear gradients of solvents A and B were used, as follows: 0 min, 10% B; 12 min, 85% 
B; 14 min, 85% B; 15 min, 10% B; 17 min, 10% B. The flow rate was 250 µL/min and 
the injection volume was 10 µL. AUCs of the monitored compounds were normalized 
to urinary creatinine, in order to overcome different urine dilutions among volunteers. 
Due to the lack of standards, information regarding the concentration of the monitored 
compounds could not be obtained.  
 
2.2.2.7. Determination of quercetin, quercetin-sulfate and quercetin-glucuronide 
in urine after cranberry consumption 
 
The same urine samples used for the previous analyses were used to determine the 
amount of quercetin absorbed from cranberry extract after supplement consumption and 
two quercetin derivatives formed after metabolism, namely quercetin-sulfate and 
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quercetin-glucuronide. The MS-chromatographic method used was the same previously 
described for PAC-A degradation products operating in negative ion mode. Quercetin 
was determined monitoring the m/z transition 301 → 150, while SRM traces 381 → 150 
and 477 → 150 were monitored for quercetin-sulfate and quercetin-glucuronide, 
respectively. For quantitative purposes, quercetin was used as reference standard. 
Calibration curve was built in the range 0.01-10 µg/mL, and all samples and calibration 
solutions were analysed in triplicate. The obtained linear curve was: y = 136640x +1211 
(R2 = 0.9982), showing a good linear response. Limit of detection (LOD = 1.2 ng/mL) 
and limit of quantification (LOQ = 5 ng/mL) were determined following USP method. 
 
2.2.2.8. Microbiology and in vitro adhesion assay 
 
The protocol used to assess the in vitro anti-adhesive activity of urine samples 
against uropathogenic E. coli was the same described in Paragraph 2.2.1.7. 
 
3. Green coffee (Coffea canephora) bean extract 
 
3.1. Materials 
 
The supplement containing a standardized dry GCBE (Coffea canephora) was 
purchased from a local market. The names of product and supplier are note reported to 
avoid any conflict of interests. The powder extract used in the experiment was a 
homogeneous batch and it was formulated in gelatin capsules, each containing 200 mg 
of product. Standard chlorogenic acid, allantoin, and 8-OHdG were purchased from 
Sigma Aldrich (Milan, Italy). HPLC-grade acetonitrile and formic acid were purchased 
from Sigma Aldrich (Milan, Italy), as well as deuterated methanol used in NMR 
analysis. Deionized water used in HPLC and UPLC analyses was filtered through a 
Milli-Q system equipped with a 0.22 µm cut-off filter (Millipore).  
 
3.2. Methods 
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3.2.1. Chemical characterization of dry GCBE 
 
Chemical characterization of dry GCBE was performed by 1H-NMR analysis and 
by HPLC-DAD-MSn. For NMR exploratory analysis of GCBE, a Bruker Avance III 
spectrometer operating at 400 MHz was used. Briefly, 150 mg of dried extract were 
weighted in Eppendorf tube and 1 mL of deuterated methanol was added. The 
suspension was sonicated for 5 minutes then the tube was centrifuged at 13,000 rpm. 
The supernatant was transferred to a NMR tube and used for the 1H-NMR analysis. For 
the chromatographic analysis, the system was composed of an Agilent 1260 
chromatographic system with 1260 autosampler, column oven and a 1260 DAD. Out of 
the column a “T” union was fitted, splitting the flow identically to the diode array and 
to a Varian 500-MS ESI-Ion Trap MS. An Agilent Eclipse XDB-C18 column (3.5 µm, 
3.0 x 150 mm) was used as stationary phase. Acetonitrile (A) and 0.1% formic acid in 
water (B) were used as mobile phase. Gradient elution was as follows: 5 min, 10% A; 
30 min, 100% A; 100% A isocratic up to 35 min. Re-equilibration time was 5 min. 
Flow rate was 125 µL/min and injected volume was 10 µL. The MS parameters were as 
follows: spray chamber temperature, 50°C; nebulizer gas pressure, 25 psi; drying gas 
pressure, 25 psi; drying gas temperature, 350°C; needle voltage, ± 4500 V; spray shield 
voltage, 600 V. Mass spectra were acquired both in negative (for phenols 
characterization) and positive (for caffeine and trigonelline characterization) mode in 
the spectral range 150-2000 Da. Compounds were identified studying their 
fragmentation spectra obtained using the tdds® utility, and comparing the spectra with 
literature (Clifford et al., 2003, Clifford et al., 2005, Clifford et al., 2006, Clifford et al., 
2008). For quantitative purposes, a DAD detector was used and chlorogenic acid and 
caffeine were used as standard compounds. Calibration curves were built in the range 1-
100 µg/mL for chlorogenic acid (at 330 nm) and 2.5-85 µg/mL for caffeine (at 254 nm), 
and all calibration solutions were analyzed in triplicate. The obtained linear curves 
were: y = 35.61 x + 0.052 (R2 = 0.9998) and y = 5.23 x +0.011 (R2 = 0.9998) for 
chlorogenic acid and caffeine, respectively. Limit of detection (LOD) and limit of 
quantification (LOQ) were determined following US Pharmacopeia methods. LOD = 
0.5 µg/mL and 1.5 µg/mL and LOQ = 1.5 µg/mL and 5.0 µg/mL, for chlorogenic acid 
and caffeine respectively.  
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3.2.2. Human pilot trial methodology 
 
 
Figure 21. Scheme of the GCBE experiment involving human volunteers. 
 
Ten healthy adult volunteers (five women and five men, 31±10 years, BMI 
23.2±2.6) were enrolled for the study and informed consent was obtained. The protocol 
(Figure 21) was conducted in compliance with the Declaration of Helsinki and the 
International Conference on Harmonization Guidelines. All subjects were non-smoking 
and normally active. No medication was taken during the study (wash out period: 7 
days). They were required to maintain a low-polyphenol diet for 7 days before product 
consumption, free of green vegetables, fruits, fruit juices and red wine, to reduce as 
much as possible the amounts of polyphenols and related metabolites excreted in urines. 
One day before the beginning of the experiment volunteers collected control urine, and 
nothing except water could be consumed for 8 h prior to GCBE consumption. Then, 
volunteers took daily 400 mg of dry GCBE (2 capsules) each day for 30 days and they 
collected 24-h urine once a week during the experiment (5 harvesting days, considering 
also the first day of supplementation). The dose was established on the basis of the 
doses of green coffee extract that are commonly introduced in food supplements. Urine 
was centrifuged at 5,000 rpm for 10 minutes, sampled in 50 mL vials and stored at -80 
°C until analysis. The body weight of volunteers was monitored before the starting of 
the experiment and during treatment. 
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3.2.3. UPLC-QTOF analysis of 24-h urine output using C-18 stationary phase 
 
To obtain a metabolite profiling of urine samples, an Agilent 1290 Infinity UPLC 
system equipped with a Waters Xevo G2 Q-TOF MS was employed. The detector was 
equipped with an ESI ionization source and was operating both in positive and negative 
modes. An Agilent Zorbax Rapid Resolution High Definition (RRHD) SB-C18 column 
(2.1 mm x 50 mm, 1.8 µm) was used as stationary phase. The mobile phase was 
composed of solvent A (acetonitrile with 0.1% formic acid) and solvent B (water with 
0.1% formic acid). Instrument settings and chromatographic method were the same 
previously described in Paragraph 2.2.1.5. Quality control samples (QC, n=12) were 
used to monitor the instrument performance. They were prepared mixing 100 µL of 
each urine sample and they were centrifuged at 13,000 rpm for 10 minutes. Sequence of 
injection comprising pool, control and treated samples was randomized to avoid any 
bias due to samples order. 
 
3.2.4. LC–MS analysis of 24-h urine output using C-3 stationary phase 
 
A specific LC-ESI-MS method was developed on a C-3 stationary phase to better 
separate polar and smaller molecular weight metabolites. An Agilent 1260 HPLC 
system equipped with a Varian 500-MS IonTrap MS was employed. The detector was 
equipped with an ESI ionization source and was operating in positive mode. Needle 
voltage was adjusted to 4.5 kV, spray shield voltage to 600 V and capillary voltage to 
750 V. The nebulizer gas pressure was 50 psi and drying gas (400 °C) pressure was 400 
psi. Centroided data were collected in the mass range 50 – 1200 Da. MSn spectra were 
acquired using the tdds® utility. 
An Agilent Zorbax RRHD 300SB-C3 column (2.1 mm x 100 mm, 1.8 µm) was 
used as stationary phase. The mobile phase was composed of solvent A (acetonitrile 
with 0.1% formic acid) and solvent B (water with 1% formic acid) and the gradient used 
was: 0 min, 2% A; 1 min, 2% A; 20 min, 90% A; 23 min, 90% A; 25 min, 2% A. The 
flow rate was 150 µL/min and the injection volume was 2 µL. Pre-processing of urine 
samples was the same previously described and QC samples (n=12) were used to 
monitor instrument performance. 
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3.2.5. Statistical data analysis 
 
Centroided and integrated UPLC-MS data were processed by MarkerLynx 
Applications Manager version 4.1 (Waters) to generate a multivariate data matrix. 
Method for data deconvolution, alignment and peak detection was the same described 
for the previous experiment, with slight modifications. The parameters used were 
retention-time range 1–10 min, mass range 50–1200 Da, mass tolerance 0.01 Da. Noise 
elimination level was set to 7.00, minimum intensity was set to 15% of base peak 
intensity, maximum masses per retention time (RT) was set to 6 and, finally, RT 
tolerance was set to 0.01 min. Isotopic peaks were excluded from analysis. Data were 
mean-centered, Pareto scaled and log-transformed before PCA and PLS-DA. Using 
SIMCA 13 (Umetrics, Umea, Sweden) platform, N-fold full cross-validation (N = 7) 
and permutation test on the responses (500 random permutations) were performed. 
Identification of biomarkers was performed as previously described. 
Data obtained from LC–MS analysis using C-3 column were converted using 
ACD Spectrus 2014 software and then processed using MZmine Software v. 2.0. 
Chromatogram deconvolution, alignment of peaks, peak integration, isotopic grouping 
and normalization were performed. Variables having more than 30% of missing data in 
both groups were excluded and a list of the ion intensities of each peak detected was 
generated, using retention time and the m/z data pairs as the identifier for each ion. Data 
were mean-centered, Pareto scaled and log-transformed before PCA and PLS-DA, using 
SIMCA 13 (Umetrics, Umea, Sweden) platform. N-fold full cross-validation and 
permutation test on the responses were performed using the same software, as 
previously described. Biomarkers were identified studying their MSn spectra and 
comparing fragmentation patterns with literature data. 
 
3.2.6. Targeted analysis of allantoin and 8-OHdG in 24-h urine samples 
 
Allantoin and 8-OHdG were quantified in urine samples using an Agilent 1260 
HPLC system equipped with a Varian 320 TQD MS detector. The stationary phase was 
a Phenomenex Kinetex EVO C-18 column (2.1 mm x 100 mm, 5 µm). The detector was 
equipped with an ESI source and was operating in positive mode. The operating 
parameters used were as follows: nebulizing gas (N2) pressure, 50.0 psi; needle voltage, 
4.5 kV; capillary voltage, 600.0 V; drying gas temperature, 380 °C; drying gas pressure, 
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25.0 psi. The mobile phase was composed of solvent A (acetonitrile with 0.1% formic 
acid) and solvent B (water with 0.1% formic acid). Linear gradients of A and B were 
used, as follows: 0 min, 5% A; 1 min, 5% A; 8 min, 90% A; 10 min, 90% A; 11 min, 
5% A and isocratic for 1 minute. The flow rate was 200 µL/min and the injection 
volume was 10 µL. For quantitative purposes, the fragmentation of allantoin [M+H]+ 
ion was monitored (m/z 159 → 116) and a standard titration curve obtained eluting 1 - 
100 ng/mL allantoin solutions in water (y = 6234.3x; R2 = 0.9923) was used. Limit of 
detection (LOD = 1 ng/mL) and limit of quantification (LOQ = 5 ng/mL) were 
determined following USP guidelines. For 8-OHdG quantification, the fragmentation of 
8-OHdG [M+H]+ ion was monitored (m/z 284 → 168) and a standard titration curve 
obtained eluting 1 - 100 ng/mL 8-OHdG solutions in water (y = 53429x; R2 = 0.9981) 
was used. Limit of detection (LOD = 0.3 ng/mL) and limit of quantification (LOQ = 1 
ng/mL) were determined following USP guidelines. Before analyses, urine samples 
were centrifuged at 13,000 rpm for 5 minutes and supernatants were directly injected in 
the instrument.  
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RESULTS AND DISCUSSION 
 
 
1. Polygonum cuspidatum 
 
1.1. Animal weight and urinary output 
 
     As reported in Table 2, no significant differences were observed either in body 
weight or in 24-h urine volume in the treated vs control group during the experiment.  
 
Table 2. Variations of body weight and 24-h urine volume of control and treated rats during the 
experiment. Values are reported as means ± SD. 
 Body weight (g) Urine volume (mL) 
Day Control Treated Control Treated 
0 108.5 ± 1.2 107.5 ± 2.0 5.5 ± 0.7 6.4 ± 1.4 
7 162.8 ± 12.9 164.8 ± 14.4 9.3 ± 2.8 11.4 ± 4.6 
14 205.8 ± 21.2 208.6 ± 27.1 12.3 ± 3.7 10.1 ± 1.8 
21 250.3 ± 34.5 248.0 ± 43.1 12.2 ± 2.3 13.5 ± 3.1 
28 283.8 ± 38.1 287.7 ± 42.3 10.8 ± 1.4 13.4 ± 1.8 
35 309.0 ± 53.9 303.5 ± 61.7 13.8 ± 3.8 12.7 ± 1.9 
49 332.0 ± 66.0 340.3 ± 69.6 15.8 ± 8.0 12.9 ± 1.9 
 
1.2. UPLC-HRMS measurements on 24-h urine samples 
 
Exemplificative chromatograms obtained from UPLC-MS analysis of 24-h urine 
samples are reported in Figure 22. A first exploratory data analysis by PCA revealed no 
presence of outliers, while PLS-DA did not detect differences in the metabolite content 
of urine at day 0 between the two groups of rats. 
As a first step of data analysis, we searched for expected metabolites directly 
related to the resveratrol metabolism in the treated group. Significant variables were 
tentatively identified as resveratrol phase II metabolites, namely resveratrol-glucuronide 
([M+H]+ m/z 405.1180 and the fragment at m/z 229.0866), resveratrol-sulfate ([M+H]+ 
m/z 309.0414 and the fragment at m/z 229.0866) and dihydroresveratrol-glucuronide 
([M+H]+ m/z 407.1344 and the fragment at m/z 231.1022), a metabolite derived from 
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the action of gut microbiota and phase II metabolic processing in the liver (Andres-
Lacueva et al., 2012). No significant traces of un-metabolized resveratrol were detected 
in rat urine samples. 
 
 
Figure 22. Typical base peak intensity (BPI) chromatograms obtained from UPLC-HRMS analysis of rat 
urine from both treated (upper panel) and control rats (lower panel). 
 
After the exclusion from the model of these resveratrol metabolites, data 
modeling was performed by ptPLS2. The obtained model highlighted a clear effect of 
both time and treatment on the urine composition. The interaction term time x treatment 
was insignificant (Q27-fold=0.003). The model showed 2 parallel and 3 orthogonal 
components. Specifically, the model showed R2=0.89 and Q27-fold=0.76 for time while 
for the treatment resulted R2=0.89 and Q27-fold=0.68. Figure 23 reports the score scatter 
plot of the model, where the evolution of the urine composition during the experiment 
can be explained by considering two main effects, one related to the dietary intervention 
and one related to the time passing. By Monte-Carlo stability selection, a reduced set of 
34 measured variables was detected as relevant in the explanation of the effects of time 
and treatment in the metabolite content of the collected urine. These were tentatively 
identified comparing the exact m/z value and fragmentation patterns with web-available 
databases and interpreting their MSe spectra. 
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Figure 23. Score scatter plot of the ptPLS2 model for UPLC-HRMS data. The plot shows modifications 
of the urine composition both due to treatment and to time passing. Symbols of different shapes represent 
metabolic changes in urine along time.  
 
Hypoxanthine, indole-3-carboxylic acid, 6-hydroxymelatonin, tetrahydrocortisol, 
17-beta-methylestra-1,3,5(10)-trien-3-ol, sebacic acid, 3-oxo-5beta-chol-6-en-24-oic 
acid, 11-dehydrocorticosterone and 19-hydroxytestosterone predominantly contributed 
to the observed urinary metabolite differences related to P. cuspidatum extract 
supplementation (Table 3). The most significant variables related to time passing, thus 
potentially related to animal aging, are reported in Table 4. 
 
Table 3. Significant variables (p-value < 0.05) related to treatment with P. cuspidatum, obtained from the 
ptPLS2 VIP-based model for UPLC-HRMS data (T>C means higher amounts in Treated than in Control, 
while T<C means higher amounts in Control than in Treated). 
Retention 
Time 
(min) 
m/z  Putative identification Compound ID (Database)  Relative amount 
2.26 137.0460 Hypoxanthine HMDB00157 (HMDB) T < C 
6.92 162.0554 Indole-3-carboxylic acid HMDB03320 (HMDB) T < C 
8.58 249.1242 6-Hydroxymelatonin HMDB04081 (HMDB) T > C 
11.17 271.2060 17-beta-methylestra-1,3,5(10)-trien-3-ol 70515 (Metlin) T > C 
11.19 733.4891 Tetrahydrocortisol ([2M+H]+) HMDB00949 (HMDB) T < C 
11.34 225.1102 Sebacic acid ([M+Na]+) HMDB00792 (HMDB) T < C 
12.77 355.2634 3-oxo-5beta-chol-6-en-24-oic acid  ([M+H-H2O]+) 
84685 (Metlin) T > C 
12.80 345.2064 11-Dehydrocorticosterone HMDB04029 (HMDB) T < C 
13.17 305.2116 19-Hydroxytestosterone HMDB06769 (HMDB) T < C 
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Table 4. Significant variables (p-value < 0.05) related to time passing during the experiment, obtained 
from the ptPLS2 VIP-based model for UPLC-HRMS data (↑ means increased amounts over time, while 
↓ means decreased amounts over time). 
Retention 
Time 
(min) 
m/z Putative identification  Compound ID (Database) Time effect 
 
3.08 413.1239 Unknown  - ↑  
4.45 318.1555 Isoleucyl-Tryptophan  HMDB28918 (HMDB) ↑  
4.65 372.2385 Unknown  - ↑  
5.80 260.1501 Unknown  - ↑  
7.06 242.1757 (±)-Hexanoylcarnitine  ([M+H-H2O]+) 
 85174 (Metlin) ↑  
8.85 409.1832 Unknown  - ↓  
10.53 435.1285 Unknown  - ↓  
13.39 410.2693 Unknown  - ↑  
13.50 488.2987 Glycocholic acid ([M+Na]+)  HMDB00138 (HMDB) ↑  
	  
 
1.3. 1H-NMR measurements on 24-h urine samples 
 
Exemplificative 1H-NMR spectra in which metabolites responsible of time and 
treatment effects are highlighted are reported in Figures 24A and 24B.  
 
 
Figure 24A. Typical 1D 1H-NMR spectrum of rat urine with enlargements of the aliphatic (0.6 – 4.5 
ppm, above panel) regions. The resonances according to the time (red), treatment (black) and both effect 
(blue) effect were assigned. 
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Figure 24B. Typical 1D 1H-NMR spectrum of rat urine with enlargements of aromatic (5.5–9.5 ppm, 
lower panel) regions. The resonances according to the time (red), treatment (black) and both effect (blue) 
effect were assigned. 
 
In the 1D spectra of treated rats urine, the resonances of resveratrol metabolites 
are evident (Figure 25). The NOESY spectrum confirms the presence of resveratrol-
glucuronide and dihydroresveratrol-glucuronide (Figure 26). 
	  
Figure 25. Representative 600 MHz 1H-NMR spectra of rat urine before (black) and after (red) oral 
administration of P. cuspidatum. In the aromatic region (6.20 – 7.40 ppm) the presence of resveratrol 
derivatives in the treated spectrum is evident. 
 
PCA analysis revealed no outliers or differences in the metabolite content of the 
urine collected at the beginning of the experiment. Data modeling performed by ptPLS2 
highlighted a clear effect of both time and treatment on the urine composition, as 
observed for UPLC-MS dataset. The interaction term time x treatment was insignificant 
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(Q27-fold = -0.02). The model showed 2 parallel and 1 orthogonal components, R2 = 0.87 
and Q27-fold = 0.81 for time and R2 = 0.60 and Q27-fold = 0.28 for treatment. Figure 27 
reports the score scatter plot of the model. It is possible to observe that two main 
effects, one related to the time passing and one related to the dietary intervention, 
concur to determine the evolution of the urine composition during the experiment.   
 
 
Figure 26. Portion of a NOESY spectrum in which NOE correlations of resveratrol (RES) and 
dihydroresveratrol (DHR) with glucuronic acid (glu) are shown. 
 
Monte-Carlo stability selection allowed us to select a reduced set of 21 bins. The 
bins related to the treatment effect are reported in Table 5 while those explaining the 
aging effect are reported in Table 6. The metabolites were identified with the help of an 
online database (HMDB), literature (Van Dorsten et al., 2006), 2D-NMR spectra, or 
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spiking.  
 
 
Figure 27. Score scatter plot of the ptPLS2 model for 1H-NMR data set. The plot shows modifications of 
the urine composition both due to treatment and to aging. Symbols of different shapes represent 
metabolic changing in urine along time. 
 
Table 5. Significant variables (p-value<0.05) related to treatment with P. cuspidatum, obtained from the 
ptPLS2 VIP-based model for the 1H-NMR data (T>C means higher amounts in Treated than in Control, 
while T<C means higher amounts in Control than in Treated). 
Bin Chemical shift (ppm) Metabolite Treated vs. Control 
[1.22- 1.28] 1.23 (d) 3-Hydroxybutyrate ↑ 
[2.46- 2.51] 2.48 (t) Dicarboxilic acid ↓ 
[3.20- 3.24] 3.22 (s) Glucose ↓ 
[3.30- 3.34] 3.32 (s) Unknown ↑ 
[3.52- 3.56] 3.56 (s) Glycine ↑ 
[4.00-4.04] 4.02 (m)  Glutamate ↑ 
[5.22- 5.26] 5.25 (d) Glucose/Glucuronate ↑ 
[8.25- 8.29] 8.26 (s) Formate ↑ 
[8.75- 8.79] 8.76 (t) Hippurate ↑ 
 
 
Table 6. Significant variables (p-value<0.05) related to rat aging, obtained from the ptPLS2 VIP-based 
model for 1H-NMR data (↑ means increased amounts over time, while ↓ means decreased amounts over 
time). 
Bin Chemical shift (ppm) Metabolite Time effect 
[1.40-1.44] 1.42 (d) Lactate ↑ 
[2.07-2.11] 2.10 (s) Acetate ↑ 
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[2.27-2.31] 2.28 (brs) Dicarboxylic acid ↓ 
[2.65-2.69] 2.68 (s) Succinate ↓ 
[2.69-2.73] 2.71 (t) 2-Oxoglutarate ↓ 
[2.82-2.86] 2.86 (d) Citrate ↓ 
[2.94-2.97] 2.95 (s) Dimethyl glycine ↑ 
[3.11-3.14] 3.13 (s) Creatinine ↑ 
[3.20-3.24] 3.22 (s) Glucose ↑ 
[3.25-3.30] 3.28 (t)/ 3.29 (s) Taurine/Betaine ↑ 
[3.41-3.46] 3.44 (t) Taurine ↑ 
[8.75- 8.79] 8.76 (t) Hippurate ↓ 
 
 
1.4. Focus on the effects of P. cuspidatum supplementation on rat aging 
 
  
 
Figure 28. Score scatter plots of the OPLS-DA models of urine samples collected from control (upper 
left) and treated rats (upper right), respectively, at the first and last weeks of treatment. The OPLS-DA 
plot in the lower panel compares urine samples collected at the last week of treatment from both control 
and treated animals. C1: control rats, 1st week of experiment; C7: control rats, 7th week of experiment; T1: 
treated rats, 1st week of experiment; T7: treated rats, 7th week of experiment. 
 
Data regarding urine collected at the beginning of the experiment and at the last 
week (49th day) were selected from UPLC-MS dataset, and they were compared by 
multivariate analysis. OPLS-DA models comparing only control (R2 = 0.75 and Q27-fold 
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= 0.50) and only treated urine samples (R2 = 0.78 and Q27-fold = 0.44) were built, and 
significant descriptors of time-passing were selected and further identified. A third 
OPLS-DA model was finally built to compare urinary output collected from both 
treated and control rats at the end of the experiment (R2 = 0.54 and Q27-fold = 0.38).  
As shown in Figure 28, all the models indicated changes of urine composition 
related to animal aging and differences between urine samples collected from the two 
groups at the end of supplementation period, as well as between treated and control 
animals at the last week. From each model, different sets of variables describing time 
effects were selected, but only significant variables that were detectable in both the 
OPLS-DA comprising controls and treated animals separately were considered as 
descriptive and further identified (Table 7). 
 
Table 7. Significant (p-value<0.05) variables descriptive for rat aging selected from OPLS-DA models of 
urine samples collected from control and treated rats, respectively, at the first and last days of treatment. 
Retention Time 
(min) m/z Putative identification 
Compound ID 
(HMDB) 
Time effect, 
control (%)* 
Time effect, 
treated (%)* 
 
3.13 153.0660 N-Methyl-2-pyridone-5-carboxamide HMDB 0004193 +146 +102 
 
3.30 220.1182 Panthotenic acid HMDB0000210 -77 -78  
3.50 297.1450 Tetradecanedioic acid ([M+K]+) HMDB0000872 -64 -63 
 
5.00 206.0454 Xanthurenic acid HMDB0000881 -106 -105  
5.41 190.0501 Kynurenic acid HMDB0000715 +281 +282  
5.80 260.1500 3-Hydroxysebacic acid ([M+ACN+H]+) HMDB0000350 +2835 +3565 
 
5.83 180.0660 Hippuric acid HMDB0000714 -62 -69  
5.84 123.0442 Benzoic acid HMDB0001870 -79 -80  
6.64 194.0821 Phenylacetylglycine HMDB0000821 +96 +39  
7.30 162.0554 4,6-Dihydroxyquinoline HMDB0004077  +262 +150  
11.17 733.4890 Tetrahydrocortisol ([2M+H]+) HMDB0000949 +60799 +6187 
 
Values are reported as % obtained comparing peak AUC at the end of the experiment to peak AUC at the beginning 
of the experiment. Positive values indicate an increase, negative values a decrease. 
 
 
Some of the identified variables were already described by other authors as 
putative markers of aging. Most importantly, blood amounts of N-methyl-2-pyridone-5-
carboxamide (2PY), a major catabolite of nicotinamide, a component of NAD, were 
reported to increase both in rats and humans with aging. The results reported by 
Slominska and collaborators show that plasma 2PY concentration in healthy young rats 
(2 months) was 0.55 ± 0.07 µmol/L, while in older rats (24 months) it was 0.84 ± 0.15 
µmol/L, although data regarding urinary excretion of the metabolite were not reported 
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(Slominska et al., 2004). Considering these data, and due to a different % increase in the 
excretion of 2PY between control and treated rats in our experiment (Table 7), the 
excretion of the metabolite was monitored throughout experimental period, by 
extracting peak AUC from the dataset. The obtained results showed an increased age-
related excretion of the metabolite (Figure 29), and different urinary amounts between 
control and treated animals were observed from the 4th week of treatment. However, 
this difference resulted to be significant only at the last week of experiment, being mean 
AUC 2PY/AUC creatinine values 53.8 and 35.7, in control and treated urine samples 
respectively. 
 
 
Figure 29. Urinary excretion profiles of 2PY throughout experimental period. The values are reported in 
the graph as means ± SD. 
 
Similarly, urinary excretion of phenylacetylglycine was monitored throughout 
experimental period. This metabolite, as hippuric and benzoic acids, derives from gut 
microbiota metabolism, and their variation in urine correlates with a modification of 
microbial activity with aging of animals (Zhang et al., 2012). As observed for 2PY, an 
increasing trend in the excretion of phenylacetylglycine was observed with animal aging 
(Figure 30), as previously described by Zhang and coll. (Zhang et al., 2012). However, 
from the 4th week of treatment, differences between control and treated rats were 
detectable, and significant lower amounts of the metabolite in urine were detected in 
treated urine at the end of the experiment (AUC phenylacetylglycine/AUC creatinine 
values were 110.3 and 70.8, in control and treated urine samples respectively). 
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Figure 30. Urinary excretion profiles of phenylacetylglycine throughout experimental period. The values 
are reported in the graph as means ± SD. 
 
1.5. Quantification of allantoin and 8-OHdG in 24-h urine samples 
 
The amounts of the two oxidative stress markers in collected urine samples, 
allantoin and 8-OHdG, were assessed monitoring their major fragments at the beginning 
and at the end of the experiment (day 49) with a specific HPLC-MS/MS method 
([M+H]+ at m/z 159/116 for allantoin and [M+H]+ at m/z 284/168 for 8-OHdG). Data 
are summarized in Table 8 and in Figure 31.  
 
Table 8. Urinary variations of 8-OHdG and allantoin from the beginning of the experiment (day 0) to the 
end (day 49). Results obtained from rats supplemented with P. cuspidatum extract (treated) are compared 
to results obtained from the control group (control). Values are represented as means ± SEM. p-values 
calculated in unpaired t test. p < 0.05 (*), p < 0.001 (***). 
8-OHdG Day 0 Day 49 t-test p-value 
Control 9.54 ± 0.49 ng/mL 10.35 ± 1.05 ng/mL 0.47 
Treated 10.83 ± 0.54 ng/mL 8.64 ± 0.92 ng/mL 0.05* 
    
Allantoin Day 0 Day 49 t-test p-value 
Control 1.75 ± 0.08 µg/mL 1.01 ± 0.18 µg/mL 0.02* 
Treated 1.54 ± 0.06 µg/mL 0.41 ± 0.05 µg/mL <0.0001*** 
 
 
The content of 8-OHdG in the urine weakly decreased for the treated rats (t-test p-
value = 0.05) while it did not change for the control rats (t-test p-value = 0.47). At the 
beginning of the experiment, the urinary concentration of 8-OHdG was 10.83 ± 0.54 
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ng/mL for the treated rats and it weakly decreased to 8.64 ± 0.92 ng/mL at the 49th day 
of treatment. Allantoin concentration significantly decreased for both control and 
treated rats (t-test p-value = 0.02 and test p-value < 0.001, respectively). Specifically, 
for control rats the allantoin concentration decreased from 1.75 ± 0.08 µg/mL to 1.01 ± 
0.18 µg/mL while for treated rats from 1.54 ± 0.06 µg/mL to 0.41 ± 0.05 µg/mL. 
Overall, the reduction of the concentration of these two markers was more relevant for 
treated rats than control rats, suggesting a reduction of oxidative stress related to 
supplementation with P. cuspidatum. 
 
	   	  
	  	   	  
Figure 31. Urinary variations of 8-OHdG (upper panel) and allantoin (lower panel) from the beginning of 
the experiment to the end. Results obtained from rats treated with P. cuspidatum extract (T0 and Tend) 
are compared to results obtained from the control group (C0 and Cend). Values are represented as means 
± SEM. p-values calculated in unpaired t test. p < 0.05 (*), p < 0.001 (***). 
 
1.6. Discussion 
 
Differences in the treated vs control animals were observed using both UPLC-
HRMS and 1H-NMR platforms. The ptPLS2 models revealed both treatment and time-
related modifications, showing a valuable application of metabolomics to both 
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nutraceutical and aging studies. Nevertheless, the two analytical techniques revealed 
different metabolites. From the UPLC-HRMS dataset, decreased levels of hypoxantine 
and indole-3-carboxylic acid were observed and were correlated to treatment. 
Hypoxanthine is normally detected in urine and blood, but increased levels could be 
related to oxidative stress (Gerritsen et al., 1997, Saiki et al., 2001). Also increased 
urinary levels of indole-3-carboxylic acid, a tryptophan metabolite normally detected in 
urine (Byrd et al., 1974), can be related to oxidative stress and were reported in diet-
induced hyperlipidemic rats (Miao et al., 2014). These data suggest that 
supplementation with P. cuspidatum extract reduces oxidative stress in healthy rats. In 
order to confirm this observation, measurements of specific oxidative stress markers, 
namely allantoin and 8-OHdG, were performed. Allantoin is formed from the stepwise 
degradation of uric acid due to the reaction with oxidative species (Kim et al., 2009) and 
is present in urine of healthy subjects. Its level is increased with increasing oxidative 
stress in the body (Tolun et al., 2010). 8-OHdG is formed by the 8-hydroxylation of the 
guanine base by reactive oxygen species, and its a product of mitochondrial and nuclear 
DNA oxidative damage (Zhang et al., 2013). The oxidized nucleoside is enzymatically 
cleaved from the DNA chains, is released in the bloodstream, and is eliminated in the 
urine (Zhang et al., 2013). This biomarker is normally present in urine of healthy 
people, and variations of its urinary levels suggest alterations of the oxidative status. 
Thus the observed reduction of the urinary levels of both these metabolites in the treated 
group supports an in vivo antioxidant effect of P. cuspidatum supplementation. 
6-hydroxymelatonin (a hydroxylated hepatic metabolite of melatonin, mainly 
excreted in urine) increased in urine from treated group. Previous studies reported that 
melatonin and its metabolites exert both immunomodulatory and antioxidant activities 
(Ozkan et al., 2012, Reiter et al., 2008). Its meaning in the P. cuspidatum mode of 
action needs to be further investigated in depth. 
Another series of metabolites related to treatment were identified as steroid 
derivatives. Tetrahydrocortisol, 17-beta-methylestra-1,3,5(10)-trien-3-ol, 11-
dehydrocorticosterone and 19-hydroxytestosterone, a metabolite derived from androgen 
and estrogen metabolisms (Watanabe et al., 1994), were detected in lower amounts in 
treated rat urine. A biliary acid derivative was also identified, 3-oxo-5beta-chol-6-en-
24-oic acid, and its urinary amount was increased in the treated group. 
Tetrahydrocortisol is a urinary metabolite of cortisol (Pavlovic et al., 2013) and its 
urinary levels can be increased by ACTH administration (Gomez-Sanchez et al., 1988). 
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This preliminary observation suggests a role for P. cuspidatum extract as stimulant of 
corticosurrenal hormones, thus being related to anti-stress or “adaptogenic” activity as 
Ginseng or similar herbal products (Nocerino et al., 2000). The role of resveratrol on 
cortisol biosynthesis was previously investigated in vitro showing that the compound is 
able to stimulate cortisol biosynthesis by activating SIRT-dependent deacetylation of 
P450scc (Li et al., 2012). The change in sterol and corticosterol levels may be related to 
some of the health promoting effects of resveratrol.  
The amounts of sebacic acid were decreased in urine after treatment. This 
metabolite is a medium chain dicarboxylic acid normally detected in urine. Sebacic acid 
and dodecanedioic acid are naturally occurring substances formed by cytochrome P-
450-mediated ω-oxidation of fatty acids in the cytosol. The levels of urinary medium 
chain dicarboxylic acid can raise when the fatty acid utilization is increased beyond the 
capacity of mitochondrial β-oxidation such as during starvation or diabetes, and it can 
be observed also during treatments with drugs that are able to inhibit fatty acid β-
oxidation (as valproic acid) (Clarke, 2005). This result indicates that P. cuspidatum 
supplementation may have a role on energetic metabolism in rats. Furthermore, the 
indication that the decreased levels of dicarboxylic acids in urine are in general 
associated with starvation may be interpreted as an indirect confirm of the known 
effects of resveratrol on decreasing blood glucose and increasing lipolysis and fatty acid 
oxidation (Szkudelska and Szkudelski, 2010). In this case, the UPLC-HRMS data are in 
agreement with the 1H-NMR data, that revealed the glucose and dicarboxylic acid 
decrement related to P. cuspidatum supplementation.  
1H-NMR showed the increase of 3-hydroxybutyrate (3-HB) in treated group. This 
metabolite is synthesized in the liver from acetyl-CoA, and can be used as an energy 
source by the brain when blood glucose is low. The increase of 3-HB is normally 
detected in ketosis thus indicating a glucose shortage, thus this effect could be 
considered as related to the possible reduction of blood glucose induced by resveratrol 
administration, as reported by other authors (Szkudelska and Szkudelski, 2010). 
Increased amount of hippurate in treated group was revealed. This observation is in 
agreement with literature data that reported the increased urinary level of hippuric acid 
due to consumption of phenolic compounds (for example from tea, wine, fruit juices) 
(Daykin et al., 2005, Krupp et al., 2012). The increased urinary excretion of hippurate 
should also be related to interaction of the treatment with gut microbiota. In fact, in a 
previously published paper hippuric acid excretion was not detected in volunteers 
Results and Discussion 
	   81 
without colon, meaning that it was formed by metabolisation inside the colon (Olthof et 
al., 2003). 
Changes in urine composition were also related to time passing, as observed by 
both UPLC-MS and NMR. Considering the UPLC-HRMS data set, several variables 
related to aging were detected but only few of them were identified. Among them, (±)-
hexanoylcarnitine was found increasing in urine over time, as previously described, due 
to an age-related gradual decline in kidney function leading to alterations in carnitine 
and acylcarnitines homeostasis (Lee et al., 2014). Furthermore, an increasing tendency 
of urinary medium-chain acylcarnitines due to aging was reported (Lee et al., 2014). 
Other two metabolites related to rat aging were identified from the UPLC-HRMS data 
set as isoleucyl-tryptophan and glycocholic acid, but further studies are needed to assess 
their role in aging processes. Many aging-related metabolites were identified by 1H-
NMR as lactate, acetate, 2-oxoglutarate, citrate, succinate and glucose, accordingly to 
previously published results (Bell et al., 1991, Wu et al., 2008). Furthermore, the 
increasing amounts of urinary creatinine observed with aging may be related to the 
greater output from the growing muscles of the larger rats and to the age-related 
increasing of glomerular filtration rate (Bell et al., 1991). Dimethyl glycine and 
hippurate are related to the gut microbiota activity, and in previously published papers 
they were considered as age-related urinary metabolites (Zhang et al., 2012). Taurine 
has been reported as a marker of liver function and its increased urinary amounts may 
be related to a decreased liver function related to aging (Schnackenberg et al., 2007). To 
explore more in depth the effects of aging on urine composition, statistical models were 
built considering only samples collected at the beginning and at the end of the 
supplementation period. Among descriptive markers, phenylacetylglycine, 3-
hydroxysebacic acid, hippuric and benzoic acids were correlated to the results obtained 
from previous 1H-NMR analysis, and more specifically, to the markers related to gut 
microbiota activity. Amounts of N-Methyl-2-pyridone-5-carboxamide, a major 
catabolite of nicotinamide and an aging marker previously described by other authors 
(Slominska et al., 2004), were found to be increased in urine with aging of rats, but 
differences between control and treated groups were observed. The increasing trend of 
excretion of this marker with animal aging was observed to be lower in treated rats 
compared to controls, indicating a possible protective effect of P. cuspidatum on age-
dependent DNA damage. In fact, N-methyl-2-pyridone-5-carboxamide is produced 
from the metabolism of NAD, which is a substrate for the poly(ADP-ribosyl)ation 
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reaction catalyzed by poly(ADP-ribose) polymerase (PARP-1), aimed to DNA 
repairing. In case of oxidative DNA damage caused by aging, the activation of PARP-1 
is induced, and consequently the use of NAD as substrate is increased (Slominska et al., 
2004). The observed decrease in the excretion of N-methyl-2-pyridone-5-carboxamide 
in animals treated with P. cuspidatum can be related to its anti-oxidant activity and to 
the consequent scavenging activity against ROS, thus preventing DNA damaging. 
A similar trend was observed for another marker, namely phenylacetylglycine, 
and also in this case significant lower amounts in urine from treated rats were detected 
at the 49th day of supplementation. This metabolite was already reported as aging 
marker by Zhang and coll. (Zhang et al., 2012), whose observed that, in urine of rats 
undergoing caloric restriction, its amounts were significantly lower (processed AUC 
normalized and logarithm transformed were 25.98±10.79 in control rats and 
15.27±13.39 in rats undergoing caloric restriction). Thus, the reduced excretion of 
phenylacetylglycine observed in the group supplemented with P. cuspidatum in our 
experiment can be linked to the caloric restriction mimetic role of resveratrol and to the 
consequent decrease of blood glucose and increase of lipolysis and fatty acid oxidation 
(Szkudelska and Szkudelski, 2010), as we observed with untargeted analysis. However, 
although these metabolic activities could be linked to the “anti-aging” effects of 
resveratrol, an in depth investigation on the involvement of phenylacetylglycine is 
needed.  
In conclusion, UPLC-MS and NMR showed their complementarity yielding two 
different patterns of metabolites describing the changes ascribed to P.cuspidatum 
supplementation and to time passing, being this latter somehow a representation of 
aging processes. The UPLC-HRMS data allowed the exploration of different patterns of 
metabolites during the experiment. The metabolites observed in the untargeted 
metabolomics data and the decreased levels of urinary oxidative stress markers are 
indicative of in vivo antioxidant effect of P. cuspidatum in healthy rats. However, no 
oxidized resveratrol or oxidized resveratrol metabolites were detected, suggesting a 
negligible role of its “direct” antioxidant activity. Moreover, UPLC-HRMS approach 
allowed the identification of steroid derivatives as markers of treatment. On the other 
hand, urinary changes observed with 1H-NMR measurements were related to hippuric 
acid increase, as previously reported for other polyphenol supplementation, and to some 
metabolites that suggest a relationship between P. cuspidatum treatment and energy 
metabolism such as glucose levels and fatty acid oxidation. 
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2. Vaccinium macrocarpon (Cranberry) 
 
2.1. Supplementation of healthy rats with a standardized dry cranberry 
extract 
 
2.1.1. Profiling of PACs in cranberry extract 
 
The total PAC-A content was 11.3 ± 1.3% w/w of dry cranberry extract, whereas 
the total content of PAC-B was 4.3 ± 0.4% w/w. PAC-A dimers constituted the 4.5 ± 
0.7% w/w of dry extract, trimers were 3.6 ± 0.2% w/w and tetramers 3.2 ± 0.2% w/w. 
PAC-B dimers constituted the 1.3 ± 0.3% w/w of dry extract, trimers were 1.8 ± 0.1% 
and tetramers 1.2 ± 0.1% w/w. 
 
2.1.2. Profiling of 24-h urine by UPLC-ESI-QTOF 
 
 
 
Figure 32. Exemplificative score scatter plots obtained from the PCA of UPLC-MS data recorded in 
negative ion mode. The plots show cranberry extract treated group (red dots) and control group (blue 
dots) at day 0, 7, 14, 21 and 35.  
 
24-h urine samples collected during the 35 days of cranberry supplementation 
were analyzed by UPLC coupled with ESI-QTOF-MS, and urinary metabolite profiles 
of both treated and control animals were obtained. Mass spectrometric data were 
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acquired both in positive and negative ion modes, in order to consider the largest 
number of metabolites, and two different datasets were obtained and used for 
multivariate analysis. Exploratory data analysis by PCA on urine samples collected at 
days 0, 7, 14, 21 and 35 resulted in partial grouping of treated versus controls (Figure 
32), supporting the changes of urine composition after oral administration of cranberry 
extract.  
 
 
Figure 33. Score scatter plot obtained from PLS-DA modeling of “positive” dataset. The plot shows 
cranberry extract treated group (red dots) and control group (black squares).  
 
Data modeling was subsequently performed by Partial Least Squares Discriminant 
Analysis (PLS-DA). The PLS-DA model for the “positive ion mode” dataset could 
explain 71% of the data variance using 3 components and the variance predicted was 
36%. Y-axis intercepts after permutation test were R2 = (0.0, 0.408) and Q2 = (0.0, 
0.216). On the other hand, the PLS-DA model built from the “negative ion mode” 
dataset could explain 80% of the data variance using 3 components and the variance 
predicted was 53%. Y-axis intercepts after permutation test were R2 = (0.0, 0.468) and 
Q2 = (0.0, 0.308). Representative PLS-DA score scatter plots for the positive and 
negative datasets are reported in Figure 33 and 34, respectively. The plots show that 
urine samples collected during treatment and controls are grouped in two clusters, 
although they partially overlap.  
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Figure 34. Score scatter plot obtained from PLS-DA modeling of “negative” dataset. The plot shows 
cranberry treated group (red dots) and control group (black squares).  
 
Time x mass variables contributing to group separation were selected on the basis 
of their variable importance on projection (VIP) value. Only variables bearing VIP 
values > 2.0 were considered significant in differentiating the two groups and were 
subsequently putatively identified. The selected variables are listed in Table 9A and 9B.  
 
Table 9A. Variables related to treatment with cranberry extract, obtained from the PLS-DA model for 
UPLC-MS data acquired in positive ion mode. 
R.T. 
(min) 
Measure
d HR 
m/z 
Significant 
fragments, m/z VIP 
Amount 
T vs C# 
p-value 
 
Putative 
identification 
Compound ID 
(Database) 
        
2.2 146.0687 112.3876 2.3 ↑ 0.890 Unknown - 
3.3 271.1205 166.0743, 138.0784, 114.0430 2.0 ↑ 0.042
* Unknown - 
2.3 282.1004 150.0538, 114.0426 2.2 ↑ 0.001* 1-Methyladenosine 
HMDB03331 
(HMDB) 
5.5 297.1261 286.1209, 279.1148, 126.0316 2.4 ↑ 0.021
* Desmosflavone HMDB38518 (HMDB) 
6.4 338.0716 162.0314, 134.0363 5.4 ↑ 0.002* 
2,8-
Dihydroxyquinoli
ne-beta-D-
glucuronide 
HMDB11658 
(HMDB) 
6.7 340.0869 164.0474, 113.0001 4.6 ↑ 0.290 
5-Hydroxy-6-
methoxyindole 
glucuronide 
HMDB10363 
(HMDB) 
7.0 431.0875 255.0444, 199.0519 4.3 ↑ 0.015* Daidzein 4'-O-glucuronide 
HMDB41717 
(HMDB) 
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7.6 447.0835 271.0399, 91.0316 2.9 ↑ 0.044* Genistein 5-O-glucuronide 
HMDB41738 
(HMDB) 
8.0 146.0364 128.0260, 85.0284 3.0 ↑ 0.221 2-Keto-glutaramic acid 
HMDB01552 
(HMDB) 
9.6 347.2061 121.0778, 105.0467, 91.0317 2.1 ↑ 0.050
* Corticosterone HMDB01547 (HMDB) 
10.3 701.5128 373.2208, 333.2260 2.0 ↑ 0.900 Unknown - 
5.3 154.0266 127.0155, 92.0268, 84.0586 3.2 ↓ 0.755 Unknown - 
6.3 206.0224 178.0267, 160.0156, 132.0208 4.3 ↓ 0.235 Xanthurenic acid 
HMDB00881 
(HMDB) 
6.5 190.0268 162.0315, 144.0206, 116.0261 3.2 ↓ 0.664 Kynurenic acid 
HMDB00715 
(HMDB) 
7.3 162.0316 144.0204, 134.0365 2.7 ↓ 0.006* 
2,8-
Dihydroxyquinoli
ne 
66378 (Metlin) 
7.5 164.0470 146.0360, 118.0411 4.4 ↓ 0.008* 5-Hydroxy-6-methoxyindole 
144618 
(Chemspider) 
8.7 255.0448 199.0528, 181.0418, 136.9998 4.2 ↓ 0.023
* Daidzein HMDB03312 (HMDB) 
8.7 285.0568 270.0324, 153.0461 2.5 ↓ 0.030* Unknown - 
9.6 271.0402 152.9947, 91.0318 4.2 ↓ 0.035* Genistein HMDB03217 (HMDB) 
10.1 373.2597 355.2486, 213.1415, 159.0931, 145.0775 2.7 ↓ 0.096 
Prostaglandin 
derivative   - 
10.2 371.2441 353.2316, 211.1254, 145.0772 2.8 ↓ 0.020
* Prostaglandin derivative   - 
*Significant level < 0.05, calculated using ANOVA. 
#The level of biomarkers in treated (T) and control (C) urine samples was evaluated by their normalized area. ↑: 
higher amounts in treated group compared to control; ↓: lower amounts in treated group compared to control. 
 
Table 9B. Variables related to treatment with cranberry extract, obtained from the PLS-DA model for 
UPLC-MS data acquired in negative ion mode. 
R.T. 
(min) 
Measured 
HR m/z 
Significant 
fragments, m/z VIP 
Amount 
T vs C# p-value 
Putative 
identification 
Compound ID 
(Database) 
        
2.2 190.9951 
161.9964, 
144.9897, 
110.9843 
2.4 ↑ 0.900 Citric acid HMDB00094 (HMDB) 
5.4 188.9616 109.0049, 96.9363 2.9 ↑ 0.020
* Catechol sulfate HMDB61713 (HMDB) 
5.9 172.9663 
160.0156, 
151.9870, 
93.0109 
4.6 ↑ 0.600 Unknown - 
6.3 289.0184 
209.0586, 
135.0208, 
112.9998 
4.4 ↑ <0.001* 
4-Hydroxy-5-(3'-
hydroxyphenyl)-
valeric acid-3'-O-
sulfate 
HMDB59975 
(HMDB) 
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6.7 241.9892 
162.0311, 
134.0120, 
112.9997 
2.2 ↑ 0.200 Unknown - 
6.7 178.0257 134.0360, 77.0181 2.0 ↑ 0.080 Hippuric acid 
HMDB00714 
(HMDB) 
7.0 271.0058 
191.0469, 
147.0563, 
96.9358 
2.2 ↑ <0.001* 
5-(Hydroxyphenyl)-
gamma-valerolactone-
O-sulfate 
HMDB59993 
(HMDB) 
7.0 461.1758 443.1646, 253.0284 5.4 ↑ 0.050
* Unknown - 
7.1 283.0612 121.0044, 102.9793 2.2 ↑ 0.020
* 2-O-Benzoyl-D-glucose 
HMDB34618 
(HMDB) 
7.7 332.9892 
265.0974, 
223.0852, 
137.0355 
4.6 ↑ 0.070 Unknown - 
7.8 297.0778 121.0407, 102.9792 3.9 ↑ 0.700 Benzoyl glucuronide 
HMDB10324 
(HMDB) 
8.1 187.0727 123.9825, 96.9358 4.3 ↑ 0.200 Azelaic acid 
HMDB00784 
(HMDB) 
6.4 211.9783 132.0203, 79.9341 7.7 ↓ 0.031
* Indoxyl Sulfate HMDB00682 (HMDB) 
8.7 253.0283 
223.0167, 
208.0289, 
90.9950 
5.0 ↓ 0.170 Daidzein HMDB03312 (HMDB) 
9.5 269.0239 159.0196, 133.0039 5.4 ↓ 0.060 Genistein 
HMDB03217 
(HMDB) 
9.7 297.0931 145.0407, 107.0256 4.0 ↓ 0.150 Enterolactone 
HMDB06101 
(HMDB) 
10.1 453.2759 409.2518, 325.1675 3.2 ↓ 0.080 Unknown - 
*Significant level < 0.05, calculated using ANOVA. 
#The level of biomarkers in treated (T) and control (C) urine samples was evaluated by their normalized area. ↑: 
higher amounts in treated group compared to control; ↓: lower amounts in treated group compared to control. 
 
Among the time x mass variables related to dietary intervention, none of them 
was identified as intact PAC-A, suggesting that only negligible amounts of such 
compounds are present in urine of the treated animals. However, two compounds, 
increased in urine after cranberry supplementation, were putatively identified as 4-
hydroxy-5-(3'-hydroxyphenyl)-valeric acid-3'-O-sulfate and 5-(hydroxyphenyl)-gamma-
valerolactone-O-sulfate, which can be related to the intestinal metabolism of PACs 
(Monagas et al., 2010). Other variables related to treatment were putatively identified as 
glucuronide derivatives of isoflavones, namely daidzein 4’-O-glucuronide and genistein 
5-O-glucuronide, whose urinary amounts were significantly increased after cranberry 
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supplementation. Conversely, lower amounts of free genistein and daidzein (introduced 
with the standard diet) were detected in treated rat urine as compared to controls. 
Genistein and daidzein were provided mainly by soy from dietary sources, as confirmed 
by HPLC-MS/MS analysis of fodder (Figure 35). 
 
 
Figure 35. Selected Ion Monitoring chromatograms of daidzein (m/z 253, upper panel) and genistein 
(m/z 269, lower panel) in fodder. Respective MS/MS spectra are reported. 
 
The same trend was observed for other two markers, namely 5-hydroxy-6-
methoxyindole and 2,8-dihydroxyquinoline, a quinoline derivative found in urine of rats 
fed with fodder containing corn (Inagami et al., 1965). These data regarding induction 
of glucuronidation are in agreement with a previously published paper that 
demonstrated glucuronidation induction in ex vivo experiment (Bártíková et al., 2014). 
Catechol sulfate, benzoyl glucuronide (Pimpão et al., 2015) and hippuric acid (Lees et 
al., 2013) are considered biomarkers of polyphenols intake formed by intestinal 
microbiota, and they have been reported in urine. Our data showed a significant 
increased amount of the first and the last metabolite after treatment, while values were 
not statistically significant for benzoyl glucuronide. 
Urinary amounts of tryptophan metabolites, namely xanthurenic and kynurenic 
acids and indoxyl sulfate, were influenced by treatment. Indoxyl sulfate, derived from 
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tryptophan metabolisation by colonic bacteria (Wikoff et al., 2009), showed significant 
decrease suggesting an influence of cranberry consumption on intestinal microbial 
activity.  
 
2.1.3. Anti-adhesive properties of urine from animals treated with cranberry 
extracts 
 
In order to study the anti-adhesive effects of urine samples after a single intake of 
cranberry, 6 healthy Sprague-Dawley rats were fed with a 100 mg/kg dose of cranberry 
extract (containing 15% total PACs) and urinary outputs were collected at 2, 4, 8 and 24 
hours after treatment. Results showed a time dependent ability to decrease bacterial 
adherence to epithelial cells (Figure 36). The adherence of uropathogenic P-fimbriated 
E. coli incubated with urine samples collected at 2 and 4 hours after cranberry intake 
was not significantly changed compared to control urine. However, urine samples 
collected 8 hours after cranberry ingestion caused a significant reduction of E. coli 
adherence to HT-29 cells. A 47% reduction in E. coli binding was still evident by 
incubating bacteria in urine collected 24 hours after cranberry consumption.  
 
 
Figure 36. Histogram representing the adhering ability of uropathogenic E. coli to HT-29 epithelial cells 
after incubation in rat urine samples collected at 2, 4, 8 and 24 hours following oral treatment with 100 
mg/kg cranberry extract or from untreated animals (control). Significance was calculated using t-test. The 
asterisk indicates a p-value <0.05. 
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2.1.4. Metabolomic profiling of urinary output at 2, 4, 8 and 24 hours after a 
single dose of cranberry 
 
In order to evaluate the changes of urinary composition after a single intake of 
cranberry (100 mg/kg dose), the urinary outputs collected at 2, 4, 8 and 24 hours after 
treatment were analyzed by UPLC-QTOF. Control urine samples were collected from 
the same rats before treatment. Exploratory PCA analysis revealed limited differences, 
as reported in Figure 37 (R2 = 0.306; Q2 = 0.202). Considering the significant anti-
adhesive activity measured for the 8 hours samples, data modeling was performed by 
PLS-DA comparing control samples vs 8 hours collection (Figure 37). The resulting 
model could explain 99% of the data variance using 3 components and the variance 
predicted was 73%. Y-axis intercepts after permutation test were R2 = (0.0, 0.992) and 
Q2 = (0.0, 0.333). 
 
 
Figure 37. PCA exploratory plots obtained from urine analysis at 2, 4, 8 and 24 hours after cranberry 
administration to rats (T) compared to control (C). The PLS-DA score plot obtained with 8 hours data of 
treated group versus control is also reported.  
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 Variables contributing to differentiate urine at 8 hours after treatment from 
control were identified as intestinal degradation products of PACs (Monagas et al., 
2010), specifically vanillic acid 4-sulfate, epicatechin, 5-(hydroxyphenyl)-gamma-
valerolactone-O-sulfate, 5-(3’-hydroxyphenyl)-gamma-valerolactone, 4-hydroxy-5-(3'-
hydroxyphenyl)-valeric acid-3'-O-sulfate and 5-(3',4'-dihydroxyphenyl)-gamma-
valerolactone (Table 10). None of the significant variables for the 8 hours samples was 
identified as intact PAC. 
 
Table 10. Significant variables discriminating for urine samples collected at 8 hours after treatment with 
cranberry extract. Data were obtained from the PLS-DA model for UPLC-MS data acquired in negative 
ion mode. 
VIP Measured HR m/z 
Significant 
fragments, 
m/z 
R.T. 
(min) 
Amount 
T vs C# p-value Putative  identification 
Compound ID 
(Database) 
        
8.9 461.1816 
285.0399, 
267.0293, 
135.0082 
5.3 ↑ 0.002* Kaempferol glucuronide HMDB29500 (HMDB) 
8.1 417.1140 241.0825 121.0290 6.3 ↑ 0.002
* Equol glucuronide HMDB41732/41732(HMDB) 
8.0 445.0734 269.0215  7.6 ↑ 0.002* Genistein glucuronide HMDB41738/41739 (HMDB) 
7.9 429.0734 223.0162 4.3 ↑ 0.002* Daidzein glucuronide HMDB41717/41718 (HMDB) 
4.4 160.0391 142.0496 4.0 ↑ <0.001* 4,6-Dihydroxyquinoline HMDB04077 (HMDB) 
3.0 271.0058 
191.0469, 
147.0563, 
96.9358 
7.0 ↑ 
<0.001* 5-(Hydroxyphenyl)-
gamma-valerolactone-
O-sulphate 
HMDB59993 
(HMDB) 
2.3 191.0335 
147.0583, 
96.8655 4.6 ↑ <0.001* 5-(3’-Hydroxyphenyl)-gamma-valerolactone 
HMDB62066 
(HMDB) 
1.8 289.0184 
209.0586, 
135.0208, 
112.9998 6.3 ↑ 
<0.003* 4-Hydroxy-5-(3'-
hydroxyphenyl)-valeric 
acid-3'-O-sulphate 
HMDB59975 
(HMDB) 
1.7 247.0265 
167.0606, 
123.9969, 
108.0111 3.0 ↑ 
<0.001* 
Vanillic acid 4-sulfate HMDB41788 (HMDB) 
1.1 289.1045 
203.1114, 
123.9971, 
109.0549, 
6.2 ↑ 0.002* Epicatechin HMDB01871 (HMDB) 
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0.6 207.0568 189.0504, 106.9703 4.8 ↑ <0.001
* 5-(3',4'-
Dihydroxyphenyl)-
gamma-valerolactone 
HMDB29185 
(HMDB) 
*Significant level < 0.05, calculated using ANOVA. 
#The level of biomarkers in treated (T) and control (C) urine samples was evaluated by their normalized area. ↑: 
higher amounts in the treated group compared to control; ↓: lower amounts in the treated group compared to 
control. 
 
2.1.5. Quantification of PAC-A in urinary output at 2, 4, 6, 8 and 24 hours after 
single dose of cranberry  
 
        In order to evaluate the amounts of intact PAC-A in urinary outputs at 2, 4, 6, 8 
and 24 hours after treatment, a targeted HPLC-MS/MS method was used. The 
chromatographic method allowed the detection of PAC-A dimers, trimers and tetramers 
in urine (a representative chromatogram is reported in Figure 38). 
 
 
Figure 38. Multi Reaction Monitoring traces extracted from the analysis of rat urine spiked with 
cranberry extract. Track A shows dimeric PAC-A (m/z transition 575 > 285), track B shows trimeric 
PAC-A (m/z transition 863 > 289) and track C shows tetrameric PAC-A (m/z transition 1151 > 285). 
 
Because of the lack of reference standards for trimeric and larger oligomeric 
PAC-A, the only available standard PAC-A dimer (PAC-A2) was used for the 
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quantification of dimers and an estimation of the amount of other oligomeric 
derivatives. Before HPLC-MS/MS analysis, urine was purified from low molecular 
weight polyphenols (Wallace and Giusti, 2010), in order to increase mass spectrometric 
sensitivity in PACs detection; the method allowed us to detect PAC-A2 down to 0.2 
ng/mL in urine. Measurements on urine samples collected 24 hours after the 
administration of cranberry extract resulted in an average PAC-A2 concentration of 
1.58 ± 0.44 ng/mL. The highest concentration of intact PAC-A2, 4.04 ± 2.87 ng/mL, 
was found at 4 hours after cranberry administration while in the control group, PAC-A 
was not detectable. Figure 39 summarizes the results. No other PAC-A or PAC-B were 
revealed. 
 
Figure 39. Urinary PAC-A2 amounts at 2, 4, 6, 8 and 24 h after cranberry extract administration to rats. 
Values are reported as means ± SD, LOQ is indicated in figure. 
 
2.1.6. Discussion 
 
In this study, the effects of supplementation of healthy rats with a cranberry 
extract containing 15% PACs were observed by monitoring the changes of urinary 
metabolome. In a first experiment, healthy rats were orally supplemented with 100 
mg/kg of cranberry extract daily (11.3 mg/kg PAC-A; 4.3 mg/kg PAC-B) for 35 days 
and 24-h urinary outputs were collected weekly. The metabolic composition of urine 
was explored by a UPLC-QTOF metabolomic approach. We observed changes in urine 
composition after treatment using both unsupervised and supervised techniques and 
markers related to treatment were identified. Significant induction of glucuronidation 
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was observed, as demonstrated by increased amounts of isoflavone glucuronides and 
decreased amounts of aglyconic isoflavones in urine samples. These findings are in 
agreement with a previously published paper (Bártíková et al., 2014), which describes 
the treatment of Wistar rats with cranberry extracts in doses of 0.5 mg for 14 days or 1.5 
mg of proanthocyanidins/kg/day for 1 day. Results showed that both cranberry dosages 
significantly enhanced microsomal UDP-glucuronosyl transferase activity, and long-
term consumption of a regular dose had more pronounced effects on enzymatic activity 
than a short-term overdose (Bártíková et al., 2014). Thus, our data confirm that the 
induced glucuronidation activity should be further investigated, considering the large 
use of cranberry in food supplements and because of the possible use by subjects during 
other pharmacological treatments. 
Changes in metabolites related to tryptophan, such as xanthurenic and kynurenic 
acids and indoxyl sulfate (this latter related to colonic bacteria catabolism) were also 
observed, suggesting a role of cranberry constituents on microbiota activity. 
Increased levels of cranberry-derived metabolites were also detected, namely 4-
hydroxy-5-(3'-hydroxyphenyl)-valeric acid-3'-O-sulfate and 5-(hydroxyphenyl)-gamma-
valerolactone-O-sulfate. Conversely, none of the variables describing the effect of 
treatment were identified as intact PAC-A.  
In a second experiment, rats were fed with a single dose of cranberry extract and 
urine samples were collected after 2, 4, 8 and 24 hours. These samples were used to 
perform adhesion assays, by treating uropathogenic E. coli, showing the highest activity 
8 hour after cranberry ingestion. In order to establish the role of intact PAC-A on 
activity, samples were analyzed using a specific targeted LC-MS/MS method. Urinary 
PAC-A2 levels were measured in the collected urine samples (at 2, 4, 8 and 24 hours 
after cranberry administration) of the treated group and the results showed levels in the 
range of ng/mL (the highest concentration detected was 4.04 ± 2.87 ng/mL at 4 hours 
after cranberry administration). The LC-MS/MS results indicated negligible quantities 
of unmodified compound detectable in urine. Those levels are far from the 
concentration used in previous in vitro tests demonstrating the anti-adhesive properties 
of PAC-A. Foo and collaborators described the anti-adhesive effects of some PAC-A 
oligomers isolated from cranberry using an in vitro model and the activity was observed 
with concentrations higher than 0.3 mg/mL (Foo et al., 2000). Our data show that a 
single administration of 100 mg/kg of extract (15 mg/kg of PACs) yielded in a 
maximum amount of 4.04 ± 2.87 ng/mL 4 hours after cranberry intake. This amount is 
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six orders of magnitude lower than the previously published data (Foo et al., 2000). 
Gupta and collaborators observed a dose dependent anti-adhesive activity of cranberry 
in an in vitro model in the range of 5 to 74 µg/mL, still much higher than the values we 
measured (Gupta et al., 2007). In a previously published paper, female Fischer-344 rats 
were treated for 10 months with cranberry extract via gavage (1 g/kg body weight, 1 
gavage/day, five days a week) and urine samples were collected at 18, 25, 42, 48 hours 
after cranberry administration (1 gavage) (Rajbhandari et al., 2011). The authors 
reported that intact PAC-A2 was detected at ng/mL, although the exact concentration 
was not specified (Rajbhandari et al., 2011). 
In our experiment, an untargeted metabolomics approach revealed slight 
differences among urine samples collected at different times after cranberry 
administration. Furthermore, the results of adhesion assays, performed by treating 
uropathogenic E. coli with the same urine samples, showed the highest activity 8 hour 
after cranberry ingestion. Significant differences in the composition of urine samples 
collected at 8 hours with respect to control samples were observed. Among the 
identified metabolites, kaempferol glucuronide, equol glucuronide, daidzein and 
genistein glucuronides were the most discriminant ones, confirming the induction of 
glucuronidation observed in the first dataset. Furthermore, significant descriptors related 
to PACs and phenolic metabolites were identified, namely vanillic acid 4-sulfate, 
epicatechin, 5-(hydroxyphenyl)-gamma-valerolactone-O-sulfate, 5-(3’-hydroxyphenyl)-
gamma-valerolactone, 4-hydroxy-5-(3'-hydroxyphenyl)-valeric acid-3'-O-sulfate and 5-
(3',4'-dihydroxyphenyl)-gamma-valerolactone. These latter metabolites derived from 
intestinal degradation of procyanidins (Monagas et al., 2010), showing their extensive 
microbial degradation prior to absorption in the intestinal lumen. 
In conclusion, metabolomics was a valuable tool to explore cranberry bioactivity. 
The changes induced by oral consumption of cranberry extract were explored in urine 
considering their entire metabolic composition. An untargeted approach showed that 
procyanidins from cranberry are poorly absorbed by the intestine and are extensively 
metabolized by gut microbiota, leading to the excretion of negligible amounts of intact 
PAC-A; considering this, PAC-A cannot be directly related to the anti-adhesive effects 
of cranberry in vivo. Furthermore, an influence on the glucuronidation of isoflavones 
was observed in the treated group, supporting an induction of glucuronidation after 
cranberry administration. The anti-adhesive activity of urine samples collected at 
different times after oral cranberry administration was studied and the highest anti-
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adhesive activity was observed for the sample collected 8 hours after gavage. 
Metabolomic analysis revealed the presence of polyphenol-derived microbial 
catabolites. These metabolites could play a crucial role against E. coli adhesion to 
epithelial cells and they can be, at least in part, responsible for cranberry activity. 
Due to the fact that cranberry supplements are intended for a preventive activity in 
humans, we decided to reproduce the supplementation experiment in a small number of 
healthy human volunteers. This further trial was intended also to obtain more detailed 
information about the absorption, metabolism and excretion of cranberry 
phytoconstituents in humans and about their bioactivity.  
 
2.2. Supplementation of healthy volunteers with a standardized dry 
cranberry extract 
 
2.2.1. Phytochemical analysis of cranberry extract and urine collection 
 
 
Figure 40. Selected Reaction Monitoring traces of PACs in cranberry extract. Red: dimeric PAC-A; dark 
green: dimeric PAC-B; orange: trimeric PAC-A; blue: tetrameric PAC-A; violet: tetrameric PAC-B; light 
green: pentameric PAC-A. 
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The phytochemical analysis revealed the presence of PAC-A and flavonoid 
derivatives in the product. The amount of procyanidins for one supplement sachet was 
105.7 ± 2.2 mg, namely 60% w/w of total cranberry extract. The relative percentage of 
PAC-A oligomers was 72.7 ± 3.1%, corresponding to 42.6% w/w of cranberry extract, 
whereas the relative amount of PAC-B oligomers was 27.3 ± 2.1%, corresponding to 
14.6% w/w of extract. The characterization of PACs in the extract is reported in Tables 
11 and 12, and representative chromatograms are reported in Figure 40. A- and B-type 
pentamers and hexamers were identified and quantified as a single molecular species, 
due to peak overlapping (traces not reported in the Figure 40). The total amount of 
quercetin aglycone for one sachet was 100 mg, but also quercetin glycosides (190 
mg/sachet) and myricetin glycosides (133 mg/sachet) were present (Table 13). 
 
Table 11. Characterization of PACs amounts in the product. 
Constituents Amount (mg/sachet)* 
  Catechin 6.6±0.3 
PAC Dimers and trimers 15.4±0.5 
PAC Tetramers 17.9±0.1 
PAC Pentamers and hexamers 15.7±0.2 
PAC > Hexamers 50.1±1.1 
  
Total PAC  amount 105.7±2.2 
*Values are reported as means ± SD 
 
Table 12. Relative amounts of PAC-A and PAC-B in dry cranberry extract. 
PAC type 
Relative % on total PAC 
amount* 
Amount (mg/sachet)* 
   A, dimers 20.9±0.3 22±0.3 
B, dimers 3.9±1.4 4.1±1.0 
A, trimers 18.8±0.6 19.8±1.0 
Other PAC-A 33.0±2.3 34.9±1.1 
Other PAC-B 23.4±0.7 24.7±1.1 
*Values are reported as means ± SD 	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Table 13. Amount of flavonoid derivatives in used product. 
Flavonoid derivative Amount (mg/sachet)* 
Myiricetin galactoside 49.7±0.5 
Myiricetin pentoside 12.8±0.4 
Quercetin galactoside 97.5±0.2 
Quercetin pentoside 35.5±0.3 
Dimethoxymyricetin hexoside 14.0±0.3 
Quercetin rhamnoside 43.6±0.3 
Myricetin 69.8±0.3 
Methoxyquercetin pentoside 4.2±0.3 
Quercetin 103.7±0.8 
Quercetin-3-(6-benzoyl)-galactoside 10.8±0.2 
*Values are reported as means ± SD 
 
Urine samples were collected at selected times, namely 2, 4, 6, 8 and 24 h after 
cranberry consumption, and these specimens were studied for their anti-adhesive 
properties against uropathogenic E.coli. 
 
2.2.3. Anti-adhesive activity of urine after cranberry consumption 
 
	  
Figure 41. Histogram representing the ability of uropathogenic E. coli to adhere to HT-29 epithelial cells 
after incubation in urine samples collected at 2, 4, 6, 8 and 24 hours following oral cranberry 
consumption or in control samples. RPMI: untreated bacteria. ** indicates p-value < 0.01 versus RPMI, 
*** indicates p-value < 0.001 versus RPMI. 
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The urine samples were tested in anti-adhesion studies against uropathogenic E. 
coli. A time dependent capacity of urine to decrease bacterial adherence to HT-29 
epithelial cells was observed (Figure 41). A slight reduction in bacterial adhesion was 
observed also testing control urine samples, although the anti-adhesive activity was not 
significant. Conversely, samples collected at 2, 4, 6, 8 and 24 hours after cranberry 
consumption revealed a significant inhibition of E. coli adhesion, being the ones 
collected at 6-8 hours the most active.  
 
2.2.4. Metabolomics profile of urine after supplement consumption 
 
Untargeted metabolomics analysis of the active urinary outputs was performed, to 
explore their composition. Urine samples collected after treatment were compared to the 
urine of same subjects collected before product consumption (controls). 
 
 
Figure 42. PLS-DA showing differences in metabolic composition of urine before and after cranberry 
consumption. Control urine samples are represented by black dots, treated urine samples by colored dots. 
Different collection times are represented by differently colored symbols in the plot: red, 2 h; green, 4 h; 
blue, 6 h; orange, 8 h; violet, 24 h. 
 
The dataset used to build the multivariate models consisted of 2565 time x mass 
variables. Urine samples collected during the experiment were analyzed by an 
explorative PCA, that revealed no presence of outliers and a tight grouping of QC 
samples in a segregated cluster, indicating the robustness of the metabolic profiling 
platform. Nevertheless, the same model did not show any distinction between urine 
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samples collected before and after supplement consumption (data not shown). Thus, 
data were further analyzed by a supervised PLS-DA. The obtained model was 
composed by 3 principal components, and R2 and Q27-fold CV were respectively 0.51 and 
0.38. The score plot of the obtained model (Figure 42) shows a grouping of control and 
treated urine samples in two distinct clusters, due to differences in metabolic 
composition related to treatment. This first result clearly shows a significant 
modification of urinary output after product administration. Furthermore, the same PLS-
DA model shows that, within the “treated” cluster, urine samples collected at different 
times after cranberry consumption are distinctly grouped, meaning that metabolic 
composition of urinary output changed through time after supplement intake. To better 
evaluate the differences among these samples, a second PLS-DA model was built, 
excluding controls. The resulting plot (Figure 43), composed by 2 orthogonal 
components (R2 = 0.82; Q27-fold CV = 0.20), shows that urine samples collected at 6, 8 
and 24 h after cranberry consumption form three separate clusters, while samples at 2 
and 4 h are partially superimposed, due to negligible variations in their metabolic 
composition. 
 
 
Figure 43. PLS-DA showing differences in metabolic composition of urine samples collected at 2, 4, 6, 8 
and 24 hours after cranberry consumption. Control samples were not included in the model. Different 
collection times are represented by differently colored symbols in the plot: red, 2 h; green, 4 h; blue, 6 h; 
orange, 8 h; violet, 24 h. 
 
Time x mass variables related to treatment and contributing to the differentiation 
of the groups at 6, 8 and 24 hours were selected based on their VIP value, and only 
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variables with VIP > 1 were considered. None of them was identified as intact PAC-A, 
PAC-B or their phase II metabolites, suggesting that only negligible amounts of such 
compounds were excreted with the urine after treatment. Nevertheless, many variables 
were identified as intestinal degradation products of PACs or other polyphenols (Mena 
et al., 2017, Monagas et al., 2010), as reported in Table 14. Specifically, the amounts of 
propionic acid, valeric acid and valerolactone derivatives and benzoic acid were found 
increased in 6 and 8 hours’ urine compared to 2 and 4 hours urine, along with O-
methoxycatechol-O-sulphate and vanillin 4-sulphate, whose could be more generally 
referred to polyphenols intake (Neveu et al., 2010, Van Der Hooft et al., 2012). In 24 
hours urine, increased levels of vanillic acid and its glycine-conjugated derivative and 
3-hydroxyhippuric acid, also related to intestinal degradation of PACs (Monagas et al., 
2010), were detected. Based on these results we could observe that, after cranberry 
consumption, PACs are extensively metabolized by intestinal microbiota and 
metabolites are excreted with the urine, thus reaching the lower urinary tract.  
 
Table 14. Significant (p-value < 0.05) ariables related to treatment with cranberry extract at 6, 8 and 24 
hours after supplement consumption 
6 hours 
VIP R.T. (min) 
[M-H]-  
(m/z) 
Amount 
vs 2-4 h* Tentative identification 
Database ID 
(HMDB) 
4.85 3.19 181.0490 ↑ 3,4-Dihydroxyphenylpropionic acid HMDB00423 
4.04 3.18 121.0287 ↑ Benzoic acid HMDB01870 
2.17 5.25 369.1188 ↑ 4-Hydroxy-5-(phenyl)-valeric acid-O-glucuronide HMDB59980 
1.41 3.88 207.0654 ↑ 5-(3’,4’-Dihydroxyphenyl)-γ-valerolactone HMDB29185 
1.40 4.48 165.0544 ↑ 3-(3-Hydroxyphenyl)propanoic acid HMDB00375 
      
8 hours 
6.27 4.00 203.0012 ↑ O-methoxycatechol-O-sulphate HMDB60013 
3.79 3.63 273.0072 ↑ 4-Hydroxy-5-(phenyl)-valeric acid-O-sulphate HMDB59981 
2.63 3.62 193.0497 ↑ 3-Hydroxyphenyl-valeric acid HMDB41666 
2.36 3.12 230.9960 ↑ Vanillin 4-sulphate HMDB41789 
1.25 7.26 363.2164 ↑ 5-(4'-Hydroxyphenyl)-gamma-valerolactone-4'-O-glucuronide HMDB59992 
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1.24 3.75 289.0334 ↑ 4-Hydroxy-5-(3'-hydroxyphenyl)-valeric acid-3'-O-sulphate  HMDB59975 
      
24 hours 
10.99 3.17 224.0559 ↑ Vanilloylglycine HMDB60026 
2.60 2.94 167.0339 ↑ Vanillic acid HMDB00484 
2.33 4.41 194.0451 ↑ 3-Hydroxyhippuric acid HMDB06116 
#The levels of biomarkers were evaluated by their normalized area. Significant level < 0.05, calculated using 
ANOVA. ↑: higher amounts compared to 2-4 h urine samples. 
 
2.2.5. Quantification of PAC-A in urine after consumption of cranberry 
extract  
 
Due to its supposed anti-adhesive activity, the amounts of intact PAC-A were 
monitored in urinary output after cranberry consumption, using a specific HPLC-
MS/MS method. The method, using TQD mass spectrometry, allowed sufficient 
sensitivity with a LOD of PAC-A2 at 0.2 ng/mL. Before analysis, urine samples were 
purified using a Sephadex LH 20 resin, using acetone to elute PACs and using 
epigallocatechin gallate as internal standard. This procedure allowed the increase of the 
signal of procyanidins in mass spectrometric analysis, due to the reduction of noise 
generated by other constituents of the extract. Despite the high sensitivity of the 
method, PAC-A2 was not detected in urine, and its level was lower than LOD in all the 
collected samples. PAC-A2 could be detected in urine samples only after a second 
independent experiment, in which the same six volunteers enrolled in the first 
experiment took the same oral dose (360 mg) of cranberry extract, following the same 
procedure described above; urinary output was finally collected after an overnight (8 
hours from supplement consumption). In this case, the average PAC-A2 concentration 
in urine was 0.40 ± 0.10 ng/mL, although an important inter-individual variability was 
observed. Intact PAC-A2 amounts were higher and detectable in these overnight urine 
samples because no other collections were previously performed, unlike the previous 
experiment. Representative chromatograms are reported in Figure 44. 
Overall, the results show that, after an oral intake of a single dose of dry cranberry 
extract, only negligible amounts of intact PAC-A reached the urine.  
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Figure 44. Comparison of chromatograms obtained from the analysis of PAC-A2 in urine samples 
collected at 8 hours (overnight) after cranberry consumption and chromatograms obtained from the 
analysis of a standard solution (calibration mix). Red and orange traces represents internal standard 
(epigallocatechin gallate) in samples collected after treatment and standard solution, respectively. Green 
and blue traces represents PAC-A2 in samples collected after treatment and standard solution, 
respectively. 
 
2.2.6. HPLC-MS/MS determination of PAC-A degradation products in 
urine after treatment  
 
Using a specific HPLC-TQD-MS/MS method, three metabolites deriving from 
microbial degradation of PACs were monitored in urine samples collected after 
cranberry consumption. The first two were 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone 
and 5-(4'-hydroxyphenyl)-γ-valerolactone-4'-O-glucuronide. Such compounds were 
selected from the discriminant variables for 6 and 8 hours urine samples in the 
untargeted analysis, respectively. Furthermore, also the sulfated derivative of 5-(4'-
hydroxyphenyl)-γ-valerolactone was monitored, since Feliciano and coll. reported the 
detection of the same metabolite in human urine after consumption of cranberry juice 
(Feliciano et al., 2016).  
Despite it was not feasible to perform a quantitative measurement, due to the 
absence of commercially available standards, an estimation of the compound was 
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obtained determining the area of peaks normalized on the creatinine amount in each 
urine sample. The analyses showed a time-dependent excretion of the metabolites, with 
a peak 6-8 hours after cranberry consumption (Figure 45). Moreover, the three 
metabolites could be still detected in urine samples collected 24 hours following 
cranberry consumption. Conversely, in control samples the three compounds were not 
detectable. 
 
 
Figure 45. Urinary excretion of three selected PACs metabolites monitored by HPLC-MS/MS. Blue: 5-
(4'-Hydroxyphenyl)-γ-valerolactone-O-sulfate; orange: 5-(4'-hydroxyphenyl)-γ-valerolactone-4'-O-
glucuronide; green: 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone 
 
2.2.7. Determination of quercetin, quercetin-sulfate and quercetin-
glucuronide in urine after cranberry consumption 
 
Quercetin and its sulfated and glucuronidated metabolites were monitored in urine 
samples using a specific HPLC-TQD-MS/MS method. After cranberry consumption, 
urinary amounts of un-metabolized quercetin were found to be low, i.e. Cmax was 0.14 ± 
0.10 µg/mL at 4 hours after supplement consumption (Figure 46). On the other hand, 
amounts of quercetin metabolites were found to be higher: Cmax of sulfate derivative 
was 3.36 ± 1.31 µg/mL, Cmax of glucuronidated was 0.46 ± 0.11 µg/mL, both at 4 hours 
after supplement intake. Results showed that quercetin is absorbed from cranberry after 
consumption of dry extract, but it is extensively metabolized mainly by phase II 
reaction and conjugated derivatives can be found at relatively high concentrations in 
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urinary output.  
 
 
Figure 46. Urinary excretion of quercetin and two related metabolites, quercetin sulfate (red) and 
quercetin glucuronide (blue). Urinary levels of un-metabolized quercetin are reported in the box. 
 
2.2.8. Discussion 
 
The use of cranberry in the treatment of UTIs has become popular during the last 
years and cranberry activity has been attributed to its high content of A-type PACs, that 
could inhibit the adherence of uropathogenic bacteria to the urinary epithelium in µM 
concentration range (Gupta et al., 2012, Gupta et al., 2007, Howell et al., 2005, 
Polewski et al., 2016). Quercetin and its derivatives have also been considered as 
possible useful compounds, due to the antioxidant and anti-inflammatory effects (Fan et 
al., 2011). Furthermore, in a recent study several flavonoids have been also considered 
in silico as potentially active compounds against β-ketoacyl acyl carrier protein 
synthase I, an enzyme targeting the fatty acid synthesis in bacteria (Sabbagh and 
Berakdar, 2015). 
Metabolomics offer the opportunity to explore the effects of complex mixtures in 
living organisms. Considering the cranberry extract, the putative active compounds 
(PAC-A) present limited intestinal absorption and extensive metabolism by gut 
microbiota (De Llano et al., 2015, Feliciano et al., 2016, Monagas et al., 2010). 
Consequently, several authors pointed out the possible role exerted by microbial 
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degradation products of PACs (phenolic acids and valerolactones, among the others) in 
the anti-adhesive activity of cranberry.  
In this study, six healthy adult volunteers consumed 1 g of a dry cranberry extract 
standardized at 42.6% w/w of PAC-A and 14.6% w/w of PAC-B, flavonoid glycosides 
and quercetin aglycone (200 mg/dose). Here, the significant anti-adhesive activity of 
urine samples collected at 2, 4, 6, 8 and 24 hours after product consumption is reported, 
as well as their composition changes using a metabolomics approach. The anti-adhesive 
activity on E. coli tested against H29 human intestinal epithelial cells was higher in the 
samples collected at 6 and 8 hours, showing significant activity compared to controls. A 
PLS-DA analysis allowed the observation of grouping between control samples and 
urine collected after treatment. The PLS-DA model was re-processed excluding 
controls, and a clusterization of samples collected at different times was observed. 
Variables describing the model were identified as PACs degradation products, probably 
formed in the intestinal environment due to microbial catabolism. Several valeric acid 
and valerolactone derivatives were detected in 6 and 8 h urine samples, namely 4-
hydroxy-5-(phenyl)-valeric acid-O-glucuronide and 5-(3’,4’-dihydroxyphenyl)-γ-
valerolactone at 6 hours and 4-hydroxy-5-(phenyl)-valeric acid-O-sulphate, 3-
hydroxyphenyl-valeric acid, 5-(4'-hydroxyphenyl)-gamma-valerolactone-4'-O-
glucuronide and 4-hydroxy-5-(3'-hydroxyphenyl)-valeric acid-3'-O-sulphate at 8 hours. 
Previously published studies reported the urinary excretion of such valeric acid and 
valerolactone derivatives after cranberry consumption in humans (Feliciano et al., 2016, 
Monagas et al., 2010), and these are related to the intestinal degradation of epicatechin, 
which in turn is formed  by the depolimerization of PACs (Monagas et al., 2010). Mena 
and coll. recently reported that 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone and its sulfate 
conjugates, representative circulating metabolites of flavan-3-ols, exhibit anti-adhesive 
activity against uropathogenic E. coli in bladder epithelial cells (Mena et al., 2017). 
Testing the same urine samples used in the untargeted analysis against E. coli, we 
observed the highest anti-adhesive activity between 6 and 8 h after cranberry 
consumption, and these data correlated with the detection of valerolactone derivatives 
as the most descriptive variables, among whom 5-(3’,4’-dihydroxyphenyl)-γ-
valerolactone at 6 h. Furthermore, using a targeted HPLC-MS/MS approach, we 
monitored the amounts of three valerolactone derivatives, namely 5-(3’,4’-
dihydroxyphenyl)-γ-valerolactone and 5-(4'-hydroxyphenyl)-γ-valerolactone-4'-O-
glucuronide, that were selected from the discriminant variables for 6 and 8-hours urine 
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samples in the untargeted analysis, respectively, and 5-(4'-hydroxyphenyl)-γ-
valerolactone. The results showed that 6 and 8 h urine samples contained the highest 
amounts of these products. The same samples were the ones that showed the highest 
anti-adhesive activity against uropathogenic bacteria. Other variables for the 6 h urine 
samples were 3,4-dihydroxyphenylpropionic acid and benzoic acid, while for 8 h urine 
were 3-(3-hydroxyphenyl)propanoic acid, O-methoxycatechol-O-sulphate and vanillin 
4-sulphate. Propionate derivatives could be related, as the valeric acid and valerolactone 
ones, to the intestinal degradation of PACs (Mena et al., 2017), as well as benzoic acid 
(Mena et al., 2017), although it could derive also from the degradation of several other 
polyphenols, as for O-methoxycatechol-O-sulphate and vanillin 4-sulphate (Neveu et 
al., 2010, Van Der Hooft et al., 2012). 
A significant anti-adhesive activity was observed also testing urine samples 
collected 24 hours after cranberry consumption. Vanillic acid, its glycine conjugate and 
3-hydroxyhippuric acid were detected as the discriminant variables, and they could 
derive from microbial degradation of PACs, being terminal products of this catabolic 
process (Monagas et al., 2010). By targeted HPLC-MS/MS analysis of the same 24 h 
samples, we detected 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone, 5-(4'-hydroxyphenyl)-
γ-valerolactone-4'-O-glucuronide and 5-(4'-hydroxyphenyl)-γ-valerolactone, although 
their amounts were lower than those observed at 6 and 8 h. The co-administration of 
quercetin resulted in the observation of quercetin glucuronide and sulphate derivatives 
in urine, but their levels appear not to be related to the anti-adhesive properties, because 
their maximum concentration was observed at 4 hours after oral administration of the 
product, non-corresponding to the higher anti-adhesive activity. Limited data are 
available about quercetin glucuronide activity. In a recent study, the compound resulted 
able to suppress ear edema induced by dimethyl benzene and peritoneal permeability 
induced by acetic acid in mice (Fan et al., 2011). Other authors reported significant 
variations of quercetin activity after glucuronidation or sulphation and suggested that 
different metabolites can have lower effects than the parent compound. However, at 
least two of the major in vivo metabolites of quercetin retained significant activity for 
the inhibition of pro-inflammatory eicosanoids, such as LTB4 and PGE2 (Loke et al., 
2008).  
Intact PAC-A was not detectable in any of the collected urine samples, nor by 
untargeted metabolomics nor performing a specific HPLC-MS/MS analysis using an 
appropriate chromatographic method. PAC-A2 could be detected in urine only in a 
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different experiment, in which the same six volunteers took orally the same dose (360 
mg) of cranberry extract and they collected urine samples after an overnight (8 hours 
from supplement consumption). In this case, the average urinary PAC-A2 concentration 
was 0.40 ± 0.10 ng/mL, meaning that only negligible amounts of intact PAC-A reach 
the urinary tract with urine. Those levels are far from the concentration used in previous 
in vitro tests demonstrating the anti-adhesive properties of PAC-A. The finding that we 
obtained confirms the results of previously published papers, showing only few ng 
(Cmax = 24 ng/mg creatinine) of PAC-A in urine after cranberry consumption (McKay et 
al., 2015), or no detection of PAC-A at all (Feliciano et al., 2016). Hence, our data 
indicate that the anti-adhesive activity of urine after cranberry consumption could not be 
related to a direct effect of PAC-A on bacteria adhering to the HT29 cells. 
Metabolomics data indicate that it is related to the urinary excretion of PACs 
degradation products formed by catabolism of gut microbiota, or at least to a synergistic 
effect of small concentrations of intact PAC-A and smaller molecular weight 
compounds formed by its degradation. As observed in the animal experiments, 
excretion concentrations of intact PAC-A were six orders of magnitude lower compared 
to the PAC-A concentrations considered active as anti-adhesive (Foo et al., 2000). Thus, 
the previously demonstrated anti-adhesive properties of PAC-A oligomers could not be 
related to the in vivo effect of cranberry.  
In conclusion, UPLC-MS-based metabolomics proved to be a useful and powerful 
tool to study phytochemical bioactivity of cranberry in humans. We observed changes 
in urine composition mainly due to small phenolics formed by extensive microbial 
catabolism, with the subsequent excretion of the derived products with the urine. The 
negligible amount of intact PAC-A excreted with urine cannot be correlated to the 
cranberry activity observed in our experiment, or at least the activity of cranberry is 
related to the interactions between its constituents and the degradation products formed 
by microbial catabolism. The highest anti-adhesive activity against E. coli correlated 
with the peaks of excretion of valerolactone derivatives, indicating that these gut 
microbiota-derived PACs metabolites are, at least in part, responsible of the observed 
effects. 
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3. Green coffee (Coffea canephora) bean extract 	  
3.1. Characterization of the phytoconstituents of dry GCBE 
 
As preliminary analysis, the dried extract was extracted in deuterated methanol 
and 1H-NMR was acquired (Figure 47). Signals indicating the presence of caffeic acid 
derivatives were detected, namely the pair of doublets at δ 7.57 and 6.28 (J=16.7 Hz) 
ascribable to trans double bond, the aromatic signals at δ 7.06 (d, 1.8 Hz) and the 
partially overlapped signals at δ 6.85 and 6.80 (Bajko et al., 2016). Signals supporting 
the presence of quinic acid (δ 4.20; 3.85; 2.18 and 2.00) were also detected (Bajko et al., 
2016), as well as the signals ascribable to caffeine (δ 7.87 and methyl groups at 3.37, 
3.55 and 3.91).  
 
Figure 47. 1H-NMR spectrum of the GCBE. 
 
Further data were obtained using LC-DAD-ESI-MSn in negative ionization mode. 
Twelve different phenolic compounds, mainly caffeoyl-quinic and feruloyl-quinic acids 
derivatives (Table 15 and Figure 48) were identified on the basis of their MSn spectra 
and comparison with literature (Clifford et al., 2003, Clifford et al., 2005, Clifford et al., 
2006, Clifford et al., 2008). Quantification was obtained using a diode array detector 
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and chlorogenic acid as reference compound. The most abundant constituents were 5-
caffeoylquinic acid (5-CQA, 4.93± 0.50 w/w) and feruloylquinic acid (FQA, 1.059 ± 
0.04 w/w), while hexahydroxydiphenoyl (HHDP)-hexoside was the less abundant 
(0.089 ± 0.01 w/w). 
 
Table 15. Polyphenolic constituents of GCBE. Analysis was performed by HPLC-MS/MS in negative ion 
mode. 
R.T. 
(min) Compound [M-H]
- (m/z) Fragments (m/z) % (w/w) 
9.3 3-CQA 353 191 85 0.593 ± 0.02 
11.5 4-CQA 353 191 85 0.308 ± 0.04 
11.8 5-CQA 353 173 93 4.93± 0.50 
12.1 F pentoside 367 193 134 149 0.177 ± 0.01 
12.7 Caffeic acid* 179 135 0.422 ± 0.06 
13.5 FQA 367 191 85 111 127 1.059 ± 0.04 
14.6 HHDP hexoside 481 301 257 0.089 ± 0.01 
14.9 3,4-diCQA 515 353 335 191 179 173 0.520 ± 0.04 
15.4 1,5-diCQA 515 353 191 179 173 0.304 ± 0.04 
15.8 3,5-diCQA 515 353 191 173 0.437 ± 0.04 
16.2 3-C-5-FQA 529 367 335 173 193 111 93 0.162 ± 0.01 
16.8 3-F-4-CQA 529 353 367 173 93 0.150 ± 0.01 
     
   Total amount 9.15 
(R.T. = Retention Time; QA = quinic acid; diCQA = dicaffeoyl quinic acid; C =caffeoyl; F = feruloyl) 
*: identification was performed comparing with reference compounds. 
 
 
Figure 48. Representative chromatogram obtained from HPLC-MS/MS analysis of GCBE in negative ion 
mode. 
 
Positive ionization mode was used to quantify caffeine and trigonelline (Table 16). 
Caffeine amount was 0.593 ± 0.02 % w/w, trigonelline one was 0.308 ± 0.04 % w/w. 
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Table 16. Amounts of trigonelline and caffeine in GCBE. Analysis was performed by HPLC-MS/MS in 
positive ion mode. 
R.T. (min) Compound [M+H]+ (m/z) Fragments (m/z) % (w/w) 
2.6 Trigonelline 138 94 92 0.308 ± 0.04 
12 Caffeine 195 138 110 83 0.593 ± 0.02 
     
   Total amount 1.01 
(R.T. = Retention Time) 
 
 
3.2.  UPLC-QTOF analysis of 24-h urine output using C-18 stationary 
phase 
 
An untargeted approach was used to explore the changes in urine composition 
related to the consumption of GCBE. At first attempt, a chromatographic method using 
a C-18 column as stationary phase was developed. Exemplificative chromatograms are 
reported in Figure 49.  
 
 
Figure 49. Exemplificative chromatograms obtained from LC-MS metabolomics profiling of urine 
collected after consumption of GCBE and control samples. Chromatograms were re-built using MZmine 
software. 
 
At first attempt, LC-MS data were analyzed by explorative PCA, in order to 
detect the presence of outliers and to assess method robustness by the analysis of QC 
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samples. The models showed that 24-h urine samples collected from different subjects 
were partially grouped in different clusters. The PCA models for “positive” and 
“negative” datasets showed grouping of QC samples in tight clusters at the origin of the 
axes, confirming the robustness of the chromatographic method and of the metabolic 
profiling platform used (data not shown) (Vorkas et al., 2015).  
The same datasets were further processed using supervised method, namely PLS-
DA, using controls and urine samples collected during treatment as groups (Figures 50 
and 51). The model built using data in positive acquisition mode was characterized by 3 
components and R2 = 0.69 and Q27-fold = 0.46. Similarly, the model built using the data 
acquired in negative ion mode was characterized by 3 components and R2 = 0.65 and 
Q27-fold = 0.39. The two datasets (positive and negative) were composed by 4600 and 
3000 variables, respectively, among whom significant descriptive ones for treatment 
were selected from loading plots depending on their VIP value. Only variables having 
VIP > 1 were considered. Two sets of 22 and 4 measured variables were detected as 
relevant in the explanation of the effects of treatment, from “positive” and “negative” 
datasets, respectively, and were tentatively identified based on their HR m/z value and 
considering their R.T. and fragmentation spectra (Table 17).  
 
 
Figure 50.  PLS-DA score plot obtained from UPLC-MS acquired in positive ion mode, using the C-18 
stationary phase. Control (blue circles) and treated (red circles) urine samples collected during the 
experiment are represented in the plot. The acronyms reported in the plot represent sample names. 
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Figure 51. PLS-DA score plot obtained from UPLC-MS acquired in negative ion mode, using the C-18 
stationary phase. Control (blue circles) and treated (red circles) urine samples collected during the 
experiment are represented in the plot. The acronyms reported in the plot represent sample names. 
 
Benzoic acid, hippuric acid, 4-hydroxybenzoic acid, quinic acid and 
dihydrocaffeic acid sulfate amounts were increased in urine collected during treatment, 
compared to controls, and they can be considered as markers of consumption of CGA, 
along with isoferulic acid, p-coumaric acid, 3(3-hydroxyphenyl)propanoic acid and 
dihydrosinapic acid (Del Rio et al., 2010, Farah et al., 2008), whose amounts were 
increased in urine after supplement consumption. Significant traces of intact CGA were 
not present in urine after treatment, indicating that those compounds are extensively 
metabolized by gut microbiota and only derived catabolites could be detected. Other 
significant variables were tentatively identified as medium-chain (C8-C10) acyl-
carnitines, whose amounts in urine were increased with intake of GCBE. Acyl 
carnitines are involved in the metabolism of fatty acids. Further compounds, namely 3-
hydroxysuberic acid (3-hydroxyoctanedioic acid) and 3-hydroxyadipic acid (3-
hydroxyhexanedioic acid) are metabolite derived from the ω-oxidation of 3-hydroxy 
fatty acids and the β-oxidation of longer-chain 3-hydroxy dicarboxylic acids (Tserng, 
1991). They are normally found in blood and urine and their amounts are increased in 
ketoaciduria (Verhaeghe et al., 1992), so in conditions that may be related to starvation.  
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Table 17. Significant variables (p-value<0.05) related to treatment with GCBE, obtained from the PLS-
DA model for the C-18 data (T>C means higher amounts in Treated than in Control, while T<C means 
higher amounts in Control than in Treated). 
 Amount 
T vs C 
VIP 
R.T. 
(min) 
HR m/z 
Tentative identification 
(adduct ion type) 
Database ID 
Positive 
T > C 8.80 5.42 312.2177 2-trans,4-cis-Decadienoylcarnitine HMDB13325 
 T > C 6.30 3.60 123.0444 Benzoic acid* HMDB01870 
 T > C 6.20 5.09 286.2020 2-Octenoylcarnitine HMDB13324 
 T > C 4.50 3.60 202.0479 Hippuric acid ([M+Na]+) HMDB00714 
 T > C 4.20 6.06 314.2332 9-Decenoylcarnitine HMDB13205 
 
T > C 4.10 5.86 326.1968 3-Hydroxyoctanoylcarnitine ([M+Na]+) HMDB61634 
 
T > C 3.00 2.71 180.0884 3-Hydroxyadipic acid ([M+NH4]+) HMDB00345 
 T > C 2.70 6.24 338.2329 Decanoylcarnitine ([M+Na]+) HMDB00651 
 T > C 2.50 4.42 139.0393 4-Hydroxybenzoic acid HMDB00500 
 T > C 2.40 5.27 330.2277 6-Keto-decanoylcarnitine HMDB13202 
 T > C 2.20 4.68 274.2018 Heptanoylcarnitine HMDB13238 
 T > C 2.10 2.95 195.0656 Isoferulic acid HMDB00955 
 T > C 2.00 5.73 288.2171 L-Octanoylcarnitine HMDB00791 
 
T > C 1.90 5.52 444.3101 Gamma-linolenyl carnitine ([M+Na]+) HMDB06318 
 
T > C 1.80 4.55 302.1425 Hydroxyvalerylcarnitine ([M+K]+) HMDB13132 
 T > C 1.70 5.07 374.2537 Dodecanedioylcarnitine HMDB13327 
 
T > C 1.65 4.19 184.0969 3-(3-Hydroxyphenyl)propanoic acid ([M+NH4]+) 
HMDB00375 
 T > C 1.58 5.72 229.0502 3-Hydroxysuberic acid ([M+K]+) HMDB00325 
 T > C 1.55 3.82 182.0808 p-Coumaric acid ([M+NH4]+) HMDB41592 
 T > C 1.50 4.36 330.2275 6-Keto-decanoylcarnitine HMDB13202 
 T > C 1.45 3.40 328.1588 3-Hydroxyhexanoyl carnitine HMDB61633 
 T > C 1.40 2.94 153.0549 4-Hydroxyphenylacetic acid HMDB60390 
       
Negative T > C 2.80 4.25 227.0340 Quinic acid ([M+Cl]-) HMDB03072 
T > C 2.60 6.04 272.1290 Glutaconylcarnitine HMDB13129 
T > C 2.32 3.43 207.0663 Dihydrosinapic acid ([M-H20-H])- HMDB41727 
T > C 1.85 3.96 261.0064 Dihydrocaffeic acid sulfate HMDB41721 
*: identification was performed comparing with reference compounds. 
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3.3.  UPLC-QTOF analysis of 24-h urine output using C-3 stationary 
phase 
 
 
Figure 52. PLS-DA score plot obtained from HPLC-MS untargeted analysis of urine, using the C-3 
stationary phase in positive ion mode. The plot was obtained using SIMCA 13 software. Control (green 
circles) and treated (blue circles) urine samples collected during the experiment are represented. 
 
The same urine samples were analyzed by LC-MS using a C-3 column as 
stationary phase, in order to have different chromatographic behavior. Also in this case, 
an untargeted approach was used. Explorative PCA model did not show discrimination 
between “treated” samples and controls. The same model showed grouping of QC 
samples in tight clusters at the origin of the axes, confirming the robustness of the 
chromatographic method and of the metabolic profiling platform used (data not shown) 
(Vorkas et al., 2015).  
To observe differences between control urine samples and ones collected during 
supplement consumption, the same dataset was processed using PLS-DA. The resulting 
model (characterized by 2 components and R2 = 0.69 and Q27-fold = 0.32) can 
emphasize the differences in urine samples due to GCBE intake (the score plot is 
reported in Figure 52). Four variables were selected as significantly discriminating 
treated urine samples from controls (Table 18), and they were tentatively identified 
studying their fragmentation spectra and by comparison with web databases and 
literature data. Along with two acyl-carnitine derivatives (O-adipoylcarnitine and 
decanoylcarnitine), the other two variables were tentatively identified as acetone and 
Results and Discussion 	  
	  116	  
vanillic acid. Carnitine derivatives and acetone are related to fatty acids metabolism, 
while vanillic acid could be related to intestinal catabolism of CGA. 
 
Table 18. Significant urinary variables (p-value<0.05) related to consumption of GCBE, detected by LC-
MS metbolomics, using a C-3 stationary phase. Beside Retention Time (R.T., minutes), experimental m/z 
values and tentative identification, variations of the urinary amounts of each metabolite in treated urine 
samples (T) compared to controls (C) are reported.   
Amount 
T vs C 
VIP 
R.T. 
(min) 
m/z Tentative identification Database ID 
T > C 3.50 7.26 76.18 Acetone* HMDB00714 
T > C 3.12 17.87 312.48 O-Adipoylcarnitine HMDB13325 
T > C 2.40 18.98 354.37 Decanoylcarnitine HMDB01870 
T > C 1.80 15.09 266.34 Vanillic acid HMDB13324 
*: identification was performed comparing with reference compounds. 
 
3.4.  Quantification of allantoin and 8-OHdG in 24-h urine samples 
 
 
Figure 53. Allantoin concentration in control urine samples and during supplementation with GCBE. Day 
0 corresponds to the first day of treatment, day 30 to the last. 
 
The amounts of the two oxidative stress biomarkers were monitored in controls 
and in urine samples collected during supplementation with GCBE. Data are 
summarized in Figures 53 and 54. Amounts of both the markers were not affected by 
consumption of GCBE, in fact the concentrations monitored did not significantly 
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change along supplementation period, as well as if compared to controls. The average 
amount of allantoin in control samples was 25.82 ± 7.08 µg/mL, whereas the average 
concentration in urine collected during treatment was 26.70 ± 6.50 µg/mL. Similarly, 
the average concentration of 8-OHdG in controls was 1.37 ± 0.40 ng/mL, whereas in 
treated was 1.38 ± 0.70 µg/mL. Over all, the results show that a regular consumption of 
a 400 mg dose of GCBE for 30 days does not affect the oxidative status in humans, 
despite the high content in CGA (9% w/w). 
 
 
Figure 54. 8-OHdG concentration in control urine samples and during supplementation with GCBE. Day 
0 corresponds to the first day of treatment, day 30 to the last. 
 
3.5.  Discussion 
 
Products containing GCBE are frequently used to manage weight gain and to 
promote weight loss, due to the claimed activity of CGA on fatty acids and glucose 
metabolisms (Shimoda et al., 2006), and due to the content of caffeine, a well-known 
stimulant (Dulloo et al., 1989). On the other hand, although the efficacy of a treatment 
with isolated CGA on weight loss, induction of fatty acids and glucose metabolisms and 
lipid re-distribution were reported both in animals and humans (Dulloo et al., 1989), the 
efficacy of GCBE is still under debate. Furthermore, the mode of action of green coffee 
extract is not fully understood and the molecular targets that have been up to now 
discovered for CGA can be considered multiple. For example, CGA derivatives were 
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studied for their antioxidants and antibacterial activities and for their interaction with 
lipid and glucose metabolism (Arion et al., 1997, Brower, 1998, Cho et al., 2010, 
Sudeep et al., 2016, Huang et al., 2016, Huang et al., 2015, Li et al., 2009, Liang and 
Kitts, 2015, Liu et al., 2015, Meng et al., 2013). Metabolomics may offer the 
opportunity to study natural bioactive compounds, such as the green coffee extracts, 
with a new holistic approach aimed to assess the global metabolite composition of 
specific biofluids (Wolfender et al., 2013). 
Hence, in this study we monitored the effects of a 30 days supplementation with 
an oral dose of 400 mg of dry GCBE (containing 9% w/w CGA and 0.5% w/w caffeine) 
in healthy non-obese volunteers, in order to mimic supplement consumption by healthy 
consumers. To perform the study, volunteers collected 24-h urine once a week during 
treatment, and these samples were finally analyzed using a metabolomics approach. 
Among variables significantly (p-value < 0.01) describing treatment with GCBE, none 
of them was identified as intact CGA; on the other hand, other variables, whose 
amounts were increased in urine during supplementation, were tentatively identified as 
benzoic acid, hippuric acid, 4-hydroxybenzoic acid, quinic acid, dihydrocaffeic acid 
sulfate, isoferulic acid, p-coumaric acid, 3(3-hydroxyphenyl)propanoic acid, 4-
hydroxyphenylacetic acid and vanillic acid. Benzoic acid derivatives and hippuric acid 
are ascribable to intestinal and microbial degradation of CGAs and other polyphenols 
(Krupp et al., 2012, Olthof et al., 2003), and produced metabolites are mainly as 4-
hydroxyphenylacetic acid (Gao et al., 2006). Also quinic acid, dihydrocaffeic acid 
sulfate, isoferulic acid, p-coumaric acid, 3(3-hydroxyphenyl)propanoic acid and vanillic 
acid can be considered as degradation products of CGA coming from catabolism by gut 
microbiota (Del Rio et al., 2010, Farah et al., 2008, Konishi and Kobayashi, 2004). 
Overall, the results of our study showed that CGA from dry GCBE were absorbed by 
intestine, but they were extensively subjected to microbial catabolism and subsequent 
phase II metabolism (as observed for dihydrocaffeic acid, that was detected as sulfate 
derivative), prior to be excreted with urine. This observation is in agreement with results 
previously published by other authors, whose reported that, after ingestion of coffee 
containing 3.395 µmol of caffeoylquinic acids (CQA), only CGA metabolites could be 
found in significant amounts in urine collected 0–24 h after coffee intake (Monteiro et 
al., 2007).  
Other variables significantly describing treatment with GCBE were tentatively 
identified as endogen metabolites, namely medium-chain (C8-C10) acyl carnitines, two 
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dicarboxylic acids (3-hydroxysuberic acid and 3-hydroxyadipic acid) and acetone. Acyl 
carnitines are mainly involved in transportation of fatty acids inside the mitochondrion 
matrix (Sharma and Black, 2009), where they are further catabolized via β-oxidation to 
produce energy. On the other hand, 3-hydroxy dicarboxylic acids as 3-hydroxysuberic 
acid and 3-hydroxyadipic acid are derived from the ω-oxidation of 3-hydroxy fatty 
acids and the subsequent β-oxidation of longer chain 3-hydroxy dicarboxylic acids 
(Tserng, 1991), while acetone derives from degradation of ketone bodies, whose are 
produced mainly by 3-hydroxy-3-methylglutaryl-CoA synthase during ketogenesis. 
Overall, these markers belong to different pathways involved in lipid transportation and 
metabolism, whose are regulated by receptor PPAR-α, the major regulator of lipid 
metabolism in the liver (Gervois et al., 2000). Activation of this receptor promotes 
uptake, utilization, and catabolism of fatty acids by upregulation of genes involved in 
the transportation, binding and activation of fatty acids, and peroxisomal and 
mitochondrial fatty acid β-oxidation (Kersten et al., 1999). Purified CGA have been 
reported to act as agonists of PPAR-α (Meng et al., 2013), but few is known about the 
activity of the extract of GCBE. Li and coll. examined the effects of isolated CGA on 
lipid and glucose metabolism in hamsters under a high dietary fat burden, and they 
studied the role of PPAR-α in these effects (Li et al., 2009). After eight weeks of 
treatment they observed a reduction of the levels of fasting serum triglyceride, free fatty 
acid, total cholesterol LDL-Cholesterol, HDL-Cholesterol, fasting glucose and insulin. 
Furthermore, CGA significantly elevated the expression level of mRNA and protein 
expression in hepatic PPAR-α (Li et al., 2009). Our results showed that, after 30 days 
consumption of dry GCBE, the amounts of markers related to lipid metabolism in urine 
were increased, suggesting an induction of fat metabolism, although significant 
alterations of volunteers body weight were not observed (data not shown). Moreover, 
these markers were related to different pathways of fatty acids metabolism regulated by 
PPAR-α, so we postulate that the effects of GCBE could be related to the agonist 
activity exerted by CGA and CGA-derived metabolites on this receptor. This hypothesis 
is consistent with previously published data. In fact, 5-CQA was shown to up-regulate 
PPAR-𝛼 mRNA expression in the liver of rats in a dose-dependent manner (Huang et 
al., 2015). 
Due to its chemical composition, green coffee is considered a rich natural source 
of antioxidants, with CGA being the most active compound (Babova et al., 2016). 
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Previous published studies assessed the antioxidant properties of CGA in animal models 
(Liang and Kitts, 2015) and of green coffee extracts in vitro (Babova et al., 2016, Liang 
and Kitts, 2015). In our study, we monitored the levels of two urinary markers of 
oxidative stress, namely allantoin and 8-OHdG. Allantoin is normally present in urine 
and is formed from uric acid through reactions with oxidative species, so its urinary 
amounts are increased with increasing oxidative stress (Tolun et al., 2010). On the other 
hand, 8-OHdG is one of the predominant forms of free radical-induced lesions of DNA. 
Because oxidative DNA lesion products are reasonably water soluble and excreted into 
the urine without being further metabolized, urinary 8-OHdG is considered a significant 
biomarker of oxidative stress (Cooke et al., 2002, Nakajima et al., 2012). Our results 
showed that the levels of both the markers were not affected by GCBE consumption and 
this finding suggest that in healthy subject the supplementation of green coffee is not 
changing levels of urinary markers of oxidative stress. 
In conclusion, in this work, urine samples of human volunteers collected during 
30 days of consumption of 400 mg of GCBE (containing 4.9% of 5-CQA, 0.5 % of 
caffeine and 0.3% trigonelline) were studied by metabolomics approach. Markers 
related to treatment were assigned to metabolites belonging to the pathways of fatty acid 
metabolism, showing an influence of green coffee extract on lipid metabolism. 
However, during the period of the experiment, the weight of volunteers did not change. 
Overall, these results could be considered, at least in part, as a further proof of the mode 
of action of GCBE, and they show that metabolomics-based studies offer new 
opportunities as new tools for the study of bioactive phytochemicals. 
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CONCLUSION 
 
Nutraceuticals are non-medicinal products that, depending on their composition, 
are considered as food supplements or, in the case they contain natural products as pure 
or isolated compounds or as natural extracts, herbal products (non-registered medicinal 
herbal products). Nutraceuticals are commonly used to prevent diseases (as, for 
example, metabolic diseases associated to aging), or, more in general, to promote a 
healthy status. Generally, natural products used in the preparation of nutraceuticals are 
complex matrixes, whose quali-quantitative chemical composition is often not 
completely defined. In many cases, only scarce information regarding the bioactivity 
and safety of these products are reported in literature, as well as the mechanism(s) of 
action of their phytoconstituents and their pharmacokinetics. Furthermore, unlike in the 
case of single drugs, the components of complex natural extracts could interact among 
others, so possible synergic or antagonistic effects between them could be possible; for 
these reasons, the design and performance of bioactivity assays could be a challenge. 
However, for this purpose, urinary metabolomics could be a suitable tool. The analysis 
of the variation of urine composition following a supplementation with natural products 
can provide information on the effects of nutraceuticals on healthy subjects or animal 
models. Specimen collection is non-invasive, long-term experiments can be easily 
conducted and urinary biomarkers of oxidative stress can also be measured, offering the 
opportunity to evaluate the redox status of the considered organism. Compared to other 
biological fluids or matrices (plasma and feces for example), sample preparation is more 
straightforward in the case of urine because of lower sample complexity and lower 
protein/peptide content. Finally, urine samples the metabolic end-products from the 
organism destined for excretion, therefore, it is prone to high biological variation.  
In this work, the application of urine metabolomics to bioactivity studies 
concerning herbal products was reported. Three natural extracts, namely P. cuspidatum 
(rich in resveratrol), cranberry (rich in type A procyanidins) and green coffee beans 
(rich in chlorogenic acids), were chosen on the basis of their importance and 
distribution on nutraceutical market and on the basis of the bioactivity studies already 
published in literature. For the study involving P. cuspidatum, a healthy animal model 
was used and metabolomics analyses were performed using an integrated approach 
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involving UPLC-MS and NMR. The results showed the complementarity of the two 
analytical platforms, yielding two different patterns of metabolites describing the 
changes ascribed to P. cuspidatum supplementation and to aging. UPLC-HRMS 
allowed to observe the decreasing of the levels of urinary oxidative stress markers 
following supplementation with P. cuspidatum, indicating an in vivo antioxidant effect 
exerted by the extract. Steroid derivatives were also identified as markers of treatment, 
among whom, more importantly, tetrahydrocortisol, suggesting a role for P. cuspidatum 
extract as stimulant of corticosurrenal hormones. Furthermore, an influence of the 
treatment on aging markers allowed to observe an effect of P. cuspidatum on aging 
processes, although the mechanisms of action involved are not yet clear. On the other 
hand, urinary changes observed with 1H-NMR measurements were related to hippuric 
acid increase (indicating the microbial catabolism of polyphenols), and to some 
metabolites that suggest a relationship between P. cuspidatum treatment and energy 
metabolism. 
Regarding the experiments involving cranberry, metabolomics was a valuable tool 
to explore its bioactivity both in healthy animal and human models. More importantly, 
similar results were obtained from the two independent experiments, showing a 
reproducibility of the effects related to treatment in rats and humans. An untargeted 
UPLC-MS approach showed the poor intestinal absorption of procyanidins from 
cranberry and their extensive degradation by gut microbiota, leading to the excretion of 
negligible amounts of intact PAC-A. Considering these results, the anti-adhesive effects 
of cranberry in vivo cannot be directly related PAC-A, or at least, they could be related 
to the interactions between its constituents and the degradation products formed by 
microbial catabolism. The study of the anti-adhesive activity of urine samples collected 
at different times after a single cranberry intake allowed to observe the highest activity 
after 6-8 hours. Untargeted analyses revealed the presence of polyphenol-derived 
microbial catabolites in the samples collected at these times. Furthermore, a targeted 
analysis on urine samples collected in the human trial showed a correlation between the 
excretion of valerolactone derivatives and anti-adhesive activity, being the peaks of 
excretion comprised between 6 and 8 hours after supplement consumption. Thus, these 
metabolites could play a crucial role against E. coli adhesion to epithelial cells and they 
can be, at least in part, responsible for cranberry activity. 
Finally, LC-MS metabolomics analyses on 24-h urine samples collected during 30 
days of supplementation with GCBE showed the absorption of CGA from green coffee 
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extract and their partial degradation by gut microbiota. The use of different 
combinations of stationary and mobile phases in the LC analyses allowed to detect 
different sets of metabolites related to treatment that were further identified as 
metabolites belonging to the pathways of fatty acid metabolism. Overall, the results 
showed an influence of supplementation on lipid metabolism, and they could be 
considered, at least in part, as a further proof of the mode of action of GCBE. Finally, 
despite the reported anti-oxidant effects of CGA in vitro, our results showed no 
significant activity in human volunteers, highlighting the differences between anti-
oxidant activity data collected using the two experimental models. 
In conclusion, metabolomics approaches could offer a unique opportunity to study 
the complex effects of natural product mixtures on healthy animal and human models. 
The use of integrated untargeted and targeted approaches, as well as LC-MS and NMR 
platforms, gives the opportunity to consider different sets of metabolites and to explore 
more exhaustively the effects of a nutritional intervention on the composition of urine in 
in vivo experiments.  
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